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Drug resistance is one of the most medically relevant forms of pathogen evolution.  
To date, vaccines have not failed with the same depressing regularity as drugs.  Does 
that then make vaccines evolution-proof?  In the face of vaccination, pathogens are 
thought to evolve in two ways: by evolving epitope changes at the antigenic target of 
vaccination (epitope evolution); or by evolving changes at other antigenic loci, some 
of which may involve virulence (virulence evolution).  The fundamental difference 
between these two forms of evolution is that virulence evolution could lead to 
disease outcomes in unvaccinated people that are more severe than would have been 
seen prior to evolution.  One of the theoretical assumptions of virulence evolution is 
that more virulent parasites will have a selective advantage over less virulent 
parasites in an immunized host, and are thus more likely to be transmitted.  The 
assumption is that more virulent parasites may be competitively more superior in 
mixed infections, or may be better able to evade/modulate the host immune response.  
Thus, the aim of this thesis was to experimentally test whether more virulent 
parasites have a within-host selective advantage in an immunized host or whether 
vaccine efficacy is more likely to depend on genetic differences at the targeted sites 
of vaccination. 
 
I used clones (genotypes) of the rodent malaria Plasmodium chabaudi originally 
derived from wild-caught Thicket (Thamnomys rutilans) rats to infect laboratory 
mice and a rodent analogue of the candidate blood-stage malaria vaccine apical 
membrane antigen 1 (AMA-1).  I found that within-host selection did not depend on 
parasite virulence, and that protective efficacy depended on genotype-specific 
differences at the vaccine target.  Vaccine-induced protection was not enhanced by 
including a number of allelic variants.  However, such genotype-specific responses 
were only observed when the vaccine was tested against genetically distinct P. 
chabaudi parasites.  When one P. chabaudi genotype was serially passaged through 
naïve mice the derived line was more virulent and was subsequently less well 
 
 
controlled by vaccine-induced immunity.  In other experiments I found within host 
competition not to be immune-mediated. Thus my results suggest that vaccination 
has the potential to select for more virulent parasites but that the selective advantage 
is likely to be independent of competition.  The selective advantage may be 
attributable to the enhanced immune evasion of more virulent parasites.  However, 
without genetic markers of virulence, the mechanisms that mediate this selection 
remain unknown. 
 
My thesis contributes towards a growing body of evidence that vaccines have the 
potential to differently alter the within-host parasite dynamics of particular pathogen 
genotypes and that the selection imposed is likely to be system specific, depending 
on the fine specificity of the vaccine-induced responses and the identity of infecting 
parasites.  Although vaccine potency may not be enhanced by including more than 
one allelic variant of an antigen, multi-valent vaccines may be one of the best ways 
to avoid the inadvertent selection for more virulent malaria parasites.   
 
1. General introduction 
 
1.1. Evolution in biomedicine 
 
Research on the evolutionary process has made notable impacts in many areas of 
biology.  In contrast, evolutionary biologists have contributed rather little to 
medicine (Ewald 1994; Maynard Smith 1998; Stearns & Hoekstra 2005; Nesse et al. 
2006).  Indeed, medicine is a profession that offers practical help.  Thus, in the first 
instance, evolutionary thinking may appear to be of little use, for example, to a 
surgeon who is performing an operation (Stearns et al. 2007).  However, the 
importance in understanding evolutionary processes has become more apparent due 
to the emergence of medically relevant traits such as drug resistance (Ash 1996; 
Levy & Marshall 2004).  In spite of resistance being a clear pathogen adaptation in 
response to drug intervention, it is surprising that the word ‘evolution’ is rarely used.  
For example, papers describing antimicrobial resistance often use ‘emerge’, ‘arise’, 
or ‘spread’ rather than ‘evolve’ (Antonovics et al. 2007).  Thus there is evidently still 
a lack of acceptance or understanding of how evolution in biomedicine may assist in 
more effective methods for disease control. 
 
To date, vaccines have not failed with the same depressing regularity as drugs.  Does 
this then mean that vaccines are evolution proof?  Unfortunately, as we will see with 
the disease examples given below, pathogen evolution in response to vaccination 
does occur.  This is because host immunity imposes massive selection on pathogen 
populations and vaccines work to elicit those immune responses.  In order not to 
repeat the same complacency which has lead to the widespread evolution of drug 
resistance it has become important that we consider how pathogens which are the 
focus of current vaccine development programmes may evolve in the face of 
vaccination (Read & Mackinnon 2008).   
 
In contrast to the staggering successes of vaccines developed before the era of 
molecular biology, diseases of current vaccine development programmes, such as 
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HIV, seasonal flu, sleeping sickness, and malaria, persist by exhibiting large amounts 
of antigenic variation.  To date, the biggest concern for vaccine developers has been 
that these diseases often induce protective responses which are strain (genotype)-
specific, where immunity is often effective against genotypes that initiate the 
response, but less effective against variant genotypes.  This can lead to the evolution 
of epitope variants in the population.  Thus, vaccines not including distinct pathogen 
antigen variants may erode any potential benefits (Francois et al. 2001).  In order to 
prevent selection of non-vaccine epitopes, vaccines against these highly diverse, 
chronic infections may have to be regularly updated to keep up with evolution (as is 
already the case with seasonal flu) or have to include several antigens and/or several 
allelic forms of one antigen to overcome antigenic diversity (McLean 1995; McLean 
1998; Scherer & McLean 2002; van Boven et al. 2005).   
 
However, selection of antigen-variants is not the only evolution that could occur in 
response to vaccination.  A number of theoretical studies have shown that 
vaccination has the potential to select for (antigen) variants at loci other than those 
targeted by vaccination, and some of these changes may involve virulence (parasite-
induced host damage) (Gandon et al. 2001; Gandon & Day 2003; van Boven et al. 
2005; André & Gandon 2006; Restif & Grenfell 2006; Gandon & Day 2007; 
Mackinnon et al. 2008; Read & Mackinnon 2008; Williams & Day 2008).  The 
thinking behind the idea of vaccine-driven virulence evolution draws heavily on the 
trade-off model of the evolution of parasite virulence (Anderson & May 1991; Bull 
1994; Ewald 1994; Frank 1996). That model posits that parasites within a species 
vary in virulence, and that in order to maximize fitness, parasites have to balance the 
purported fitness costs of virulence (truncation of the infectious period by host death) 
against the purported fitness benefits of virulence (production of more transmission 
forms per unit time and/or longer time before immune clearance) (Anderson & May 




















Figure 1.1.  (A) The trade-off model of the evolution of virulence and (B) schematic 
representation of the comparison between a wild type strain and vaccine-favoured variant.  
(A) The model assumes a decelerating functional relationship between transmission rate, b 
and parasite-induced host mortality, a (virulence) (top panel).  Because early host death 
curtails parasite transmission, the life time transmission success (R0, the total number of 
secondary infections produced by a primary infection in a population of susceptible hosts) of 
a parasite is maximal at intermediate levels of virulence (bottom panel).  Figures reproduced 
from Ebert & Bull (2003) and Ebert & Herne (1996).  (B) The lifetime reproductive success 
(a relevant measure of fitness at endemic equilibrium) is plotted in naïve hosts (in black) and 
in vaccinated hosts (in white) for both strains.  The efficacy of the vaccine is evaluated in 
naïve hosts while the benefit is evaluated in vaccinated hosts (in both cases, relative to the 
performance of the wild-type strain).  Figure reproduced from Gandon and Day (2006).   
 
 
The trade-off model of virulence evolution greatly clarifies how the damage a 
parasite causes to a host evolves in response to a change in some key factor of 
parasite biology (Frank & Schmid-Hempel 2008).  In theory, vaccination has the 
potential to induce change in parasite biology by altering the costs and benefits of 
virulence.  For instance, the cost of excessive virulence may be removed by 
vaccination, as the vaccine protects the host from death and in doing so keeps those 
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more virulent parasites alive.  Thus, vaccination could induce higher levels of 
virulence (when measured in an unvaccinated host) because it drives such variants to 
higher frequency (Gandon et al. 2001; Gandon & Day 2003; André & Gandon 2006; 
Ganusov & Antia 2006) (Fig. 1.1B).   
 
As mentioned above, one of the benefits of parasite virulence is assumed to be a 
greater total number of pathogen transmissible forms across the course of infection 
(Mackinnon & Read 1999a; Messenger et al. 1999; Mackinnon & Read 2004b).  This 
could be achieved by a number of different ways.  For instance, higher virulence may 
result in a greater number of transmissible forms per day of infection, an increase in 
the transmission period (duration of infection) due to reduced immune 
clearance/parasite immune evasion, or a combination of processes (Anderson & May 
1982; Mackinnon & Read 2004a; Mackinnon & Read 2004b; Frank & Schmid-
Hempel 2008; Schmid-Hempel 2008) (Fig. 1.2).  Functional relationships between 
virulence and immune evasion were first described for the rabbit virus myxomatosis 
(Fenner & Ratcliffe 1965; Fenner & Myers 1978; Anderson & May 1982; Fenner 
1983; Anderson & May 1991).  The virus was introduced into wild rabbit 
populations in Australia as a biological control measure.  That relationship indicated 
that the most virulent strains that killed their hosts were also those which were less 
rapidly cleared (Anderson & May 1991).  All major parasite groups have been shown 
to deploy immune evasion mechanisms (Blaxter et al. 1992; Benedict et al. 2002; 
Hornef et al. 2002; Orange et al. 2002; Sacks & Sher 2002; Corley & Strand 2003).  
For example, some pathogens may secrete proteins that suppress the immune system 
by interfering with host signalling pathways and inflammatory processes (Hornef et 
al. 2002). Others may up-regulate the production of smokescreen molecules whose 
purpose is to distract the immune system from functionally important pathogen 
molecules.  High levels of antigenic variation may allow some pathogens to stay 
ahead of the proliferating immune response (Brown & Brown 1965; Phillips et al. 
1997; Nash 2002; Mackinnon & Read 2003; Mackinnon & Read 2004b; Dzikowski 
& Deitsch 2006; Dzikowski et al. 2006; Finlay & McFadden 2006; MacGregor & 
Matthews 2008).  These are just a few examples of the sophisticated mechanisms of 
immune evasion.  Enhanced immunity through vaccination may select for those 
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pathogens which deploy some of these mechanisms, as they are more likely to avoid 

























Figure 1.2.  Possible fitness benefits of virulence hypothesised under the trade-off model of 
parasite virulence.  More virulent strains might produce a greater number of transmission 
stages per day if they are less well controlled by host immunity or more aggressively exploit 
host resources, an increased period of transmission due to poor immune clearance, or a 
combination of both processes.   
 
 
One of the other benefits associated with virulence can occur during within-species, 
between strains, parasite social interactions, where it is frequently argued that 
virulent strains will be competitively superior within hosts, so that within-host 
selection will favour increased virulence (Bremermann & Pickering 1983; van 
Baalan & Sabelis 1995; Frank 1996; Gandon et al. 2001; Alder & Losada 2002).  
This has been seen in the rodent malaria model Plasmodium chabaudi in laboratory 
mice, where more virulent genotypes suppress the densities and transmission of less 
virulent genotypes in mixed infections (de Roode et al. 2005b; Bell et al. 2006).  Just 
as the relative fitness of drug-resistant strains, could be substantially enhanced when 
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co-infecting drug-sensitive competitors are removed by chemotherapy (Hastings 
1997 ; Hastings & D'Alessandro 2000; Hastings 2003; Mackinnon 2005a; Hastings 
2006; Wargo et al. 2007), vaccination may similarly affect the rate of evolution of 
epitope variants (Lipsitch & Samore 2002; Read & Mackinnon 2008).   
 
The aim of this thesis was to experimentally investigate whether any fitness benefits 
of parasite virulence result in a disproportionate advantage in hosts immunized with 
a recombinant candidate malaria vaccine antigen. All else equal, it follows that a 
relative fitness advantage means that vaccination could lead to the evolution of 
increased virulence. The primary motivation for this work came from the 
‘Combination B’ malaria vaccine, one of the first malaria vaccines to make it to field 
trials (Genton et al. 2002; Genton et al. 2003).  The vaccine comprised three P. 
falciparum antigens which were known to be expressed during the pathogenic blood 
stage of infection: Merozoite Surface Protein 1 (MSP-1), MSP-2 and the Ring-
Infected Erythrocyte Surface Antigen (RESA) (Saul et al. 1999).  MSP-2 exists as 
two allelic families (variants) in P. falciparum known as 3D7 and FC27 (Smythe et 
al. 1990).  The 3D7 variant was included in the vaccine formulation.  In a double-
blind, placebo controlled trial the vaccine was given to 120 children aged between 5 
and 9 years old.  In a follow up study, despite a reduction in the frequency of the 3D7 
variant in the vaccinees, the prevalence of the FC27 variant, which was not included 
in the vaccine, was unaffected (Table 1.1).   Interestingly, the FC27 variant itself had 
previously been associated with more morbid (virulent) cases (Engelbrecht et al. 
1995).  This was the first field evidence that a vaccine against malaria could exert 
selective pressure.  However, what was not clear from those studies was whether the 
vaccine had exerted selection that was strain-specific (Fluck et al. 2004; Fluck et al. 
2007) or whether more virulent variants had a selective advantage in immunized 
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 Treatment group 
 Placebo Vaccine 
3D7 allele 21 11 (.33) 
FC27 allele 6 11 (.66) 
 
 
Table 1.1. New infections following vaccination with Combination B.  A new infection was 
considered to have occurred when an MSP2 strain that was not detected in the same child at 
week 0 or 4 was found at week 8, 10, 12, 14, 16 or 18.  Twenty-one new 3D7-type infections 
were detected in placebo recipients, and only 11 were detected in vaccinees.  In contrast, 
only 6 new FC27-type infections were found in placebo recipients, compared with 11 in 
vaccinees.  The numbers in brackets indicate the frequency of each allele in those who 
received the Combination B vaccine.  There was a significant difference between the allelic 
types in this efficacy (χ2 = 4.1; p=.042); the vaccine made no difference to the prevalence of 
the FC27-type parasites.   
 
 
Over the past decade our laboratory has established one of the rodent malarias, P. 
chabaudi, as a model for studying the evolution of virulence (Mackinnon et al. 2002; 
Mackinnon & Read 2004a; de Roode et al. 2005a; de Roode et al. 2005b; Mackinnon 
et al. 2005b) (see section 1.4 below).  The experiments I present in this thesis use a 
bank of genetically diverse P. chabaudi parasites that vary in virulence to infect 
laboratory mice immunized with the candidate malaria vaccine known as Apical 
Membrane Antigen 1 (AMA-1).  I specifically asked: (i) whether parasite antigenic 
differences at the targeted vaccination locus and/or at other loci (which may be 
involved in virulence) influence vaccine-imposed selection; (ii) whether 
immunization with more than one antigen variant significantly improves host health 
and/or alters vaccine-imposed selection compared to when immunization is with one 
of the variants; (iii) whether vaccination has the potential to alter competitive 
interactions between genetically diverse malaria parasites.   
 
Although I base my thesis on malaria, I hope my findings will contribute towards an 
increased evolutionary understanding of how vaccines may impose selection on other 
diseases currently the focus of vaccine design programmes.  In doing so I hope 
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provide information for the better design and use of vaccines for improved animal 
and human health in the future. 
 
1.2. Evidence for vaccine-driven evolution 
 
As mentioned above there are currently two separate views on how vaccines may 
impose selection upon pathogen populations: epitope evolution and the evolution of 
virulence (van Boven et al. 2005; Restif & Grenfell 2006).  First, studies on epitope 
evolution focus on understanding how vaccines select for antigenic variants which 
are able to evade the protective effects of the vaccine (McLean 1995; McLean 1998; 
Wilson et al. 1998; Wilson et al. 1999; Francois et al. 2001; Scherer & McLean 
2002; van Boven et al. 2005; Restif & Grenfell 2006).  Second, studies on vaccine-
induced evolution of virulence (parasite-induced host damage) are more concerned 
with how vaccines may alter the costs and benefits of parasite virulence (Gandon et 
al. 2001; Gandon & Day 2003; André & Gandon 2006; Gandon & Day 2007; Read 
& Mackinnon 2008; Williams & Day 2008).   
 
The distinction between epitope and virulence evolution is heuristically useful and 
likely to be unambiguous in many cases.  Therefore in the sections below I have 
separated the two processes for clarity.  However, in some cases the distinction may 
be less clear as some epitopes will be virulence determinants (as may have been the 
case with the MSP2 FC27 variant in the Combination B malaria vaccine).  However, 
the public health distinction remains: vaccine-driven virulence evolution will lead to 
disease outcomes in unvaccinated people more severe than would have been seen 
prior to vaccination; epitope change will not.   
 
This thesis is concerned with investigating how a vaccine against the blood stage of 
malaria infection may impose selection on Plasmodium populations: will vaccine-
imposed selection result in epitope evolution, virulence evolution, or perhaps a 
combination of both processes?  Before I get into the specificities of the malaria 
model system I will use for addressing these questions, it appears appropriate that I 
should provide a number of disease examples where vaccine-driven evolution is 
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assumed to have occurred.  However, first I would like to begin by describing some 
diseases where vaccines have been successful, with apparently no adverse 
evolutionary consequences.   
 
Vaccination has spared millions of people the effects of devastating disease and 
should rightly be claimed a medical triumph.  For example, vaccination has 
eradicated smallpox, is close to eradicating polio and controls a number of other 
diseases including Haemophilus influenza type B (Hib), measles, mumps, rubella, 
pertussis and diphtheria (Atkinson et al. 2000).  However, the most striking common 
feature between these diseases is that they all cause acute childhood infections.  
Thus, the infection either kills the host or provides life-long sterilizing immunity.  In 
the pre-vaccination era, there must have been intense selection for those diseases to 
over-come natural immunity but it is evident they did not.  Some have argued that 
vaccines against these acute diseases were easy: natural immunity was already 
evolution-proof and all that was needed was for vaccines to mimic natural immunity 
(Read & Mackinnon 2008).  Obviously, not all infectious diseases are alike, thus one 
should not assume that all vaccines are evolution-proof.   
 
The diseases targeted by current vaccine development are markedly different to acute 
childhood infections.  For instance, HIV, flu, sleeping sickness, and malaria are 
pathogens rich in diversity, and can result in chronic infections, presumably due to 
high levels of antigenic diversity and immunosuppressive properties.  These diseases 
provide a challenge for vaccine developers as natural selection has provided a way of 
overcoming natural immunity.  For example, comparing measles and influenza, due 
to continual antigenic evolution of influenza, vaccines must be continually updated 
to maintain their effectiveness, while with measles they do not (Boni 2008; Gog 
2008).  This makes vaccination a more effective control strategy for measles than for 
influenza, because influenza can, in effect, evolve to circumvent this control 
measure.  The measles versus influenza situation demonstrates that an understanding 
of the evolutionary consequences of vaccination is crucial for designing successful 
vaccination programs. 
 
Chapter 1 – General introduction        9 
1.2.1.  Epitope evolution 
Conventionally, epitope evolution may be regarded as a mutational change at the 
antigenic target of vaccination leading to the emergence of de novo mutants.  
However, vaccine-induced epitope evolution can also cause the emergence of pre-
existing strains which are different at the target epitope(s) to the vaccinating strain.  
The following diseases provide examples where a change in gene frequency has 
occurred following vaccination and thus are likely to fall under the heading of 
epitope evolution. 
 
First, there is strong evidence that hepatitis B virus (HBV) populations are evolving 
in response to widespread vaccination through changes at target epitopes.  HBV is a 
major cause of liver disease including liver cirrhosis and hepatocellular carcinoma 
(Yokosuka & Arai 2006).  The use of HBV vaccines started in the late 1980s in 
developed countries and dramatically reduced the incidence of disease (FitzSimons 
et al. 2005).  The neutralizing (protective) antibodies induced by vaccination target 
epitopes located within the a determinant, a common immunodominant region on the 
outer protein coat (surface antigen).  In 1990, the first mutation (a single amino acid 
substitution) in the S gene coding for the a determinant of the surface antigen was 
described (Carman et al. 1990).  Since then several other mutants have been 
discovered (Ghany et al. 1998; Protzer-Knolle et al. 1998).  Thus, in the presence of 
vaccination there appears to be a selective advantage to mutation in the target site of 
vaccination.  What remains to be determined is whether these mutants will inflict 
significantly greater host disease in the unvaccinated population.   
 
Second, whole-cell vaccines against Bordetella pertussis (the causative agent of 
whooping cough) resulted in a worldwide reduction in disease incidence. The current 
vaccine contains a number of proteins, including pertactin (Prn) and pertussis toxin 
(Ptx).  Prn facilitates attachment to host cells, and Ptx is involved in immune evasion 
and possibly resource extraction.  Since the introduction of vaccines containing these 
proteins, changes in allele frequency have been recorded worldwide: non-vaccine 
alleles tend to be more frequent in vaccinated individuals than in unvaccinated 
individuals (Mooi et al. 1998; van Loo et al. 1999).  For instance, in Finland and 
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Holland, the frequency of the vaccine-type pertactin allele (Prn1) went from 
essentially 100% in the pathogen population to less than 5% after the introduction of 
nationwide vaccination (van Loo et al. 1999; Elomaa et al. 2005).  In addition, 
mutations in these two surface proteins have also been suggested as a reason for 
disease resurgence in the adult host population (WHO 2001; McIntyre et al. 2002; 
Ntezayabo et al. 2003).  It is possible that these mutants have a selective advantage in 
vaccinated individuals as they are more able to evade vaccine-induced immunity.   
 
Third, vaccination against infections with Streptococcus pneumoniae may provide an 
example where epitope evolution has arisen due to strain replacement: removal of 
one strain by vaccination evolves a niche for another strain to fill.  S. pneumoniae is 
responsible for diseases such as meningitis, septicaemia, and pneumonia.  The 
bacterium consists of 90 known serotypes with variable prevalence and virulence 
(Smith et al. 1993).  Vaccines generally consist of between 7 and 11 of these 
serotypes (types of capsular polysaccharides).  Since the widespread use of a 7-valent 
conjugate vaccine began in the United States in 2000, there has been a decrease in 
disease incidence caused by those strains targeted by the vaccine.  Non-vaccine 
serotypes have increased in frequency in both disease cases and asymptomatic 
carriage (McEllistrem et al. 2003; Huang et al. 2005; Flannery et al. 2006).  
However, those non-vaccine serotypes are less virulent (induce less host 
damage/sickness).  Thus, although there has been no net change in disease 
prevalence, vaccination has selected for those strains which are less nasty.  
 
Fourth, immunization with the detoxified toxin (‘toxoid’ vaccine) against 
Corynebacterium diphtheriae has reduced the disease from a major child killer to 
one rarely seen at all.  The disease is characterized by lesions, which are due to the 
production of a specific phage-encoded cytotoxin, found particularly in the tonsils, 
pharynx, larynx, and nose.  Various authors have attributed decreased disease to be 
due to reductions in the frequency of the toxin-encoding phage in the bacterial 
population (Pappenheimer 1982; Ewald 1994; Ewald 1996; Ewald 2002; Soubeyrand 
& Plotkin 2002).  The premise behind this is that in the presence of anti-toxin 
immunity there will be an evolutionary cost of toxin production to C. diptheriae.   
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The only data showing this evolution comes from Romania during the third quarter 
of last century (Pappenheimer 1982).  However, given that the diphtheria toxoid 
vaccine is imperfect (Schneerson et al. 1996) the production of more toxin may be an 
alternative way to overcome the effect of the toxoid vaccine (Gandon et al. 2002) 
   
Finally, the examples given so far of epitope evolution have come from uncontrolled 
field observations, therefore it is difficult to attribute the changes in gene frequency 
solely to selection imposed by vaccination.  Disease resurgence for example, is 
usually due a number of complex factors.  Major reasons can include low 
immunization coverage rates in adults and infants, waning immunity in the adult 
population and large movements of the population.   
 
The current roll-out of vaccines against Human Papillomavirus (HPV), the primary 
etiologic factor in the development of cervical cancer (Bosch et al. 1995) may 
provide a disease where the effects of vaccination on the pathogen population can be 
measured over real-time.  More than 35 distinct HPV types are know to infect the 
genital tract (Bernard et al. 1994).  Certain types (types 16, 18) are designated high 
risk because of their association with cervical and other anogenital cancers (Trottier 
& Franco 2006).  HPV infections can cause genital warts or lead to penile or anal 
cancer, although at rates well below the rates of cervical cancer in women (Partridge 
& Koutsky 2006).  In 2006, a quadrivalent vaccine against types 6, 11, 16 and 18 
was licensed by the Food and Drug Administration (FDA) for use in females who are 
9 to 26 years of age (FDA 2006).  The Advisory Committee on Immunization 
Practices (ACIP) has also voted to recommend routine HPV immunization of 11-to 
12-year old females (CDC 2006).  A theoretical framework has recently been used to 
predict epitope evolution in HPV (Poolman et al. 2008).  That model demonstrated 
that depending on the degree of cross-immunity elicited by the vaccine, vaccination 
may either expand or contract the available niche of HPV.  Monitoring the 
evolutionary consequences of HPV in the population will require collaborations 
between health workers, experimental biologists and bio-mathematicians.  If these 
collaborations occur, there is great potential for HPV to be one of the first diseases 
where the evolutionary consequences of vaccination can be determined. 
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1.2.2.  Virulence evolution 
 
The classic example of virulence evolution in response to host immunity is the 
European rabbit-myxoma virus system.  In the natural host (Sylvilagus brasiliensis), 
myxoma virus causes a benign cutaneous fibroma.  However, in European rabbits 
(Oryctolagus cuniculus) myxoma virus is lethal.  The virus was deliberately 
introduced as a mechanism of biological control into wild European rabbit 
populations in Australia.  Over the following years the virus first declined rapidly in 
virulence.  Later virulence then increased again, as tests on non-coevolving control 
rabbits showed.  At the same time the wild rabbits evolved to suffer less from the 
original virus (Fenner & Kerr 1994).  This impressively documented example shows 
that virulence can evolve rapidly with large changes in the face of immunity, and that 
hosts evolve to reduce the costs of parasitism. Arguments for vaccine-driven 
virulence evolution imply that if hosts immunity can drive virulence upwards, 
vaccines which act to mimic or enhance natural immunity will similarly drive the 
evolution of virulence (Gandon et al. 2001; Gandon et al. 2003; André & Gandon 
2006; Gandon & Day 2007; Mackinnon et al. 2008; Read & Mackinnon 2008; 
Williams & Day 2008).   
 
Vaccine-driven virulence evolution is thought to have occurred in the avian cancer-
causing herpes virus, Marek’s Disease Virus (MDV).  MDV causes substantial loss 
to the poultry industry each year.  Vaccination started in the 1960s after the virus 
became economically important with the intensification of the chicken industry post 
World War II.  Vaccination was with a live virus from a related non-oncogenic 
strain.  This first generation vaccine initially yielded good control, but within a 
decade it was not providing adequate protection against virulent strains that appeared 
in the 1970s.  One subsequent vaccine was introduced and similarly failed.  
Importantly, virulent strains have the ability to infect and exploit vaccinated and 
unvaccinated birds and are more virulent in these hosts (i.e. they induce more 
extreme symptoms) (Witter 1997; Read et al. 2004).  Importantly, the failed vaccines 
were undermined by strains that were antigenically identical to the oncogenic strains 
of the pre-vaccine era.  Thus, changes in viral aggression and immunosuppressive 
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capacity, not antigenic type, caused the vaccine failure (Witter 2001; Davidson & 
Nair 2004).   
 
Similar to MDV, vaccine-driven evolution may provide an explanation as to why 
strains of a birnavirus, which causes the enteric and respiratory disease of chickens 
known as infectious bursal disease (IBD), have not been controlled by vaccination 
programmes. Since vaccinations begun in the 1980’s, failure has been described in 
poultry operations around the world.  In the United States, the re-emergence was due 
to the evolution of antigenically novel strains against which classical IBD vaccines 
were not sufficiently protective.  In contrast, evolved European strains belong to the 
ancestral IBD serotype but are more aggressive.  Like the newly evolved MDV 
strains, these very virulent European strains cause more severe disease in 
unvaccinated birds, with mortality rates of up to 60% (van den Berg et al. 2000; 
Rautenschlein & Haase 2005; Nouen et al. 2006). 
 
The first controlled experimental evidence that vaccination may drive the evolution 
of virulence came from our laboratory using the rodent malaria P. chabaudi 
(Mackinnon & Read 2004a).  In that study, one ancestral P. chabaudi genotype was 
serially passaged (i.e. the syringe transfer of parasite infected blood from one host to 
another) through whole-parasite immunized mice or naïve mice.  Immune-derived 
lines evolved to be more virulent than lines that had evolved in naïve hosts, even 
after mosquito transmission, when virulence was measured during infection of non-
immunized mice.  An implication of that study was that more virulent genotypes had 
a selective advantage in an immunized host.  That study by Mackinnon and Read 
(2004a) was a motivator for many of the experiments presented in this thesis.   
   
1.2.3.  Other possible vaccine-adapted phenotypes 
 
Epitope and virulence evolution have been described as the main pathogen 
phenotypes that vaccination may alter.  However, it is likely that a combination of 
different phenotypes may be favoured in vaccinated populations.  A few of these 
include: enhanced immunosuppression, for instance by production of 
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immunomodulatory substances; the establishment of a ‘smokescreen’ effect that may 
have the advantage of distracting the immune system from functionally important 
molecules; changes in patterns of antigenic variation may occur, and/or antigenic 
repertoires and rates of change; changes in tissue tropism and immunologically 
privileged sites and/or increased sequestration; and activation of alternative host cell 
invasion pathways (Read & Mackinnon 2008).  It is likely that these are just a few of 
the possible outcomes that could occur in response to vaccination and there are likely 
a number of other pathogen strategies for evading protective responses in addition to 
those mentioned.   
 
1.3. Thesis aims 
 
As I have described above, vaccination could impose selection on the parasite 
population by driving the evolution of epitope variants which are able to escape 
immunity or by altering one or more of the costs and benefits associated with 
parasite virulence.  Here I use clonal genotypes of the rodent malarias P. chabaudi to 
experimentally investigate which parasite traits are most likely to influence selection 
during vaccination with the candidate malaria vaccine AMA-1.  These results are 
relevant to the design and implementation of future malaria vaccines and will 
hopefully generate an increased recognition of the need to understand immediate 
epidemiological benefits and the longer-term evolutionary risks of interventions for a 
number of different diseases. The following specific questions form the basis of each 
chapter.   
 
• For two antigenically distinct AMA-1 variants, are the protective effects of 
immunization due to strain (genotype) specific differences at the target 
epitopes, or is a more virulent P. chabaudi genotype better at evading 
vaccine-induced heterologous immunity? [Chapter 2] 
 
• Across six P. chabaudi genotypes, how does genetic diversity at the AMA-1 
locus and genotype virulence play out during immunization?  When two of 
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the genotypes are identical at the AMA-1 locus, but differ in their virulence, 
does vaccination induce protective responses which are more effective 
against the genotype of lesser virulence? [Chapter 3] 
 
• If strain-specific responses are such a big problem to vaccine developers, are 
multi-allele vaccines a solution to antigenic polymorphisms?  What are the 
effects of single and multi-allele vaccines on within-host selection of variants, 
and does parasite virulence mediate the level of evasion from vaccine-
induced immunity? [Chapter 4] 
 
• Serial passage of a P. chabaudi genotype through whole-parasite immunized 
mice has previously been shown to drive the evolution of virulence more 
rapidly than those evolved through naïve mice.  Does serial passage drive the 
evolution of a P. chabaudi genotype which is less well controlled by AMA-1 
vaccination? [Chapter 5] 
 
• Selection for more virulent genotypes is known to occur during mixed P. 
chabaudi infections.  Could vaccination alter these competitive interactions?  
To investigate this I depleted mice of CD4+ T cells and asked whether 
immune modulation alleviated or exacerbated competitive interactions 
between genetically diverse P. chabaudi parasites [Chapter 6]. 
 
• Following on from Chapter 6, does direct immunization with AMA-1 (known 
to induce strain-specific immune responses) alleviate or enhance the 
competitive interactions between two genotypes which differ in their 
virulence? [Chapter 7] 
 
 
In Chapter 8, I discuss how the main findings of this thesis address the questions laid 
out above, and the implications of this for future vaccine development research on 
the evolution of virulence, and the relevance of using animal models.   
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Malaria is a disease caused by parasites of the genus Plasmodium.  Classically, four 
species of Plasmodium were known to infect humans: P. falciparum, P. vivax, P. 
malariae and P. ovale, of which P. falciparum is the most common and causes the 
most severe disease.  However, during a recent epidemic in Malaysian Borneo a 
large number of cases were found to be due to P. knowlesi, a malaria parasite of Old 
World Monkeys (Garnham 1966; Cox-Singh et al. 2008).  Thus, it is now 
appreciated that there are likely to be a number of other species that can naturally 
infect humans.   
 
Malaria is endemic in more than 90 countries, principally in the developing world, 
with 300-500 million new infections each year and one million deaths, mainly in 
children and pregnant woman (Hentschel 2002).  Malaria parasites undergo a 
complicated life cycle (Fig. 1.2).  Infection is initiated by inoculation of sporozoites, 
an infectious form of the parasite, through mosquitoes.  Sporozoites multiply in the 
liver, with a single sporozoite yielding 30,000-40,000 merozoites that are released 
into the blood stream.  Each of these can invade a red blood cell (RBC).  Inside a 
RBC, the merozoite transforms into a trophozoite.  This divides asexually to generate 
up to 32 merozoites for P. falciparum and around 8 for the rodent malaria P. 
chabaudi. This process of asexual replication repeats itself every 48 (P. falciparum) 
and 24 (P. chabaudi) hours, and, in humans, results in the fevers characteristic of 
malaria.  After invading a RBC, a small proportion of asexual parasites convert into 
male or female gametocytes, which are essential for transmitting the infection to 
other hosts through female anopheline mosquitoes (Hisaeda et al. 2005).  In the 
mosquito, gametocytes turn into gametes which fertilize each other to form an 
ookinete which crosses the mosquito’s mid gut wall where it encysts and forms an 
oocyst.  Meiosis is followed by asexual replication resulting in new sporozoites 
which migrate to the salivary glands where, during the blood-meal of a mosquito, 
they are injected in to a new host.  The various effector functions of the host immune 
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system are similarly complex with numerous components of the response operating 
at different stages of the parasite’s life cycle (Fig. 1.3).  Human disease severity in 
the field is remarkably variable ranging from asymptomatic infections to life-
threatening cerebral malaria (Alles et al. 1998).  Variation in severity of malaria may 
be attributed to a number of factors including geography, nutritional status, disease 
load, immunity and host genetics (Baird 1998; Phillips 2001; Mackinnon et al. 2002; 

















Sporozoites: Antibodies block invasion of hepatocytes
Liver stage: IFNγ-relelased by CD8+ and CD4+ T 
cells induces NO production by hepatocytes; CD8+ 
CTL and NK cells exert cytotoxicity and induces 
fas/fas ligand-mediated apoptosis; NK cells plus 
antibodies exert ADCC
Merozoites: antibodies block invasion of the RBC, 
mediate organization and ADCI
Toxins: antibodies block toxins avoiding clinical 
disease and severe malaria
Infected RBC: antibodies mediate opsonization.  ADCC 
complement-mediated cell lysis and block adhesion to 
endothelial cells CD4+ T cells and monocytes secrete 
cytokines with parascidic/parastostiatic effects
Sexual stages: antibodies block fertilization or 
attachment/passage of the ookinete through the 
mosquito gut
Figure 1.3. Life cycle of Plasmodium depicting the potential targets and mechanisms of 
protective immune responses.  Figure reproduced from (Hoffmann & Miller 1996). 
 
 
1.4.2. Malaria vaccines 
 
Four stages of the malaria parasite life cycle have been the targets of vaccine 
development efforts (Fig. 1.4).  The first two stages are referred to as the ‘pre-
erythrocytic stages’ (i.e. before the parasite invades the human red blood cells); these 
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are the sporozoites inoculated by the mosquito into the human bloodstream, and the 
parasites developing inside human liver cells.  The other two targets are the stages 
when the parasite is invading or growing in the RBCs (blood, merozoite, or 
erythrocytic stage); and the transmission stages, when the parasites emerge from 
RBCs and fuse to form a zygote inside the mosquito vector (gametocyte, gamete, or 
sexual stage).  Despite continued efforts there are still currently no effective malaria 
vaccines.  Many candidate malaria vaccines are directed at the disease-causing forms 
of the malaria life-cycle, the asexual blood-stage.  Erythrocyte invasion is a complex 
process that requires contact, adherence and reorientation of the red blood cell by the 
merozoite.  This is a rapid process involving a number of parasite proteins that are 
located on the surface of the merozoite and thus accessible to circulating antibodies.  
Eighteen clinical trials with asexual blood-stage vaccines have been registered in the 
main clinical trials registries (websites: http://www.clinicaltrials.gov or 
http://www.who.int/trialsearch/).  The most advanced asexual blood-stage vaccines at 
present are based on recombinant forms of merozoite surface proteins (MSP) 1, 2 
and 3, apical membrane antigen 1 (AMA-1) and the glutamate rich protein (GLURP) 
(Reed et al. 2006).  
 
RTS,S
Figure 1.4.  Examples of vaccine targets of the malaria life cycle.  CS= circumsporozoite; 
RTS,S (sequences of the CS protein and the hepatitis B surface antigen (HBsAg); TRAP= 
thrombospondin-related adhesive protein; EXP-1 = exported antigen 1; LSA1 = liver stage 
antigen 1; MSP-1 = merozoite surface protein 1; GLURP = glutamate-rich protein; AMA-1 
= apical membrane antigen 1; Pf = P. falciparum; Pv = P. vivax.  Figure reproduced from 
(Ballou et al. 2004a). 
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1.4.3.  Apical membrane antigen 1 (AMA-1) 
 
AMA-1 is a promising vaccine candidate as it possesses fewer polymorphisms than 
other merozoite antigens (Anders et al. 1998; Hodder et al. 2001).  AMA-1 is 
expressed in the sporozoite (Silvie et al. 2004), hepatic (Krzych et al. 1995; Bodescot 
et al. 2004) and erythrocytic (Triglia et al. 2000; Carvalho et al. 2002; Ballou et al. 
2004b; Mitchell et al. 2004; Cortes et al. 2005; Greenwood 2005) stages of the 
Plasmodium life cycle.  There is still much to be determined with the respect to the 
role of AMA-1 in erythrocyte invasion.  However, failure to disrupt ama-1 in 
Plasmodium (Triglia et al. 2000) and Toxoplasma gondi (Hehl et al. 2000) strongly 
suggests that AMA-1 has vital functions.  It appears as though AMA-1 is originally 
trafficked as an 83-kDa protein to micronemes of the apical complex of the 
merozoite (Fig. 1.5A) (Triglia et al. 2000; Carvalho et al. 2002; Ballou et al. 2004b; 
Mitchell et al. 2004; Greenwood 2005).  AMA-1 undergoes proteolytic processing 
into smaller fragments, and at the time of merozoite release, a 66kDa processed form 
is distributed around the merozoite surface (Peterson et al. 1989; Narum & Thomas 
1994; Howell et al. 2005).  The protein likely represents a key link between the weak 
initial contact involving MSPs and irreversible tight associations formed with 
microneme proteins (Cowman & Crabb 2006).  The AMA-1 gene sequence has been 
determined for a number of different isolates of P. falciparum (Peterson et al. 1989; 
Thomas et al. 1990; Marshall et al. 1996; Oliveira et al. 1996) and for other 
Plasmodium species (Marshall et al. 1989; Peterson et al. 1990; Waters et al. 1990; 
Cheng & Saul 1994; Kappe & Adams 1996).  The amino acid sequence is a classical 
type 1 membrane protein with a large NH-terminal putative ectodomain  and a 
presumed transmembrane domain towards the COOH-terminus (Anders et al. 1998).  
The ecodomain of PfAMA-1 is largely composed of three domains: a relatively N-
terminal domain 1, a central domain II, and a C-terminal domain III (Nair et al. 2002; 
Bai et al. 2005; Pizarro et al. 2005).  Reduction and alkylation is required to stabilize 
the eight intramolecular disulphide bonds which are essential for inducing protective 
immune responses (Anders et al. 1998) (Fig. 1.5B). A number of different studies 
have demonstrated that each of these domains may be required to generate protective 
immunity against malaria.  For instance, domain I appears to exhibit the most 
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polymorphisms, with clustering occurring at one end of a hydrophobic cleft, thought 
to be associated with a ligand binding site (Bai et al. 2005; Coley et al. 2007).  X-ray 
crystallography and cell culture experiments have demonstrated a crucial role for 
domain II in the attachment/invasion of red blood cells (Fraser et al. 2001; Nair et al. 
2002; Bai et al. 2005; Feng et al. 2005; Pizarro et al. 2005; Collins et al. 2007).  
Finally, genetic analyses have demonstrated domain III to be under balancing 
selection, and that some anti-domain III antibodies can block invasion (Nair et al. 







Figure 1.5.  Schematic diagram of the parasite merozoite stage (A), and the structure of the 
three domains of AMA-1 and the disulphide bonds recognized by protective immune 
responses (B).  (A)  The major organelles and cellular structures of the merozoite are 
highlighted.  AMA-1 is trafficked to the microneme where it is proteolytically cleaved 
before relocalization to the merozoite outer membrane (B)    The AMA-1 ectodomain 
consists of three domains that are interlinked by disulphide bonds.  Letters represent amino 
acids with darker shaded letters showing amino acid substitutions occurring among P. 
chabaudi strain DS and DK (556KA) used in this thesis.  Figures reproduced from Hodder et 
al. (1996) and Cowman & Crabb (2006). 
 
 
Because AMA-1 is relatively conserved in the genus it has been possible to use this 
protein from murine and primate Plasmodium species in vaccine efficacy trials in 
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monkeys, apes and mice (Marshall et al. 1989; Peterson et al. 1990; Anders et al. 
1998).  Murine P. chabaudi AMA-1 can be expressed and purified from E. coli 
constructs and  trials comparing the full-length AMA-1 (AMA-1A) with the refolded 
ectodomain (AMA-1B) found highly significant protection with AMA-1B 
immunization of mice (Anders et al. 1998).  Since then AMA-1 has been confirmed 
as a promising vaccine candidate.  Naturally acquired antibody to P. falciparum 
AMA-1 (PfAMA-1) in endemic populations is associated with protection from the 
most virulent human malaria, P. falciparum (Thomas et al. 1994; Johnson et al. 
2004; Polley et al. 2004; Cortes et al. 2005; Rodrigues et al. 2005).  Immunization 
with AMA-1 induces antibodies that inhibit invasion, conferring protection against 
parasite challenge in a number of animal models (Deans et al. 1988; Collins et al. 
1994; Crewther et al. 1996; Anders et al. 1998; Narum et al. 2000; Stowers et al. 
2001; Stowers et al. 2002; Healer et al. 2004).  Humans as well as other species 
immunized with single allele AMA-1 vaccines have raised antibodies conferring 
protection from erythrocyte invasion in vitro (Hodder et al. 2001; Kocken et al. 
2002).  Moreover, there are currently at least six different vaccines based on the 
AMA-1 allele from the P. falciparum 3D7 strain currently in efficacy trials in 
humans (Polhemus et al. 2007; Maher 2008; Thera et al. 2008).   
 
1.4.4.   Plasmodium chabaudi model 
 
Although malaria must ultimately be understood in humans, much of our knowledge 
on the pathogenesis of disease depends on studies in non-humans species (Miller et 
al. 2002; Lamb et al. 2006). This is particularly critical in the current context, where 
one of the key phenotypes (virulence) can only be assayed in a live host.  Mouse 
malaria models offer an opportunity to study the mechanisms involved in malaria 
disease since there are some similarities between infection in humans and mice.  For 
instance, both P. falciparum and P. chabaudi have a lack of preference for young red 
blood cells (reticulocytes) over older ones (normocytes) (Jarra & Brown 1989; 
Clough et al. 1998).  Both species also display cytoadherence: the sticking of 
parasitized cells to other host cells (Rowe et al. 1995; Roberts et al. 2000) and 
undergo clonal variation (Biggs et al. 1991; Roberts et al. 1992).  However, there are 
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also several potentially important differences.  For instance, P. chabaudi infections 
frequently reach parasitaemias an order of magnitude higher than that found in 
human malaria infections (Collins & Jeffery 1999; Mackinnon & Read 1999a), and 
the relative importance of strain-transcending and strain-specific immunity may 
differ.  A fuller evaluation of the strengths and weaknesses of the P. chabaudi model 
will be assessed in the General Discussion of my thesis (Chapter 8). 
 
There are four species of Plasmodium that infect mice (P. chabaudi, P. yoelli, P. 
berghei and P. vinckei) and these were originally isolated from wild-caught thicket 
rats (Thamnomys rutilans) in Africa (Carter & Walliker 1976; Beale et al. 1978; 
Landau & Boulard 1978).    To obtain clonal genotypes (lines of parasites derived 
from a single parasites) from these field samples, each isolate (each from a different 
host) were injected into groups of 14-30 mice with an inoculum expected to contain 
an average of one parasite (Beale et al. 1978).  Successful infections were thus 
assumed to have been established by a single parasite which produced a clonal 
population.  Clonal genotypes were shown to be distinct using electrophoretic 
enzyme analysis (Carter 1978).  Some of the isolates from which clonal genotypes 
were derived comprised more than one species of parasite, the predominant one 
being P. chabaudi, with occasional P. yoelli.  Therefore, after cloning, the species of 
each genotype was confirmed as P. chabaudi by morphology (Carter & Walliker 
1975).  Clonal genotypes of P. chabaudi are stored as frozen stabilites in liquid 
nitrogen with subscript codes used to identify their position in clonal history 
(Mackinnon & Read 1999b).  These genotypes have significant genetic variation in 
virulence, measured as anaemia, weight loss and mortality during infection of 
laboratory mice (Mackinnon & Read 1999a).  Experiments from our laboratory have 
utilized the availability of P. chabaudi genotypes to study parasite genetic variation 
upon which selection can act.  Competition experiments between P. chabaudi 
genotypes which differ in their virulence have now strongly demonstrated that more 
virulent genotypes have a competitive advantage over less virulent genotypes; they 
produce more asexual and mosquito-infective stages (gametocytes) and are less 
rapidly cleared by the host (Mackinnon & Read 1999a; de Roode et al. 2003; 
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Ferguson et al. 2003; de Roode et al. 2004a; de Roode et al. 2004b; de Roode et al. 
2005a; de Roode et al. 2005b; Bell et al. 2006).   
 
In nature, infections with malaria frequently consist of more than one Plasmodium 
genotype (Babiker et al. 1991; Conway et al. 1991; Arnot 1998; Babiker et al. 1999; 
Smith et al. 1999; Tanner et al. 1999; Jafari et al. 2004).  Mixed infections can arise 
due to the bite of a single mosquito inoculating more than one genotype or via 
successive bites from multiple mosquitoes infected with different genotypes (Grech 
et al. 2008).  A substantial body of epidemiological evidence is consistent with 
competitive interactions observed in laboratory experiments of P. chabaudi 
(Daubersies et al. 1996; Arnot 1998; Smith et al. 1999; Bruce et al. 2000; Hastings 
2003; Talisuna et al. 2006).   
 
In theory, competitive interactions between different strains could be mediated by a 
number of different biological processes, including the host immune response (Read 
& Taylor 2001).  One study from our laboratory indicated that competition could be 
immune-mediated (Råberg et al. 2006).  In those experiments, competitive 
suppression of an avirulent P. chabaudi genotype was significantly reduced in nude 
mice, which cannot produce mature T cells, than in control mice.  As mentioned 
above our laboratory has demonstrated competition to be a potent source of selection 
for virulence.  Thus, the study by Råberg et al. (2006) inadvertently raised the 
possibility that current vaccination programmes, which are aimed at inducing T cell-
dependent responses, might exacerbate within-host competition.  In other words, 
vaccination may select for the competitive fitness benefit associated with virulence. 
 
Consistent with competition experiments demonstrating that vaccines may enhance 
selection for virulence (Råberg et al. 2006), serial passage (i.e. the syringe transfer of 
malaria infected blood from one host to another) of a single P. chabaudi clone 
through whole-parasite immunized hosts, derived a parasite line which contained 
variant genotypes which induced more virulent infections in naïve mice compared to 
those lines which were derived by serial passage through immunologically naïve 
mice (Mackinnon & Read 2004a).  An explanation for this was that immunity 
Chapter 1 – General introduction        24 
selected for more virulent genotypes which were less well controlled.  In another 
study, which did not involve serial passage, a more virulent P. chabaudi genotype 
was less well controlled during immunization of mice with the putative vaccine 
candidate AMA-1 than a less virulent genotype  (Grech et al. 2008 in prep ).  Thus, 
all of the empirical experiments described so far implied that more virulent variants 
may have a selective advantage in an immunized host. 
 
In contrast, however, competitive interactions between genetically diverse P. 
chabaudi strains were neither exacerbated nor alleviated during direct immunization 
experiments with AMA-1 or with live parasites (Grech et al. 2008).  That study 
suggested that vaccination may not drive the evolution of virulence by exacerbating 
within host competition.   
 
Thus, prior to this thesis, it was unclear which of the parasite fitness benefits 
associated with virulence (increased transmission, reduced immune clearance or 
competition) might allow more virulent strains to have a disproportionate advantage 
in immunized hosts.  This thesis has aimed to expand on the previous studies from 
our laboratory in an attempt to clarify whether any of the parasite benefits associated 
with virulence influence selection imposed by vaccination with AMA-1.  A strong 
grasp of these concepts could prove important in the design of future malaria 
vaccines. 
 
1.5. Concepts and terminology 
 
Throughout my PhD I attended and presented at various conferences and gave 
departmental seminars.  I became increasingly aware of how sensitive people can be 
to the use of terminology to describe certain processes of my research project.  I use 
the following definitions of these apparently controversial terms. 
 
First, I will define the terms isolate, genotype and line in the context of P. chabaudi, 
the rodent malaria model I use in the experiments of this thesis.  I define an isolate as 
a sample of parasites collected from wild-caught thicket rats (Thamnomys rutilans) 
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on a unique occasion.  An isolate may contain more than one species of Plasmodium, 
and more than one genotype of a given Plasmodium species.  I define a clonal 
genotype as an infection derived in the laboratory from the asexual blood form of a 
single haploid P. chabaudi parasite.  I define a line as parasites which have 
undergone a particular treatment (for instance passage through immunized mice).  
Parasites in a line usually have certain characteristics in common, but are not 
necessarily genetically identical.  
 
Second, I use the terms immunization and vaccination interchangeably.  Essentially I 
am describing the process by which immunity is induced.  This may be by directly 
administering an adjuvant together with an antigen that is derived from or similar to 
the infecting agent.  The response following vaccination will be termed vaccine-
induced immunity, which will have consequences for both host and infecting agent. 
 
Third, immunization is administered with the aim of generating protective responses.  
In the literature, the definition of a positive protective response is very much system 
specific.  For example, immunologists often equate a positive response to be the 
generation of antibodies to the immunizing antigen or successful passive transfer of 
antibodies from one individual to another (often measured in vitro using techniques 
such as ELISA), even though there is no evidence that hosts were protected against 
anything.  Protection can be directed measured as alleviation of host disease 
symptoms or as a reduction in the number of infecting pathogens.  To measure 
whether immunization had induced host responses I measured three parameters: 
antibody levels, protection from disease, and protection from P. chabaudi parasite 
density.  Antibodies to the immunizing antigen were measured in serum by ELISA .  
I used protection from weight loss and/or red blood cell loss as indicators of 
protection from disease.  Protection from parasite density was measured by 
quantifying the total number of parasites in a host using either real time qPCR or 
counting blood smears.   
 
Fourth, throughout my thesis I will often refer to protective responses against malaria 
infection being strain/strain-specific.  A strain-specific response is one which is 
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effective in protecting individuals against malarial infection with parasites of the 
same (homologous) strain that induced the response, but is often less effective 
against challenge infection with parasites of a different (heterologous) strain (Mendis 
et al. 1991; Anders et al. 1998; Martinelli et al. 2005; Cheesman et al. 2006).   
 
Fifth, this thesis is concerned with how vaccination may drive evolutionary change in 
a pathogen population.  One of these changes may involve pathogen virulence.  
Virulence is a term that can be used to describe the ability of any agent of infection 
to produce disease (defined in turn as harm to host).  In this thesis, virulence is 
measured by the number of asexual P.  chabaudi parasites, and by the degree of 
weight and red blood cell loss in mice during an infection.   
 
Sixth, there have been a number of studies which have begun to look at the selective 
forces within a host which could lead to the evolution of virulence.  For instance, 
where mixed infections are common, natural selection is expected to favour higher 
levels of parasite virulence if virulent strains have a competitive advantage, as they 
do in P. chabaudi (de Roode et al. 2003; de Roode et al. 2005a; de Roode et al. 
2005b; Bell et al. 2006).  In my thesis I discuss within-host selection in the context of 
changes in strain (strain) frequency following immune modulation.  Competition is 
one source of within host selection that could cause changes in frequency.  Changes 
in frequency could also occur even if co-infecting strains are not competing i.e. are 
not affected by the presence of another strain.  For instance changes in frequency will 
occur if one strain performs better in an immunized host. 
 
Finally, the choice of terminology to describe variants that are favoured in vaccinated 
hosts has caused the most complaint at meetings I have attended.  For example, the 
terms ‘vaccine-escape’ or ‘vaccine-resistant’ variants capture the essential concept, 
but seem to mean different things to different people.  ‘Escape’ and resistance’ are 
used by many in the biomedical community to mean the special case of mutations at 
protective epitopes.  For example, vaccine escape of HBV mutants has been found to 
be due to mutations in the hepatitis B surface antigen (HBsAg) (Zanetti et al. 1988; 
Lee et al. 1991; Torresi 2002; Coleman 2006; Gibb et al. 2007).  As I have described 
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above, epitope alterations are only one form of vaccine adaptation.  Throughout this 
thesis I have tried to use the term which captures the form of adaptation that has 
occurred for a particular pathogen.  Essentially all that matters is that these epitope or 
virulence variants are selectively favoured by vaccination.  This may mean they are 
better able to invade/infect/penetrate the defences of a vaccinated host, or that once 
inside the immunized host, they have a higher per day transmission rate, or that they 
are cleared less quickly by the immune system than are wild type strains (Read & 
Mackinnon 2008). 
 
1.6. Thesis arrangement 
 
Each chapter in my thesis has been written up as a free-standing paper, therefore 
each has their own abstract, introduction and discussion.  This inevitably means there 
is some repetition, particularly of methods and rationale.  However, with this style I 
hope that any repetitiveness is off-set by the conceptual clarity that comes from 
papers.  It also reflects the modern reality that science has to be reported in papers.  
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Apical membrane antigen 1 (AMA-1) is a promising malaria vaccine candidate.  
Polymorphisms in this antigen are of concern to vaccine developers as these are 
thought to play a major role in vaccine-induced strain (genotype)-specific immunity.  
However, protection against malaria may not just depend on polymorphisms in the 
target antigen of vaccination, but on other genetically-encoded parasite traits, some 
of which may involve virulence.  In this study AMA-1 derived from two separate 
Plasmodium chabaudi genotypes was used to immunize laboratory mice, and 
reciprocal parasite challenge trials were performed.  These two genotypes had 
previously been shown to differ in AMA-1 sequence and in virulence.  Thus, the aim 
of the study was to determine whether immunization induced protection that was 
strain-specific, and/or whether the more virulent genotype was less well controlled.   
I found vaccination with AMA-1 reduced parasites in a strain-specific manner, but 
that the affect was asymmetrical, with the virulent genotype being better controlled.  
In addition, we found that immunization did not protect against anaemia with the less 
virulence genotype, but immunization with either antigen reduced anaemia induced 
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by the virulent genotype.  My results provide no support for the hypothesis that 
virulent genotypes may be harder to control by vaccination.  The most appropriate 
method to reduce inadvertent selection via strain-specific immunity may be to 
include more than one antigen allele in vaccine preparations.  I further suggest that 
measurements of disease as well as the parasitological status of the host should be 





The genetic diversity of the Plasmodium genome appears to be a major reason that 
those people living in areas where malaria is endemic often require repeated 
exposure to generate an effective immune response (Ferreira et al. 2004).  A number 
of animal and human studies suggest that immunity against malaria is strain 
(genotype)-specific: effective immunity to one strain of a given malaria parasite does 
not imply immunity to other distantly related strains (Jeffery 1966; Cardigan & 
Chaicumpa 1969; Powell et al. 1972; Jarra & Brown 1989; Crewther et al. 1996; 
Jones et al. 2000; Martinelli et al. 2005; Cheesman et al. 2006).  Strain-specific 
immunity is of particular concern to malaria vaccine developers as most vaccine-
candidate antigens are highly polymorphic surface proteins (Tanabe et al. 1987; 
Mendis et al. 1991; Miller et al. 1993; Thomas et al. 1994; Marshall et al. 1996).  
Thus, a vaccine which does not match all or most of the local variants at a testing site 
may be ineffective (Richie & Saul 2002; Saul 2007). 
 
However, malaria parasites have other genetically-encoded traits upon which 
selection may act, and some of these may involve virulence (parasite-induced host 
harm) (Frank 1996; Mackinnon & Read 1999a; Mackinnon & Read 1999b).  
Classical models of parasite virulence describe that in order to maximize fitness, a 
parasite should optimize the costs and benefits of virulence (Frank 1996; Dieckman 
et al. 2002).  A considerable body of theory now predicts that natural immunity, or 
mechanisms which act to enhance it such as vaccination, are likely to alter the costs 
and benefits of parasite virulence (Gandon et al. 2001; Gandon & Day 2003; van 
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Boven et al. 2005; André & Gandon 2006; Restif & Grenfell 2006; Gandon & Day 
2007; Mackinnon et al. 2008; Read & Mackinnon 2008; Williams & Day 2008).  
Experimental evidence has started to appear in support of vaccine-driven evolution.  
First, under controlled laboratory conditions, a clonal genotype of the rodent malaria 
P. chabaudi evolved virulence more rapidly when serially-passaged through whole-
parasite immunized mice than when passed through non-immunized mice 
(Mackinnon & Read 2004a).  An implication of that study was that more virulent 
genotypes in the derived lines had a selective advantage in an immunized host.  
Second, in another study which did not involve serial passage, a more virulent P. 
chabaudi genotype was less well controlled than those genotypes of lesser virulence 
during infection of mice immunized with a rodent analogue of the malaria vaccine 
candidate Apical Membrane Antigen 1 (AMA-1)  (Grech et al. 2008 in prep).  More 
virulent genotypes may have a selective advantage if they can replicate more rapidly 
or can sustain higher densities for longer, making them relatively less vulnerable to 
any given concentration of immune effectors (Mackinnon & Read 1999; Chotivanich 
et al. 2000; Deans et al. 2006). 
 
Thus vaccine-imposed selection could arise because of strain-specific immunity, 
because of virulence differences, or a combination of both process, if for instance, 
virulence determinants are also targets of strain-specific responses.  In one field trial 
of a malaria vaccine known as “Combination B” in Papua New Guinea, it was 
unclear whether vaccination had imposed selection that was strain-specific, or 
whether the vaccine was less able to control more virulent strains (Genton et al. 
2002; Genton et al. 2003; Fluck et al. 2004; Fluck et al. 2007).  The vaccine 
consisted of three recombinant blood-stage proteins, merozoite surface protein 1 
(MSP-1), MSP-2, and ring-infected erythrocyte surface antigen (RESA).  The MSP-2 
antigen is known to be highly polymorphic and the different msp-2 alleles can be 
grouped into two families, FC27 and 3D7 (Smythe et al. 1990).  Despite the FC27 
type previously being known to cause more virulent infections (Engelbrecht et al. 
1995), the 3D7 type was included in the vaccine formulation.  Among parasites 
subsequently acquired by vaccinees, 3D7-type alleles were rarer than in people given 
a placebo whereas the prevalence of the FC27 form was unaltered (Genton et al. 
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2003).  Thus, vaccination selected against the variant contained in the vaccine.  This 
could have been because of strain-specific immunity, or because the virulent form, 
FC27, was less successfully controlled by vaccine-induced immunity. 
 
In this study I aimed to investigate whether vaccination with AMA-1, is more likely 
to select for parasites in a strain-specific manner, or whether other parasite traits, 
which may involve virulence determinants at other antigenic loci, allow those more 
virulent strains to have a selective advantage in an immunized host.  AMA-1 is a 
merozoite protein and is thought to be essential for erythrocyte invasion (Triglia et 
al. 2000; Carvalho et al. 2002; Ballou et al. 2004; Mitchell et al. 2004; Cortes et al. 
2005; Greenwood 2005).  Immunization with AMA-1 confers protection against 
parasite challenge in a number of animal models (Deans et al. 1988; Collins et al. 
1994; Crewther et al. 1996; Anders et al. 1998; Narum et al. 2000; Stowers et al. 
2002; Healer et al. 2004).  Antibodies from the immune sera of animals and humans 
immunized with AMA-1, as well as sera from those people who live in areas where 
malaria is endemic, can prevent erythrocyte invasion in vitro (Thomas et al. 1994; 
Hodder et al. 2001; Kocken et al. 2002; Johnson et al. 2004; Polley et al. 2004; 
Cortes et al. 2005; Rodrigues et al. 2005).  In laboratory mice, the availability of 
genotypically distinct P. chabaudi genotypes has previously provided an 
experimental system for examining the impact of genetic diversity on the efficacy of 
AMA-1 vaccination (Marshall et al. 1989; Crewther et al. 1996; Anders et al. 1998).  
The nucleotide sequence of P. chabaudi AMA-1 (PcAMA-1) genotype DS differs 
from genotype DK (556KA) by 79 amino acids (Marshall et al. 1989; Crewther et al. 
1996).  Immunization of mice with the refolded ectodomain of DS AMA-1 or with 
rabbit antibodies raised against the same antigen have been shown to induce 
responses which are ineffectual against challenge with the heterologous DK 
genotype (Crewther et al. 1996). Interestingly, these genotypes are also known to 
differ in virulence; genotype DS achieves a higher number of total parasites across an 
infection compared to DK.  Because reciprocal trials to test whether the more 
virulent DS strain is less affected by DK AMA-1 immunization have not been 
performed, it is not possible to say whether DK vaccine breakthrough is due to 
antigenic differences or to virulence differences, or both.   
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Here experimental mice were immunized with AMA-1 derived from either P. 
chabaudi strain DS or DK and then infected with either one of the strains.    The aim 
of the study was to test whether AMA-1 induced selection that was strain-specific, or 
whether the more virulent DS genotype had a selective advantage and was thus less 
affected by heterologous immunization compared to the less virulent DK genotype.   
 
 
2.3. Material and Methods 
 
2.3.1   Parasites and hosts 
 
Isolates containing P. chabaudi adami were originally collected from wild-caught 
thicket rats (Thamnomys rutilans) in the Congo (Brazaville) (Carter and Walliker 
1976).  Isolates were cloned, genotyped and stored in liquid nitrogen with subscript 
codes used to locate their position in clonal history.  In this experiment we used P. c. 
adami genotype DS218 and DK112 originally genotyped from isolates 408XZ and 
556KA respectively.     Hosts were inbred female C57BL/6J mice aged six to eight 
weeks fed on 41B maintenance diet (Harlan, UK).  Their drinking water was 
supplemented with 0.05% para-amino benzoic acid to enhance parasite growth 
(Jacobs 1964) and they were kept in a 12L:12D cycle.  
 
2.3.2. Immunizations, parasite challenge and sampling  
 
Two experiments were performed (Table 2.1).  Immunization protocols followed 
those of Anders et al. (1998) and Crewther et al. (1996).  In the first, immunization 
was with the highly immunogenic ectodomain of the full AMA-1 protein derived 
from either parasite genotype DS or DK.  The AMA-1B ectodomain was expressed 
and purified from E. coli constructs as described elsewhere (Anders et al. 1998).  In 
the second experiment, immunization was via the passive transfer passive of 
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hyperimmune sera from rabbits which had previously been immunized with AMA-
1B derived from parasite genotype DS or DK. 
 
 
Clone DK infection   
  
DS infection 
Experiment Control DK AMA-1 DS AMA-1 Control DK AMA-1 DS AMA-1 
Experiment one 5 5 5 5 6 6 
Experiment two 4 4 4 4[1] 4 4 
 
 
Table 2.1. Experimental design.  In experiment one, mice were immunized with 
recombinant AMA-1 antigen emulsified in Montanide ISA 720 (10 µg/100 µl) or with a 
control emulsion of PBS and Montainide (100 µl).  Boost immunizations occurred 4 weeks 
after the primary immunization and two weeks prior to parasite challenge with either 
genotype (clone) DS or DK.  In experiment two, mice were immunized with three 
milligrams of purified anti-DK AMA-1 or anti-DS AMA-1 IgG from the sera of immune 
rabbits one day before parasite infection and again 3 hours before parasite infection.   
Control mice were injected with a sham inoculation of rabbit serum of the same isotype.  
Figures show the number of mice in each treatment group.  In experiment two one mouse 
died as indicated by the number in brackets. 
 
In experiment one, mice were randomized into three treatment groups.   Injections 
were performed intra-peritoneally with 10 µg of either DS AMA-1 or DK AMA-1 
antigen emulsified in 100 µl of the adjuvant Montanide ISA 720 (Seppic, Paris, 
France).   Control mice were injected with a sham inoculation which was an 
emulsion of 100µl PBS in the same concentration of Montanide ISA 720.  Boost 
immunisations were conducted 4 weeks after the primary immunisation.  Two weeks 
after the boost immunization, mice within each of the three treatment groups were 
randomized into two groups and infected intra-peritoneally with 105 parasites of 
genotype DS or DK.   
 
In experiment two, rabbits were immunized with refolded AMA-1B derived from 
parasite genotype DS or DK emulsified in Montanide ISA 720.  For the primary 
immunizations, rabbits received a total of 100-200 µg of emulsified antigen between 
two intra-muscular sites.  Rabbits were boosted at 4-8 week intervals with the same 
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amount of antigen injected intra-muscularly and subcutaneously.  Immunoglobulin G 
(IgG) was isolated from the sera of rabbits by affinity chromatography on protein A-
Sepharose columns (Pharmacia/Amrad).  Prior to immunization, experimental mice 
were randomized into three treatment groups.  For passive transfer to mice, three 
milligrams of purified anti-DK AMA-1 or anti-DS AMA-1 IgG was administered 
intra-peritoneally one day before parasite infection and again 3 hours before parasite 
infection.   Control mice were injected with a sham inoculation of rabbit antibody of 
the same isotype (IgG Sigma I5006).  Before parasite challenge, mice within each of 
the three treatment groups were randomized into two groups and infected intra-
peritoneally with 105 parasites of genotype DS or DK.   
 
I followed the infection dynamics for 29 days.  As of the first day of parasite 
infection (day 0), I daily measured body weights and took blood samples from the 
tail of experimental mice to estimate RBC density (by flow cytometry; Beckman 
Coulter).  As of day 4 post-parasite infection onwards, I took daily blood samples 
from the tail to make Giemsa-stained blood smears for estimating daily parasite 
densities.  I chose day 4 as this is around the first day that parasites can be detected in 
the blood using microscopy.  Since P. chabaudi has a 24 hour replication cycle, the 
total number of parasites in any period can be estimated by summing the daily 
parasite counts.   
 
2.3.3. Isotype ELISA 
 
In the first experiment, three days prior to parasite challenge, ELISA assays were 
used to check that antigen immunizations had generated an antibody response.  All 
mice were assayed for both anti-DS AMA-1 and anti-DK AMA-1 total IgG and 
IgG2b antibodies.  I used IgG2b as previous work in my laboratory showed that 
C57BL/6 produce this allotype in response to P. chabaudi infection (K. Grocock, A. 
Graham unpublished).  Protection induced by immunisation with recombinant AMA-
1 in C57 mice is isotype independent (Burns et al. 2004).  Serum fractions were 
separated by centrifugation from 20 µl of blood samples taken from the tail and 
stored at -80oC.  High binding 96 well ELISA maxisorb immunoplates (Nunc) were 
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coated with either DS AMA-1 or DK AMA-1 at a concentration of 1µg/ml in 0.06M 
carbonate buffer (0.04M NaHCO3, 0.02M NaCO3, pH 9.6) in a final volume of 50 µl 
per well. Plates were stored at 4oC overnight to allow the antigen to bind.  Non-
specific binding was blocked by incubating wells with 5% BSA: carbonate buffer 
(200 µl/well) for 2 hours at 37oC.  Wells were then washed three times in Tris-
buffered saline with 0.01% Tween (TBST).  Serum samples were detected in a serial 
dilution 1/100-1/204800 using TBST as a diluent, in a final volume of 50 µl per well 
and incubated for 2 hours at 37oC.  Wells were washed three times in TBST.  HRP 
conjugated goat anti-mouse IgG2b detection antibody (Southern Biotech 1100-05) 
was diluted 1/4000 in TBST to a final volume of 50 ul per well.  Plates were 
incubated for 1 hour at 37oC.  Wells were washed three times in TBST followed by a 
final wash in distilled water.  ABTS peroxide substrate (Insight biotechnology) was 
added at 100 µl per well and allowed to develop at room temperature for 20 minutes.  
Optical density was read at 405 nm using a spectrophotometer.  IgG2b isotype 
antibody titres were calculated as the reciprocal of the greatest dilution at which 
optical density (O.D.) was greater than the mean (plus 2 standard deviations) O.D 
values observed for naïve mouse sera assayed against both DS and DK AMA-1 at 
1/100 dilutions. 
 
2.3.4. Trait definition and statistical analyses 
 
In the first experiment, prior to parasite challenge, anti-DS AMA-1 and anti-DK 
AMA-1 total IgG and IgG2b antibodies were measured in mouse sera from all 32 
mice giving a total of 64 measurements.  Since P. chabaudi has a 24 hour replication 
cycle, the total number of parasites in any period can be estimated by summing the 
daily parasite counts.  Mice infected with genotype DK actually gained weight so 
weight loss was not a suitable measure of virulence.  All other data were analysed 
using General Linear Models (GLMs) in MINITAB (Minitab, version 14).  To meet 
normality and homogeneity of variance assumptions, data on antibodies and red 
blood cell density were log transformed while all parasite densities were square route 
transformed. GLMs were used to test whether the magnitude of protection differed 
between the antigen immunizations (DK AMA-1 or DS AMA-1); that is whether 
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there was a statistical interaction between infecting genotype and immunizing 
treatments.  Maximal models (response variable = infecting genotype + immunizing 
treatment + infecting genotype x immunization treatment) were tested in the first 
instance, and minimal models were obtained by dropping non-significant terms 
successively, beginning with highest order interactions, to obtain the significant 
minimal model.  In experiment two one mouse died; this mouse was included in the 
calculation of daily densities until death, since death occurred as initial parasiteamias 
were declining.   
 
2.4.  Results 
 
Table 1 gives details of the two experiments, including sample sizes.   
 
2.4.1. Pre- parasite infection antibody titres  
 
In experiment one, anti-DS AMA-1 and anti-DK AMA-1 IgG and IgG2b antibodies 
were measured in mouse sera to ensure our antigen immunization successfully 
generated antibody responses.  Anti-DK and anti-DS AMA-1 total IgG and IgG2b 
antibody titres were higher in antigen-immunized mice than in sham-immunized 
controls (Fig. 2.1A; total IgG sham-immunized versus antigen immunized: 
F1,62=68.72, p=<0.001; Fig 2.1B; IgG2b sham-immunized versus antigen immunized: 
F1,62=8.92, p=0.004).  Among antigen immunised mice only, immunization with DS 
AMA-1 induced higher total IgG titres than immunization with DK AMA-1 on both 
DS and DK AMA-1 coated ELISA plates (Fig. 2.1C; immunization: F1,41=23.03, 
p=<0.001; immunizing treatment x ELISA antigen: F1,40=1.18, p=0.28).  Conversely, 
IgG2b antibodies were specific for the antigen they had been exposed to during 
immunization (Fig. 2.1D; immunizing treatment x ELISA antigen: F1,40=9.99, 
p=0.003).  For example, anti-DS AMA-1 IgG2b antibody tires were higher when 
assayed against the homologous DS antigen than the heterologous DK antigen and 
vice versa.  Among antigen-immunized mice, antibody titres (total IgG or IgG2b) 
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were not predictive of protection from either parasite density or disease (data not 
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Figure 2.1.  Total IgG or IgG2b antibody levels from the serum of experiment one mice.  In 
A and B, each of the treatments used to immunize mice (sham-inoculated control, DS AMA-
1 or  DK AMA-1) and the AMA-1 test antigen used to coat ELISA plates are shown on the x 
axis.  Each dot represents the antibody titre against a particular immunizing antigen.    
Horizontal lines indicate the mean antibody levels.  Total IgG and IgG2b antibody levels in 
antigen immunized groups of mice were higher than in sham inoculated controls (p=<0.001, 
p=0.004 respectively).  In C and D, each line represents the least means square of the 
immunizing antigen x ELISA antigen interaction with the associated standard error.  Open 
squares represent immunization with DS AMA-1 and open triangles represent immunization 
with DK AMA-1 
 
Chapter 2- Differences at the target locus 38
 
 
2.4.2. Genotype differences 
 
Considering sham-immunized control infections only, genotype DS achieved higher 
total parasite densities than did DK (Fig. 2.2; F1,14=25.40, p=<0.001).  Similarly, in 
sham-immunised mice, infection with DS induced more anaemia than did genotype 
DK (Fig. 2.3; F1,15=14.80, p=0.002).  These genotype differences in performance and 
virulence did not differ between the two experiments (infecting genotype x 
experiment: F1,14=0.02, p=0.88 and F1,14=0.67, p=0.43 respectively).  Thus, as 
reported previously (Crewther et al. 1996), DS was indeed the more virulent of the 
two genotypes. 
2.4.3. Protective effects of vaccination on parasite density 
 
The level of anti-parasite protection depended on the infecting genotype and the type 
of immunization (Fig. 2.2; immunizing treatment x infecting genotype: F2,46=7.02, 
p=0.002), but in a similar way for antigen immunization and passive transfer of 
hyperimmune sera (immunizing treatment x infecting genotype x experiment: 
F2,44=1.13, p=0.33). Visual inspection of Fig. 2.2 shows two things: (i) DK, the less 
virulent genotype, is less well controlled by immunization, having achieved similar 
parasite densities in the face of heterologous immunization as it did in the absence of 
immunization.  In contrast DS, the more virulent genotype, is reduced by both types 
of immunization. (ii)  Immunization with DS AMA-1 only generated homologous 
protection, whereas DK AMA-1 induced homologous and heterologous protection.  
Together, these results show that protection was asymmetrically strain-specific, and 
that the less virulent genotype was less well controlled by heterologous 
immunization. 
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Figure 2.2. Parasite genotype density kinetics for experiment one (left panels) and 
experiment two (right panels).  Each line represents the mean of up to 6 mice (+/- 1 s.e.m.) 
during infection with genotype DK (A,C) or genotype DS (B,D) under either sham 
inoculated control (solid black line), DK AMA-1 (open triangles) or DS AMA-1 (open 
squares).  Figure 2E illustrates the total parasite density interaction when the data from 
experiment one and two were combined.  Each bar represents the least squares mean of up to 
6 mice (+/- 1 s.e.m) during infection with genotype DK (grey bars) or genotype DS (black 
bars). 




















































































































































































Figure 2.3. Effect of Plasmodium chabaudi infecting genotype and immunization treatment 
on red blood cell densities for experiment one (left panels) and experiment two (right 
panels).  Each line represents the mean of up to 6 mice (+/- 1 s.e.m.) during infection with 
genotype DK (A,C) or genotype DS (B,D) under either sham inoculated control (solid black 
line), DK AMA-1 (open triangles) or DS AMA-1 (open squares).  Figure 3E illustrates the 
maximum change in red blood cell loss interaction when the data from experiment one and 
two were combined.  Each bar represents the least squares mean of up to 6 mice (+/- 1 s.e.m) 
during infection with genotype DK (grey bars) or genotype DS (black bars). 
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2.4.4. Protective effects of vaccination on virulence 
 
Protection from anaemia depended on the immunization and the infecting genotype 
(Fig 2.3; immunization x infecting genotype: F2,46=4.70, p=0.014), and similarly for 
antigen immunization and passive transfer of hyperimmune sera (immunizing 
treatment x infecting genotype x experimental block: F2,44=1.72, p=0.19).  Visual 
inspection of Fig. 2.3 reveals no significant difference in red blood cell losses 
between control and immunized mice infected with DK (Fig. 2.3A,C,E; 
Immunization: F2,24=1.43, p=0.26).  Immunization protected against anaemia during 
infection with genotype DS (Fig. 2.3B,D,E; Immunized versus sham: F1,27=5.08 
p=0.003) with the magnitude of protection being similar under DS or DK AMA-1 
(DS AMA-1 versus DK AMA-1: F1,18=1.79 p=0.19).  Thus, as with the parasite data, 
protection from anaemia due to infection with genotype DS was similarly generated 








The aim of this study was to determine in vivo whether a more virulent P. chabaudi 
genotype (DS) was less well controlled by heterologous immunization than a less 
virulent genotype (DK).  Thus, I was testing whether more virulent parasites have a 
selective advantage in an immunized host or whether vaccine efficacy depended on 
strain-specific differences at the target locus.  I found that anti-parasitic protection 
was asymmetrically strain-specific, but it was the less virulent genotype that was less 
well controlled by heterologous immunization (Fig. 2.2).  In terms of protection from 
anaemia, both antigens were equally protective during infection with the virulent 
genotype (Fig. 2.3).  My results were comparable for direct antigen immunization or 
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via the passive transfer of hyperimmune rabbit serum, and consistent with previous 
studies which have shown that immunization with DS AMA-1 failed to protect 
against heterologous challenge (Crewther et al. 1996).  Thus, vaccine efficacy may 
depend on differences at a target locus, but a single antigen immunization need not 
always induce protection that is strain-specific.  The potency of a vaccine may be 
increased by surveillance for the most common or most cross-reactive allelic variants 
at a vaccine testing site. 
 
Do my results here go any way to explaining the selection observed in the field trial 
of the ‘Combination B’ malaria vaccine (Genton et al. 2002; Genton et al. 2003)? In 
that trial it was implied that strain-specific selection had resulted as representatives 
from both MSP-2 allelic families had not been included in the formulation (Fluck et 
al. 2004; Fluck et al. 2007).  However, since the FC27 allelic family, which was not 
included in the vaccine and was subsequently unaffected, had previously been 
associated with more morbid infections (Engelbrecht et al. 1995), it was also possible 
that the vaccine was just less effective at protecting against more virulent variants 
(Mackinnon & Read 2004a; Mackinnon et al. 2008; Read & Mackinnon 2008).  My 
results go against those latter arguments that a more virulent variant may be less well 
controlled, and that strain-specificity may result from not including a number of 
allelic variants, or from choosing a variant which induces less cross-strain protection.   
 
The results from my study apparently contradict those experiments by Mackinnon et 
al. (2004a), which suggested virulent variants may have a selective advantage in an 
immunized host.  An explanation for the discrepancy between the two studies could 
be that that accelerated evolution of virulence as previously reported may be a 
feature only seen during serial passage of a single P. chabaudi genotype through 
whole-parasite immunized hosts.  In the results presented here, which did not involve 
serial passage, we saw no evidence that a virulent genotype is more likely to be 
selected.  In order to resolve these discrepancies in future experiments I will evolve 
P. chabaudi through AMA-1 immunized hosts (See Chapter 8.4 Future directions).   
 
It is clear from my results that the two different antigens were not equally protective.   
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DK AMA-1 induced anti-parasitic protection that was asymmetrical, and was equally 
protective as DS AMA-1 at protecting against anaemia during DS infection.  On the 
other hand, DS AMA-1 only generated protection against homologous parasite 
infection.  The cross-strain protection I observed here could be explained by the 
ability of some inhibitory antibodies raised under DK AMA-1 vaccination able to 
recognize conserved epitopes in the heterologous genotype, or  by cross-reacting 
with other P. chabaudi antigens, or AMA-1 like sequences, in natural protein 
complexes (Hodder et al. 2001).  In this experiment I also measured antibodies in 
vitro purely as an indicator that a response had been generated against the 
immunizing antigen (Fig. 2.1).  However, I did note that total IgG was cross-
genotype reactive, while IgG2b was predominantly genotype-specific, recognizing 
the antigen that it had been exposed to during immunization.  However, since the 
precise antibody isotypes induced by AMA-1 immunization that are required for 
parasite clearance are still unclear (Burns et al. 2004), we do not draw anything 
conclusive from these results.     
 
As observed in this study and as attributed previously by others (Crewther et al. 
1996; Healer et al. 2004), immunization with DS AMA-1 induced protection that 
was strain-specific.  To the best of my knowledge, there are no reports that variants 
of AMA-1 have different intrinsic virulence, so that any strain-specific immunity 
induced by including just one antigen, should not directly alter virulence.  However, 
caution should be taken when vaccines contain antigens involved in pathogenesis e.g. 
red cell invasion, as these could be inadvertently linked to virulence.  Population-
wide surveillance for the most common allelic variants at a vaccine testing site may 
reduce the chance of selection.  Another approach has been to design vaccines which 
combine more than one allele of an antigen (Hoffmann & Miller 1996; Bolad & 
Berzins 2000; Richie & Saul 2002; Polley et al. 2007).  For example, one group 
immunised rhesus monkeys with a mixture of two allelic forms of PfAMA-1 
designated AMA1-C1, or the component alleles and measured responses in vitro 
using growth inhibition assays (GIA) and ELISA (Kennedy et al. 2002; Malkin et al. 
2005; Miura et al. 2007a).  However, antibodies were similarly effective regardless 
of whether immunization was with a single variant or AMA1-C1.  Thus, questions 
Chapter 2- Differences at the target locus 44
had been raised to the necessity of using multi-allele vaccines [Chapter 4, Appendix 
1   (Barclay et al. 2008b )].  
 
Here I found DK AMA-1 was the most effective vaccine at inducing both cross-
strain protection from parasites and disease, and reducing homologous parasite 
densities.  In spite of this it was ineffective at alleviating host disease during 
homologous challenge.  Thus, my results highlight the importance of considering 
measurements of disease as well as the parasitological status of the host during 
vaccine efficacy studies.    
 
In conclusion, I found that vaccination with AMA-1 reduced parasites in a strain-
specific manner, but that the effect was asymmetrical, with the virulent genotype 
being better controlled.  Thus, my results provide no support for the hypothesis that 
virulent variants may be harder to control, and more strongly support the hypothesis 
that vaccine efficacy may depend on strain-specific differences at a target locus.  
However, since a number of blood-stage vaccine antigens are involved in 
pathogenesis, one of the safest ways to avoid inadvertent selection may be to include 
all known variants of a locus in vaccine formulations.   So far, in vitro studies by 
others have indicated that the inclusion of more than one allelic form of an antigen 
may not increase vaccine potency (Kennedy et al. 2002; Malkin et al. 2005; Miura et 
al. 2007b; Lalitha et al. 2008).  As the results presented here highlight the importance 
of measuring host disease as well as parasitological status of the host, in future 
experiments I plan to investigate in vivo any benefits of including more than one 
antigen allele in vaccine formulations  [ Chapter 4,  Appendix 1  (Barclay et al. 
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Vaccines against malaria have the potential to impose selection in a number of ways.  
Selection for non-vaccine strains is expected to occur if vaccination induces 
protective immune responses that are strain-specific.  However, malaria parasites 
also differ in virulence (parasite-induced host damage). Where virulence is (for 
instance) associated with immunosuppression, or immunoevasion, more virulent 
genotypes may have a selective advantage over less virulent genotypes in an 
immunized host.  In this study I tested whether more virulent P. chabaudi parasites 
had a selective advantage during immunization with the malaria vaccine candidate 
Apical Membrane Antigen 1 (AMA-1).  I found no selective advantage to virulence: 
vaccination reduced those parasites which were most similar to the vaccine target to 
a greater extent than those that were different.  My results apparently contradict 
previous studies which have suggested that there is a within-host advantage to 
Chapter 3-Virulence or sequence diversity 47
virulence.  Selection imposed by vaccination is likely to depend on the fine 




Much of our current knowledge on Plasmodium genetic variability comes from 
molecular studies of proteins which are putative malaria vaccine candidates.  The 
genes for merozoite stage vaccine antigens are known to be highly polymorphic 
(Escalante et al. 1998; Mahajan et al. 2005) such that antibodies raised to one form of 
the protein bind less efficiently to heterologous forms present in other genotypes 
(strain-specific immunity) (Richie & Saul 2002; McKenzie et al. 2008).  
Polymorphisms are of particular concern to vaccine developers as the success of a 
particular vaccine may depend on the genetic relatedness to the vaccine strain at 
individual target sites (Richie & Saul 2002).   
 
However, malaria parasites also differ in virulence (here defined as parasite-induced 
host harm) (Frank 1996; Mackinnon & Read 1999a).  Studies in P. chabaudi have 
demonstrated that the variation in virulence observed during infection of laboratory 
mice are likely to be due to differences in a number of genetically-encoded parasite 
traits (Taylor & Read 1998; Mackinnon & Read 1999a; Mackinnon & Read 1999b; 
de Roode et al. 2005b; Bell et al. 2006).  In the field, different ‘strains’ of the human 
malaria P. falciparum are thought to be responsible for differences in disease severity 
(Deans et al. 2006).  In theory, these genetically-encoded traits may allow more 
virulent strains to have a selective advantage in an immunized host, when virulence 
is for instance associated with immunosuppression, or immunoevasion, (Gandon et 
al. 2001; Mackinnon & Read 2004a; Mackinnon & Read 2004b; Mackinnon et al. 
2008).   
   
The trial of the malaria vaccine known as ‘Combination B’ in Papua New Guinea 
provided the first field evidence that a vaccine against this disease could exert 
selective pressure (Genton et al. 2002).  This vaccine contained a single antigen from 
each of three polymorphic loci of P. falciparum.  One of these loci, Merozoite 
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Surface Protein 2 (MSP-2), is dimorphic, with each parasite having an allele from 
one of two allelic families (labelled 3D7 and FC27).  The MSP-2 allele in the 
Combination B vaccine came from the 3D7 family.  Among parasites subsequently 
acquired by vaccinees, 3D7-type alleles were rarer than in people given a placebo, 
thus, vaccination selected against the variant contained in the vaccine.  Interestingly, 
the FC27 allelic family is associated with more virulent infections (Engelbrecht et al. 
1995).  Thus, what was not clear from this field trial was whether the vaccine 
imposed selection that was strain-specific (Fluck et al. 2004; Fluck et al. 2007) or 
whether more virulent parasites were less well controlled because they had a 
selective advantage. 
 
More virulent genotypes could have a selective advantage in an immunized host by 
utilizing a number of advantages associated with virulence.  For instance, during 
infection of naïve hosts, more virulent P. chabaudi genotypes transmit more 
successfully, are less rapidly cleared by the host, and have an advantage in 
competition over less virulent genotypes (Mackinnon & Read 1999a; de Roode et al. 
2005b; Bell et al. 2006; Mackinnon et al. 2008; Read & Mackinnon 2008).  In 
theory, one or more of those virulence benefits may also accrue or even be enhanced 
by vaccination.  For instance, if more virulent genotypes persist for longer as 
immunity develops in naïve mice it is likely that these strains will be less rapidly 
cleared by vaccine-induced immunity. 
 
Consistent with this, P. chabaudi serially passaged (by syringe transfer of parasites 
in blood from one host to another) through whole-parasite immunized mice became 
more virulent than parasites passaged through naïve mice, even after mosquito 
transmission (Mackinnon & Read 2004a).  In another study, which did not involve 
serial passage, more virulent P. chabaudi genotypes were less well controlled by 
immunization with the putative vaccine candidate Apical membrane Antigen-1 
(AMA-1) than were less virulent genotypes (Grech et al. 2008 in prep). 
 
However, competition experiments failed to find a within host advantage to virulence 
in mice vaccinated AMA-1 (Grech et al. 2008).  Furthermore, reciprocal 
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immunization and parasite challenge trials with AMA-1 derived from two P. 
chabaudi genotypes which differed in virulence appeared to induce protective 
responses that were asymmetrically strain-specific (Chapter 2).  In that experiment 
the more virulent DS genotype was better controlled by heterologous immunization 
than the less virulent genotype. 
 
In light of this mixed evidence, I extended the earlier experiments of Grech et al. 
(2008 in prep) to ask whether vaccination with AMA-1 is more likely to impose 
selection in a strain-specific manner or whether virulent genotypes will be less well 
controlled.  The aim of this study was to determine whether vaccination with a 
different AMA-1 antigen to the study by Grech et al. (2008 in prep) was also less 
able to control more virulent genotypes.  These results should inform current malaria 
vaccine programmes, many of which are focused on reducing strain-specificity by 
including a number of different antigens or variants of a particular antigen in vaccine 
formulations. 
 
AMA-1 is a promising vaccine candidate for human malaria as it possesses fewer 
polymorphisms that other candidate merozoite antigens (Anders & Smythe 1989; 
Hodder et al. 2001).  There are currently at least six different vaccines based on the 
AMA-1 allele from the P. falciparum 3D7 strain currently in efficacy trials in 
humans (Polhemus et al. 2007; Maher 2008; Thera et al. 2008).  However, 
polymorphic sites in the AMA-1 protein have been shown to be of immunological 
importance (Peterson et al. 1989; Marshall et al. 1996; Polley & Conway 2001; 
Polley et al. 2003; Dutta et al. 2007).  For instance, anti-AMA-1 antibodies from 
animals and human field sera inhibit parasite growth in a strain-specific manner 
(Crewther et al. 1996; Anders et al. 1998; Hodder et al. 2001; Polley et al. 2003; 
Cortes et al. 2005; Polhemus et al. 2007).  Allelic replacement experiments have 
directly implicated sequence polymorphisms in antigenic escape (Healer et al. 2004), 
and cross strain inhibition assays suggest that the extent of escape correlates with 
sequence difference between the vaccine and the target strain (Kennedy et al. 2002).  
AMA-1 polymorphism has not to my knowledge ever been associated with parasite 
virulence. 
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3.3. Materials and Methods 
 
 
3.3.1. Parasites and hosts 
 
Blood isolates were originally collected from wild-caught thicket rats (Thamnomys 
rutilans) from different geographical areas of the African continent (Carter & 
Walliker 1976; Beale et al. 1978).  P. c. chabaudi were isolated from the blood of 
rats of the Central African Republic, while P. c. adami were isolated from the blood 
of rats of the Congo (Brazzaville).  Laboratory rodents were infected with sub-
inoculations of blood and the parasites were cloned and genotyped.  Clonal 
genotypes were  stored as frozen stabilites in liquid nitrogen with subscript codes 
used to identify their position in clonal history (Beale et al. 1978; Mackinnon & Read 
1999a) 
 
In this experiment I used P. c. adami genotypes DS444 and DK217 (originally 408XZ 
and 556KA respectively) and P. c. chabaudi CB1268, BC237, AQ224, and AS12193.   
Herein these genotypes will be referred to as DS, DK, CB, BC, AQ and AS.  These 
genotypes were selected to look at the role of genetic diversity on vaccine efficacy.  
Parasite genotypes AQ, AS and BC have been shown to differ in their sequence at 
the AMA-1 locus but are known to be of similar virulence.  Parasite genotypes AS 
and CB are known to be identical at their AMA-1 locus but CB is known to be more 
virulent than AS.  Hosts were inbred female C57BL/6JolaHsd mice aged 6-8 weeks 
(Harlan England) were maintained as described previously (de Roode et al. 2004b). 
 
3.3.2. Sequence analyses of the ama-1 alleles of P. chabaudi 
 
The following ama-1 alleles were originally sequenced by Grech et al. (2008 in prep) 
and are stored in GenBank with the associated accession numbers: Genotype DK 
(EU219729), AS (EU1052842), CB (EU219733), AQ (EU219730) and BC 
(EU219732).  Primers were designed to amplify the ama-1 gene as two fragments.  
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Primer sequences for fragment 1 were: forward 5' CTTGGGTAATTGTTCCGA 3' 
and reverse 5' GGTTTCCCAATCTTCACG 3'.  Primer sequences for fragment 2 
were: forward 5' GGGTCCAAGATATGTAG 3' and reverse 5' 
TGGTGTTGTGTGTGATGC 3'.  Grech et al. (2008 in prep) derived the AS virulent 
(ASvir)  line by serial passage of the ancestral AS genotype through immuologically 
naïve mice (See Chapter 5) and sequenced parasites in the line using the above 
primers.  AMA-1 from genotype DS was amplified by PCR as two fragments. 
Primer sequences for fragment 1 were: forward 5' CTTGGGTAATTGTTCCGA 3' 
and reverse 5' GGTTTCCCAATCTTCA CG 3'.   
Primer sequences for fragment 2 were: 5' TGAGAATCAACCATTTTGTTTTA 3' 
and reverse 5' CATCTTTTCTGCTTTGGGCT 3'.   
PCR was performed using Platinum® Taq DNA polymerase (Invitrogen), with the 
thermocycle profile ; 95oC for 7mins, then 93 oC for 1 min, 52oC for 1 min and 72oC 
for 1 min (x 30 cycles) ending at 72oC for 10mins.  Sequencing was performed by 
the University of Edinburgh sequencing service. 
 
For phylogenetic analyses, two P. yoelii sequences (GenBank accession numbers 
U4597, U45971) and a single P. berghei sequence (GenBank accession number 
U45969) were chosen as outgroup taxa.   Maximum likelihood (ML) phylogenetic 
trees were inferred using PAUP* (Swofford 2003) using the best-fit transversion 
model of nucleotide substitution (TVM+I) as identified by Modeltest (Posada & 
Crandall 1998) and tree bisection-reconnection branch swapping.   The robustness of 
each node in the resultant tree was determined using a ML bootstrap re-sampling 
process incorporating the best-fit ML model with 1,000 replications.   
 
To further investigate the relationship between DS, DK and AQ, recombination 
detection analysis was conducted using the complete sequence data set.  Potential 
recombination break-points were identified using the GARD algorithm (Pond et al. 
2006) available as part of the datamonkey package (www.datamonkey.org).  An 
identified breakpoint was verified by manually breaking the sequence alignments up 
into two regions, and running ML phylogenetic trees followed by a bootstrap 
analysis (as above) on each region of the alignment separately.  
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3.3.3. Immunizations and isotype ELISA 
 
I used an immunization protocol adapted from Anders et al. (1998).  Prior to 
immunization, mice were randomized into two groups (Table 3.1).  Immunization 
was with the highly immunogenic ectodomian of the full AMA-1 protein derived 
from parasite genotype DS.  Mice were injected intraperitoneally with 10 µg of 
protein emulsified in 100 µl of the adjuvant   ISA 720 (Seppic, France).  Control 
mice were injected with 100 µl emulsion of PBS in ISA 720.  Boost immunisations 





















Table 3.1. Experimental design.  Immunization was either a sham-immunization or with DS 
AMA-1.  Groups of mice were immunized with one of the four treatments before being 
separated into groups of 5 or 6.  Infection was either with parasite genotype (clone) DS, CB, 
BC, AQ, AS or DK.  During the experiment 6 mice were found dead as indicated by the 
numbers in brackets. 
 
To ensure my antigen immunization successfully generated antibody responses, 
IgG2b antibodies in mice sera were measured 3 days prior to parasite challenge by 
ELISA using DS AMA-1 coated wells.  I measured the quantity of antigen-specific 
IgG2b antibodies since protection induced by immunisation with recombinant AMA-
1 in C57 mice is isotype independent (Burns et al. 2004) and previous work in my 
laboratory showed that C57BL/6 produce IgG2b in response to P. chabaudi infection 
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(K. Grocock, A. Graham unpublished).  Sera fractions were separated by 
centrifugation from 20 µl of blood taken from a tail snip and were stored at -80oC.  
High binding 96 well ELISA Maxisorb immunoplates (Nunc) were coated with DS 
AMA-1 at a concentration of 1µg /ml in 0.06M carbonate buffer (0.04M NaHCO3, 
0.02 M NaCO3, pH 9.6) in a final volume of 50 µl per well. Plates were stored at 4oC 
overnight to allow the antigen to bind.  Non-specific binding was blocked by 
incubating wells with 5% BSA: carbonate buffer (200 µl/well) for 2 hours at 37oC.  
Wells were then washed three times in Tris buffered saline with 0.01% Tween 20 
(TBST).  We used end-point dilution methods to detect IgG2b titres: serum samples 
were detected in a serial dilution 1/100-1/204800 using TBST as a diluent, in a final 
volume of 50 µl per well and incubated for 2 hours at 37oC.  Wells were washed 
three times in TBST.  HRP conjugated goat anti-mouse IgG2b detection antibody 
(Southern Biotech 1100-05) was diluted 1/4000 in TBST to a final volume of 50 µl 
per well.  Plates were incubated for 1 hour at 37oC.  Wells were washed three times 
in TBST followed by a final wash in distilled water.  ABTS peroxide substrate 
(Insight Biotechnology) was added at 100 µl per well and allowed to develop at room 
temperature for 20 minutes.  Optical density was read at 405nm using a 
spectrophotometer.  IgG2b isotype antibody titres were calculated as the reciprocal 
of the greatest dilution at which optical density (O.D.) was greater than the mean 
(plus 2 standard deviations) O.D values observed for naïve mouse sera assayed 
against both DS and DK AMA-1 at 1/100.  
 
3.3.4. Parasite challenge and monitoring of within host dynamics 
 
Groups of treated mice (control sham-immunized or DS AMA-1 immunized) were 
injected intra-peritoneally with 105 parasitized red blood cells (RBCs) of either 
genotype DS, CB, BC, AQ, AS or DK (Table 1).  I followed the infection dynamics 
for 29 days.  As of the first day of parasite infection (day 0), we daily measured 
weight and took blood samples from the tail of experimental mice to estimate RBC 
density (by flow cytometry; Beckman Coulter).  From day 4 post parasite infection 
onwards I took blood samples from the tail to make Giemsa-stained blood smears for 
estimating daily parasite densities.  We chose day 4 as this is around the first day that 
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parasites can be detected in the blood using microscopy.  Since P. chabaudi has a 24 
hour replication cycle, the total number of parasites in any period can be estimated 
by summing the daily parasite counts.   
 
3.3.5. Trait definition and statistical analyses 
As in Chapter 2, mice infected with genotype DK actually gained weight and 
therefore weight loss was not a suitable measure of virulence.  All data were 
analysed using General Linear Models (GLMs) in MINITAB (Minitab, version 14).  
To meet normality and homogeneity of variance assumptions, data on antibodies and 
red blood cell density were log transformed while all parasite densities were square 
route transformed.  To capture any vaccine-induced protection from anaemia, for 
each genotype, we analyzed the minimum red blood cell density and the mean red 
blood cell density across the course of infection.  GLMs were used to test whether 
the magnitude of protection induced by DS AMA-1 vaccination differed between the 
six genotypes (DS, DK, AS, CB, AQ, BC); that is whether there was a statistical 
interaction between infecting genotype and immunizing treatment.  Maximal models 
(response variable = infecting genotype + immunizing treatment + infecting 
genotype x immunization treatment) were tested in the first instance, and minimal 
models were obtained by dropping non-significant terms successively, beginning 
with highest order interactions, to obtain the significant minimal model.  
 
3.4. Results 
Table 3.1 gives details of the immunization treatments, infecting genotype and 
sample size of the experiment.  Some mice died; these were included in the 
calculation of daily densities until death, and in the analyses of peak parasite 
densities since death always occurred as initial parasitaemias were declining.   
 
3.4.1.  Sequence diversity within the AMA-1 region of P. chabaudi genotypes 
Table 3.2 and Fig. 3.1A illustrate the ama-1 nucleotide sequence similarity between 
genotype DS, from which the vaccine was derived, and the other genotypes 
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previously sequenced by Grech et al. (2008 in prep).  We found genotype AQ to be 
the most similar to the vaccine genotype, sharing 95.8% ama-1 nucleotide sequence 
similarity.  Genotype AS was 94.3% while CB was 94.2% identical to the vaccine 
antigen.  Genotype AS and CB were chosen to look at the role of virulence during 
vaccine-efficacy and differed from each other by one synonymous mutation.  
Genotype BC shared 94.2% nucleotide sequence identity to the vaccine antigen and 
differed from AS and CB by one non-synonymous mutation.  Genotype DK was the 
most diverged differing from the vaccine antigen by 93.3% (Table 3.2). 
 
To further investigate phylogenetic relationships, recombination detection analysis 
was conducted using the complete sequence data set.  This analysis supported the 
presence of a recombination event occurring between DS, DK and AQ at 
approximately the 765th nucleotide position (Fig. 3.1B and C).  Before the 
breakpoint, the ama-1 sequence of genotype AQ was more similar to sequence of the 




  DS AQ AS CB BC DK 
DS   50 67 69 69 79 
AQ 29   85 84 86 63 
AS 34 49   1 1 85 
CB 34 49 0   2 36 
BC 34 49 1 1   36 









Table 3.2. Relatedness of parasite genotypes across the ectodomain of AMA-1.  The 
numbers above the black diagonal line indicate the number of nucleotide differences 
between each of the parasite genotypes.  The numbers below the black diagonal indicate the 
number of amino acid differences between each of the parasite genotypes.  DS is the 
genotype from which the AMA-1 vaccine was derived. 





Figure 3.1. Maximum likelihood (ML) phylogenies of the AMA-1 genes of P. chabaudi 
(genotypes AQ, AS, AS-avir, BC, CB, DK, DS), P. berghei and P. yoelii (outgroup). 
Horizontal branch lengths represent the number of nucleotide substitutions per site.  (A)  ML 
phylogeny of the complete gene with ML bootstrap values shown at each node based on 
1,000 replications.  (B,C)  ML phylogenies showing the recombination event between AQ, 
DK and DS with a break-point at nucleotide position 765 (the tree represented in b was 
derived from nt 1-765, and c from 765-1512). 
 
3.4.2. Pre- parasite challenge anti- AMA-1 IgG and IgG2b antibody titres  
 
Fig. 3.2 illustrates the total IgG and IgG2b antibody titres from control sham-
immunized and DS AMA-1 immunized mice.  Immunization with DS AMA-1 
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induced antibody titres that were higher than sham-immunizations (Fig 3.2A, total 
IgG, sham immunized v antigen immunized: F1,62=452.04, p=0.001; Fig. 3.2B, 
IgG2b, sham immunized v antigen immunized: F1,62=31.88, p<0.001).  There were 
some non-responders to the antigen immunization.  However, antibody titres prior to 
challenge did not predict subsequent parasite intensities (Fig. 3.3, all correlations p 
>0.2), so that mice with low antibody titres were not necessarily less well protected 







































































































































































Figure 3.2. Total IgG and IGg2b antibody titres from the serum of mice assayed on DS 
AMA-1 coated ELISA plates.  Mice were either sham-immunized or immunised with DS 
AMA-1.  Total IgG (A) and IgG2b (B) antibodies titres were measured.  The dots in each 
panel represent the antibody titre for individual mice.  Horizontal lines indicate mean 
antibody levels.  Total IgG (p<0.001) and IgG2b (p<0.001) antibody titres were higher in 
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Figure 3.3. The relationship between pre-parasite infection total IgG and IgG2b antibodies, 
and the number of parasites subsequently present in DS AMA-1 immunized mice. Total IgG 
(A) and IgG2b (B) antibodies were measured.  The symbols in each panel represent 
individual mice infected with either genotype DS (diamonds), CB (squares), BC (triangles), 
AQ (circles) AS (cross) or DK (single dash).  There was no correlation between pre-parasite 
challenge antibodies and the total parasite density for any of the genotypes (p>0.2).  One 
CB-challenged mouse had very high antibody titres and very low parasite densities 
(indicated by the arrow). 
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3.4.3.  Genotype differences in virulence and parasite densities 
 
The kinetics of parasite density and red blood cell density of the six parasite 
genotypes in DS AMA-1 immunized and in sham-immunized mice are illustrated in 
Figures 3.4 and 3.5.  As found previously (Mackinnon & Read 1999a; de Roode et 
al. 2005a; Bell et al. 2006; Grech et al. 2008 in prep ), in sham-immunized animals 
the total parasite densities and anaemia induced by the different genotypes varied 
significantly (Fig. 3.4; F5,24=7.24, p=<0.001, and Fig. 3.5; F5, 23=6.98, p=<0.001 
respectively).  Specifically comparing parasite genotypes AS and CB which had 
identical amino acid sequences at the target region of AMA-1, sham-immunized 
hosts infected with parasite genotype CB had higher parasite densities and were more 
anaemic than sham-immunized hosts infected with AS (parasites: F1,8=13.88, 
p=0.006; anaemia: F1,7=9.39, p=0.018).  Thus, CB was the more virulent of these two 
genotypes.  The other parasite genotypes ranked in the following descending order of 














































































































































































Figure 3.4. Legend on next page 
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Figure 3.4. Effect of Plasmodium chabaudi genotype (clone) and immunization on parasite 
density kinetics.  (A-F) The infecting genotype is indicated in the top left corner of each 
graph.  (B) One antigen immunized mouse infected with CB had lower parasite densities 
than the rest of the mice in that group indicated by the thin dashed line.  Each thick line 
represents the mean change in parasite density over time per treatment group (+/- 1 s.e.m).  
(G) Each data point represents the least square means and associated standard error for each 
parasite genotype.  Solid lines represent the dynamics in control sham-immunized hosts 
while the dashed lines represent the dynamics in vaccinated hosts.  Significant protection 
was conferred against homologous parasite DS and heterologous AQ but not against any of 







3.4.4. Protective affects of immunization on parasite density 
 
Across the course of infection, the anti-parasite effect of vaccination differed among 
parasite genotypes (Fig. 3.4A-G; infecting genotype x immunization: F5,52=4.14, 
p=0.003).   
Vaccination conferred protection against hosts infected with the homologous parasite 
DS (DS vaccinated versus DS control; F1,9=20.36, p=0.001) and the heterologous 
parasite with the greatest sequence similarity AQ (AQ vaccinated versus AQ control 
F1,9=9.06, p=0.015).   No protection was conferred against hosts infected with the 
more virulent genotype BC (BC vaccinated versus BC control; F1,9=2.27, p=0.16) or 
the less virulent genotypes AS (AS vaccinated versus AS control; F1,8 =2.01, p=0.19) 
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Figure 3.5. Effect of Plasmodium chabaudi genotype (clone) and immunization on red 
blood cell density kinetics.  (A-F) The infecting genotype is indicated in the top left corner of 
each graph. (B) One antigen immunized mouse infected with CB had higher red blood cell 
densities than the rest of the mice in that group indicated by the thin dashed line.  Each thick 
line represents the mean change in parasite density over time per treatment group (+/- 1 
s.e.m).  (G) Each data point represents the least square means and associated standard error 
for each parasite genotype.  Solid lines represent the dynamics in control sham-immunized 
hosts while the dashed lines represent the dynamics in vaccinated hosts. Significant 
protection was conferred against homologous parasite DS and the heterologous genotype CB 
but not against any of the other genotypes.  
 
 
Visual inspection of Fig. 3.4B and G may suggest that vaccination provided 
protection against the heterologous genotype CB.  However, pairwise comparison 
found vaccination did not afford protection (CB vaccinated versus CB control; F1,9 
=2.57, p=0.14).  An explanation for the statistical and visual differences can be 
explained by the fact that the least square means error plotted in Fig. 3.4G does not 
show the error contributed by the one mouse vaccinated with DS AMA-1 and 
infected with genotype CB, which had higher IgG2b antibody levels, lower parasite 
densities and did not suffer from anaemia compared to the other mice in that 
treatment group (see Fig 3.3, 3.4 and 3.5).  That mouse was an outlier in all statistical 
analyses.  However the statistical output did not change whether that mouse was 
included or not.   
 
Specifically comparing parasite genotypes AS and CB which were chosen to look at 
the role of virulence in vaccine efficacy, we found that vaccination conferred better 
protection against infections with genotype CB than AS, and this was true whether 
the analysis included (infecting genotype x immunization: F1,17=4.71, p=0.004) or 
excluded (infecting genotype x immunization: F1,16=6.02, p=0.026) the outlier mouse 
mentioned above.  Thus, there was no evidence that vaccination was less effective 
against the more virulent genotype CB.  If anything it was more protective against 
this genotype than the genotype of lesser virulence AS. 
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Together these results suggest that vaccination generated the most effective anti-
parasitic protection against those strains which were most similar to the vaccine 
antigen.  Vaccination reduced densities of the homologous genotype DS and the 
heterologous genotype AQ, which out of all the heterologous genotypes was most 
similar at the ama-1 sequence to the immunizing antigen (Table 3.2, Fig. 3.1).  There 
was no evidence that virulence played a role in vaccine efficacy. 
 
3.4.5. Protective affects of vaccination on virulence  
 
Vaccination protected against anaemia (Fig.3.5; immunization: F1,56=6.76, p=0.012), 
but whether the extent of the protection differed among parasite genotypes was 
ambiguous.  Formally there was no evidence that it did (immunization x infecting 
genotype: F5,51,=2.19, p=0.069), but this result was marginal, and pairwise 
comparisons indicated protection was afforded during infection with the homologous 
parasite genotype DS (DS vaccinated versus DS control: F1,8=8.57, p=0.019) and 
against the heterologous genotype CB (CB vaccinated versus CB control: F1,8=47.24, 
p<0.001).  Vaccination protected against anaemia due to infection with genotype CB 
whether the outlier mouse in the statistical analyses mentioned above was included in 
the analysis or not.  No protection was conferred against hosts infected with 
genotype AQ (AQ vaccinated versus AQ control F1,8=0.08, p=0.77), BC (BC 
vaccinated versus BC control; F1,8=2.66, p=0.14) AS (AS vaccinated versus AS 
control; F1,7 =1,34, p=0.29) or DK (DK vaccinated versus DK control F1,7=0.34, 
p=0.58). 
  
These results show that vaccination protected against anaemia during infection with 
the homologous genotype DS.  However, unlike the pattern observed with the 
parasite data, vaccination did not protect against infection with genotype AQ which 
was most similar at the ama-1 sequence to the immunizing antigen.  Out of the 
heterologous genotypes, vaccination afforded most protection from anaemia during 
infection with genotype CB.   
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3.5. Discussion 
 
The motivation for the experiments presented here came from the trial of the 
Combination B malaria vaccine (Genton et al. 2002; Genton et al. 2003).  In that trial 
it was unclear whether vaccination had imposed selection that was strain-specific 
(Fluck et al. 2004; Fluck et al. 2007) or whether more virulent parasites had a 
selective advantage in vaccinated hosts.  Consistent with my previous studies 
(Chapter 2), the data we present here go against the latter argument.  I found that 
immunization with AMA-1 derived from P. chabaudi genotype DS induced 
protection that was strain-specific: vaccination reduced those parasites which were 
most similar to the vaccine target to a greater extent than those that were different. 
There was no evidence that vaccine-induced immunity was less effective against 
virulent genotypes.  For example, when we compared two genotypes which had 
identical AMA-1 protein sequences but differed in virulence, there was no evidence 
that more virulent genotype (CB) was harder to control.  If anything vaccination was 
less effective against the less virulent genotype (Fig. 3.4 and 3.5).  In contrast, 
neither ama-1 sequence diversity nor virulence appeared to more strongly influence 
protection from anaemia. 
 
Phylogenetic analyses revealed that the ama-1 sequence of genotype AQ most 
closely resembled genotype DS from which the vaccine was derived (Fig. 3.1, Table 
3.1).  Vaccination was most effective at reducing parasite densities during infection 
with that genotype (Fig. 3.4).  However, a recombination detection analysis 
identified a breakpoint nucleotide at position 765 for genotypes DS, DK and AQ 
supporting the presence of a recombination event.   
 
Intragenic recombination has been proposed as a mechanism of generation of 
diversity in AMA-1 (Eisen et al. 1999), as well as other merozoite proteins such as 
MSP-1 (Tanabe et al. 1987; Miller et al. 1993; Tanabe et al. 2007) and MSP-2 
(Marshall et al. 1991; Snewin et al. 1991).  Sequence analysis of a Papua New 
Guinea isolate (KF1916) revealed that the AMA-1 allele appeared to have arisen by a 
recombination event from alleles classified as members of two different allelic 
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families.  The KF1916 AMA-1 was identical to the FC27 AMA-1 allele (family I) 
from nucleotide positions 1-558, after which 25 nucleotide substitutions were 
observed.  The FCR3 AMA-1 allele (family II) was identical to the KF1916 allele 
from nucleotide position 558 to the 3' end (Eisen et al. 1999). 
 
In my study I found that the AQ AMA-1 allele more commonly resembled the 
vaccine genotype DS between nucleotide positions 1-765, and resembled genotype 
DK for the remainder of the sequence.  This allelic diversity in the ama-1 gene of 
genotype AQ presumably occurred during meiotic recombination in the Anopheles 
mosquito, when gametocytes belonging to either genotype DS or DK were also 
present.   
 
The breakpoint nucleotide position is of interest given the recent data investigating 
the regions of the AMA-1 ectodomain which may generate protective immunity. For 
instance, domain I appears to exhibit the most polymorphisms, with clustering 
occurring at one end of the hydrophobic cleft, thought to be associated with a ligand 
binding site (Bai et al. 2005; Coley et al. 2007).  X-ray crystallography and cell 
culture experiments have demonstrated a crucial role for domain II in the 
attachment/invasion of red blood cells (Fraser et al. 2001; Nair et al. 2002; Bai et al. 
2005; Feng et al. 2005; Pizarro et al. 2005; Collins et al. 2007).  Finally, genetic 
analyses have demonstrated domain III to be under balancing selection, and that 
some anti-domain III antibodies can block invasion (Nair et al. 2002; Mueller et al. 
2003).  In my analyses, the recombination breakpoint occurred close to where 
domain II started, so that genotype AQ was actually more similar to DK for domain 
II.  Thus, my finding that anti-DS antibodies were more effective against AQ implies 
that the conserved target epitope lies upstream of the breakpoint, perhaps in domain 
1. 
 
My results strongly imply that the anti-parasite affects of AMA-1 vaccination 
correlate with sequence similarity between the infecting strain and the vaccine 
antigen, and that vaccine efficacy is unaffected by the virulence of challenge 
parasites  This data apparently contradicts a previous study which, using the same 
Chapter 3-Virulence or sequence diversity 67
genotypes as we used here, found evidence that both sequence similarity and parasite 
virulence affected vaccine efficacy (Grech et al. 2008 in prep ). Most notably, 
protection was significantly better against AS than against CB, the two genotypes 
which differed in virulence but have identical amino acid sequences.   The only 
obvious difference between the two studies was that Grech et al. (2008 in prep) 
immunized with DK-derived AMA-1 antigen whereas I used DS AMA-1.  The most 
likely explanation for the contrast in results is therefore that different immunizing 
antigens can impose selection in different ways.  For example, some antigens may 
generate protective antibodies that have higher affinity to certain AMA-1 residues, or 
other AMA-1 like protein sequences, in some parasites more than others (Hodder et 
al. 2001).  Serial passage of a P. chabaudi through whole-parasite immunized mice 
evolved virulence more rapidly than did serial passage through immunologically 
naïve hosts (Mackinnon & Read 2004a).  In this study I saw no parasite advantage to 
virulence.  An explanation for the contrast in results could be explained by 
differences in the immune response induced by single antigen immunizations in 
comparison to whole-parasite immunization.  Furthermore, perhaps selection for 
virulence is especially obvious when antigenically identical parasites are evolved, or 
when immunization is with many highly diverse antigens, as must occur with live 
parasite immunization.  In future experiments I will evolve single P. chabaudi 
genotypes through AMA-1 immunized mice to measure whether this vaccine has the 
potential to drive the evolution of similar rapid virulence. 
 
My observations suggest that single AMA-1 vaccine antigens may not be sufficient 
to protect against Plasmodium populations in the field due to allelic heterogeneity.  
Perhaps one of the best solutions to avoid inadvertent selection for more virulent 
strains, as apparently happened with the Combination B vaccine, may be to include 
all known variants of a particular antigen in a vaccine formulation.  One group 
investigated whether the potency of an AMA-1 vaccine increased by including more 
than one allele (Kennedy et al. 2002; Malkin et al. 2005; Miura et al. 2007).  The 
resulting antibodies were similarly effective during parasite invasion assays 
regardless of whether immunization was with a single allele or a mixture of two.  In 
Chapter 4 of this thesis we have extended on those studies to test in vivo whether a 
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bi-allelic AMA-1 immunization affords the host greater protection from parasites and 
disease, and how this alters within host selection. 
 
In this study I found that heterologous anti-parasitic protection did not correlate with 
anti-disease protection, and vice versa.  For example, immunization reduced the 
parasite densities of genotype AQ but did not provide significant protection against 
anaemia caused during infection with that genotype.  The fact that there are two 
different types of malarial immunity - immunity against parasites and immunity 
against disease - is poorly understood on a molecular basis although widely 
appreciated (Schofield & Grau 2005).  An explanation for the two different responses 
observed here could be that the specificity of the anti-AMA-1 antibody response lies 
with the generation of inhibitory antibodies which may target a hypervariable region 
located around a conserved hydrophobic pocket on domain I common between the 
vaccine antigen and genotype AQ (Coley et al. 2007).  These inhibitory antibodies 
may be faster at inhibiting parasite invasion of red blood cells than the mechanisms 
of red blood cell replacement (erythropoiesis) (Chang & Stevenson 2004).  These 
results imply that for vaccine studies to be executed most effectively, disease 
symptoms, as well as the parasitological status of the host, should be measured.   
 
Vaccines which can control disease symptoms without preventing parasite 
transmission may have important evolutionary consequences (Gandon et al. 2001).  
For instance, vaccines against Bordetella pertussis, the causative agent of whooping 
cough, have controlled disease symptoms but not bacterial colonization.  Thus, 
vaccination has been attributed as the reason for persistence and re-emergence in the 
adult host population (WHO 2001; McIntyre et al. 2002; Ntezayabo et al. 2003).  If 
selection imposed by vaccination heavily depends on the fine specificity of the 
immune response, it will become increasingly important that we understand how 
each of six AMA-1 based vaccines currently in human trails may alter Plasmodium 
populations.  Such studies will provide important information on the evolutionary 
consequences of AMA-1 vaccination. 
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4. Mixed allele malaria vaccines: host protection and 
within-host selection 
This chapter, with a few minor editorial changes, has been published as Victoria C. 
Barclay, Brian H.K. Chan, Robin F. Anders, Andrew F. Read. 2008. Mixed allele 
malaria vaccines: Host protection and within-host selection.  Vaccine in press (See 




Malaria parasites are frequently polymorphic at the antigenic targets of many 
candidate vaccines, presumably as a consequence of selection pressure from 
protective immune responses. Conventional wisdom is therefore that vaccines 
directed against a single variant could select for non-target variants, rendering the 
vaccine useless.  Many people have argued that a solution is to develop vaccines 
containing the products of more than one variant of the target.  However, we are 
unaware of any evidence that multi-allele vaccines better protect hosts against 
parasites or morbidity. Moreover, selection of antigen variants is not the only 
evolution that could occur in response to vaccination.  Increased virulence could also 
be favored if more aggressive strains are less well controlled by vaccine-induced 
immunity.  Virulence and antigenic identity have been confounded in all studies so 
far, and so we do not know formally from any animal or human studies whether 
vaccine failure has been due to evasion of protective responses by variants at target 
epitopes, or whether vaccines are just less good at protecting against more aggressive 
strains.   
Using the rodent malaria model Plasmodium chabaudi and recombinant apical 
membrane antigen 1 (AMA-1), I tested whether a bi-allelic vaccine afforded greater 
protection from parasite infection and morbidity than did vaccination with the 
component alleles alone.  I also tested the effect of mono- and bi-allelic vaccination 
on within-host selection of mixed P. chabaudi infections, and whether parasite 
virulence measured in unvaccinated hosts predicts pathogen titres in immunized 
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hosts.  I found that vaccination with the bi-allelic AMA-1 formulation did not afford 
the host greater protection from parasite infection or morbidity than did mono-allelic 
AMA-1 immunisation.  Mono-allelic immunization increased the frequency of 
heterologous genotypes in mixed genotype infections.  There was no evidence that 
any type of immunization regime favoured virulence.  A single AMA-1 variant is a 
component of candidate malaria vaccines current in human trials; my results suggest 
that adding extra AMA-1 alleles to these vaccines would not confer clinical benefits, 
but that that mono-allelic vaccines could alter AMA-1 allele frequencies in natural 
populations. 
 
4.2. Introduction  
 
Malaria parasite antigens which are the targets of protective immune responses are 
frequently polymorphic, with antigen-coding genes having multiple allelic forms 
(Richie & Saul 2002). Polymorphisms likely arise as a consequence of immune-
mediated selection because host responses can be more effective against parasites of 
the immunising genotype than against different genotypes (strain-specific immunity) 
(Jeffery 1966; Mendis et al. 1991; Anders et al. 1998; Martinelli et al. 2005; 
Cheesman et al. 2006).  Sequence polymorphisms have been directly implicated in 
antigenic escape (Kennedy et al. 2002; Healer et al. 2004; Saul 2007), and in malaria 
endemic areas, immunity is acquired slowly, probably because repeated exposure is 
required to generate an effective response against a repertoire of genotypes 
(McGregor et al. 1956; McGregor 1974; Day & Marsh 1991).  The existence of 
antigenic polymorphism is therefore of considerable concern to malaria vaccine 
developers because it implies that single antigen vaccines will have trouble inducing 
protective immunity against polymorphic targets (Hodder et al. 2001; Genton et al. 
2003; Fluck et al. 2004; Genton & Reed 2007). 
 
One approach to minimizing vaccine-induced strain specificity has been to design 
vaccines which combine more than one allele of an antigen (Hoffmann & Miller 
1996; Bolad & Berzins 2000; Richie & Saul 2002; Polley et al. 2007).  However, the 
inclusion of more than one allelic form of an antigen may not be sufficient to 
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overcome substantial polymorphisms (Saul 2007), and there is little experimental 
evidence that multi-allele vaccines actually afford the host more protection from 
morbidity than do single antigen vaccines. 
 
Furthermore, selection of antigen-variants is not the only evolution that could occur 
in response to widespread vaccination.  Theoretically, vaccination has the potential to 
cause evolutionary change in parasite virulence (parasite-induced host damage) by 
altering the way natural selection acts on parasite populations (Gandon et al. 2001; 
Gandon & Day 2003; André & Gandon 2006; Restif & Grenfell 2006; Gandon & 
Day 2007; Mackinnon et al. 2008; Read & Mackinnon 2008; Williams & Day 2008).  
In experimental evolution experiments, the rodent malaria Plasmodium chabaudi 
became virulent more rapidly if serially passaged through mice previously 
immunized with live parasites (Mackinnon & Read 2004a).  The most likely 
explanation for this is that more aggressive variants are less well controlled by 
immunity. 
 
To date, we still do not fully understand how vaccines will alter gene frequencies in 
malaria parasite populations.  Evidence for selection in the field comes from a small 
phase 1-2b trial of the “Combination B” blood-stage malaria vaccine (Genton et al. 
2002).  This vaccine contained a single antigen from each of three polymorphic loci 
of P. falciparum.  One of these loci, Merozoite Surface Protein 2 (MSP-2), is 
dimorphic, with each parasite having an allele from one of two allelic families 
(labelled 3D7 and FC27).  The MSP-2 allele in the Combination B vaccine came 
from the 3D7 family.  Among parasites subsequently acquired by vaccinees, 3D7-
type alleles were rarer than in people given a placebo. Vaccination thus selected 
against the variant contained in the vaccine.  Interestingly, the FC27 allelic family is 
associated with more virulent infections (Engelbrecht et al. 1995).  Therefore, it is 
not clear whether the vaccine-imposed selection was due to immune specificity 
(Fluck et al. 2004; Fluck et al. 2007) or whether the vaccine was less good at 
controlling more virulent infections.   
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Many candidate vaccines against malaria are directed against the asexual blood 
stage, with the principal target being the merozoite.  Apical Merozoite Antigen-1 
(AMA-1) is a promising vaccine candidate as it possesses fewer polymorphisms than 
other merozoite antigens (Anders et al. 1998; Hodder et al. 2001).  AMA-1 is thought 
to play a major role during erythrocyte re-modelling and invasion (Cowman & Crabb 
2006).  Immunization with AMA-1 confers protection against parasite challenge in a 
number of animal models, probably by inducing antibodies which inhibit invasion 
(Deans et al. 1988; Collins et al. 1994; Crewther et al. 1996; Anders et al. 1998; 
Narum et al. 2000; Stowers et al. 2002; Healer et al. 2004).  Furthermore, humans 
and other species immunized with single-allele AMA-1 vaccines raise antibodies 
which inhibit erythrocyte invasion in vitro (Hodder et al. 2001; Kocken et al. 2002).  
In endemic populations, naturally acquired antibody to P. falciparum AMA-1 
(PfAMA-1) is associated with protection from falciparum malaria (Thomas et al. 
1994; Johnson et al. 2004; Polley et al. 2004; Cortes et al. 2005; Rodrigues et al. 
2005).  At least six different vaccines based on the AMA-1 allele from the P. 
falciparum 3D7 strain are currently in efficacy trials in humans (Polhemus et al. 
2007; Maher 2008; Thera et al. 2008).  
 
However, there are more than 60 polymorphic sites in the P. falciparum AMA-1 
protein, and most of these are non-randomly dispersed point mutations on domain I 
(Peterson et al. 1989; Marshall et al. 1996; Polley & Conway 2001; Polley et al. 
2003; Dutta et al. 2007).  These point mutations may be of immunological 
importance.  Protection in mice is strain-specific, and growth and invasion inhibition 
assays (GIA) and ELISA show that antibodies from animals and human field sera 
inhibit growth in a strain-specific manner (Crewther et al. 1996; Anders et al. 1998; 
Hodder et al. 2001; Polley et al. 2003; Cortes et al. 2005; Polhemus et al. 2007).  
Allelic replacement experiments have directly implicated sequence polymorphism in 
antigenic escape (Healer et al. 2004), and cross strain inhibition assays suggest that 
the extent of escape correlates with sequence distance between the vaccine and the 
target strain (Kennedy et al. 2002). In an attempt to overcome strain-specificity, 
vaccine researchers are beginning to combine allelic variants of AMA-1.  For 
example, one group immunized rhesus monkeys with a mixture of two allelic forms 
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of PfAMA-1 (designated AMA1-C1) or the component alleles and measured 
responses in vitro using GIA and ELISA (Kennedy et al. 2002; Malkin et al. 2005; 
Miura et al. 2007).  The resulting antibodies were similarly effective regardless of 
whether immunization was with a single variant or AMA1-C1.  Another group 
immunized mice and rabbits with two allelic variants of domain I and II of AMA-1 
ectodomain from P. falciparum isolates.  The anti-AMA-1 antibodies obtained with 
both proteins were active in an in vitro parasite growth invasion/inhibition assay, but 
to no greater extent than with either of the variants alone (Lalitha et al. 2008).  
Together these results have raised questions about the necessity of using multi-allele 
vaccines.   
 
Here I use the rodent malaria P. chabaudi and two alleles of the blood-stage malaria 
vaccine candidate AMA-1 to investigate (i) whether immunization with a single or 
bi-allelic AMA-1 variant formulation afforded the host the greatest protection from 
morbidity and parasite infection, (ii) how these different vaccination regimes can 
alter clonal genotype frequencies in mixed infections, and (iii) whether more virulent 
genotypes are better at evading heterologous vaccine-induced protective responses.    
 
 
4.3. Materials and methods 
 
4.3.1. Parasites and hosts  
 
Isolates containing P. chabaudi adami were originally collected from wild-caught 
thicket rats (Thamnomys rutilans) in the Congo (Brazaville).  In this experiment we 
used P. c. adami genotype DS500 and DK122 originally genotyped from isolates 
408XZ and 556KA respectively (Carter and Walliker 1976).  The nucleotide 
sequence of P. chabaudi AMA-1 (PcAMA-1) genotype DS differs from genotype 
DK (556KA) by 79 amino acids (Marshall et al. 1989; Crewther et al. 1996).  Hosts 
were inbred female C57BL/6J mice age 6-8 weeks (Harlan England) maintained as 
described previously (de Roode et al. 2004a).  Studies by others (Crewther et al. 
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1996) and my own pilot studies showed that these genotypes differ in virulence 
during infection of C57BL/6 female mice, with genotype DS generating substantially 
more parasites and inducing greater weight and red blood cell loss relative to DK. 
4.3.2. Immunizations and isotype ELISA 
 
Here I used an immunization protocol adapted from Anders et al. 1998 (Anders et al. 
1998).  Prior to immunization, mice were randomized into four groups of eighteen 
(Table 4.1).  Immunization was with the highly immunogenic ectodomain of the full 
AMA-1 protein termed AMA-1B.  For mono-allelic immunizations (hereafter 
referred to as DS AMA-1 or DK AMA-1), groups of mice were injected 
intraperitoneally with 10 µg of the appropriate protein emulsified in 100 µl of the 
adjuvant Montanide ISA 720 (Seppic, France).  For bi-allelic immunizations, mice 
were injected with a mixture of 5 µg of both DS and DK AMA-1, giving the same 
total dose of antigen as for the single antigen immunizations, again emulsified in   
ISA 720.  Control mice were injected with 100 µl emulsion of PBS in ISA 720.  
Mice were given a single booster immunization with the same amount of antigen 

















Sham-immun   DS 6 3 2 
Sham-immun 18 DK 6   
Sham-immun   DS+DK 6   
DK AMA-1   DS 6   
DK AMA-1 18 DK 6   
DK AMA-1   DS+DK 6   
DS AMA-1   DS 6 1  
DS AMA-1 18 DK 6   
DSAMA-1   DS+DK 6 1  
Bi-allelic   DS 6 2 1 
Bi-allelic 18 DK 6   
Bi-allelic   DS+DK 6   
Total    72 7 3 
 
Table 4.1.  Experimental design.  Immunization was either with DK AMA-1, DS AMA-1, a 
formulation containing an equal mix of both forms of AMA-1 (bi-allelic), or immunization 
with adjuvant only (‘sham-immune’).  Groups of 18 mice were immunized with one of the 
four treatments before being separated into groups of 6.  Infection was with parasites of 
genotype (clone) DK alone, genotype DS alone or a mixture of both. During the experiment 
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7 mice were found dead and 3 had to been euthanized due to severe morbidity.  
Euthanization was at predetermined levels of morbidity prescribed by animal care protocols. 
 
To ensure that antigen immunization successfully generated antibody responses, and 
to determine whether there was any cross-reactivity between the antibodies generated 
to the different immunizing antigens, I first carried out a pilot experiment.  A total of 
11 mice were immunized with DS AMA-1, 11 with DK AMA-1, and 10 were sham-
immunized.  I estimated the quantity of IgG2b antigen-specific antibodies in all mice 
sera 11 days after the booster immunisation by ELISA using wells coated with DS 
AMA-1 or DK AMA-1.  Thus the sera from 32 mice were tested in 64 wells.  I used 
IgG2b as previous work in my laboratory showed that C57BL/6 produce this isotype 
in response to P. chabaudi infection (K. Grocock, A. Graham unpublished).  
Protection induced by immunisation with recombinant AMA-1 is isotype 
independent (Burns et al. 2004).  Given the lack of cross-reactivity I observed in this 
pilot experiment (see Results below), in the main experiment, I measured IgG2b 
isotype antibodies to each antigen separately only from the sera of mice immunized 
with a mixture of DS and DK AMA-1 and in sham-immunized control mice.   
 
In both the pilot and main experiments, serum fractions were separated by 
centrifugation from 20 µl of blood taken from a tail snip and were stored at -80oC.  
High binding 96 well ELISA Maxisorb immunoplates (Nunc) were coated with 
either DS AMA-1 or DK AMA-1 at a concentration of 1 µg /ml in 0.06M carbonate 
buffer (0.04M NaHCO3, 0.02M NaCO3, pH 9.6) in a final volume of 50 ul per well. 
Plates were stored at 4oC overnight to allow the antigen to bind.  Non-specific 
binding was blocked by incubating wells with 5% BSA: carbonate buffer 
(200ul/well) for 2 hours at 37oC.  Wells were then washed three times in Tris 
buffered saline with 0.01% Tween 20 (TBST).  We used end-point dilution methods 
to detect IgG2b titres: serum samples were detected in a serial dilution 1/100-
1/204800 using TBST as a diluent, in a final volume of 50 µl per well and incubated 
for 2 hours at 37oC.  Wells were washed three times in TBST.  HRP conjugated goat 
anti-mouse IgG2b detection antibody (Southern Biotech 1100-05) was diluted 1/4000 
in TBST to a final volume of 50 µl per well.  Plates were incubated for 1 hour at 
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37oC.  Wells were washed three times in TBST followed by a final wash in distilled 
water.  ABTS peroxide substrate (Insight Biotechnology) was added at 100 µl per 
well and allowed to develop at room temperature for 20 minutes.  Optical density 
was read at 405 nm using a spectrophotometer.  IgG2b isotype antibody titres were 
calculated as the reciprocal of the greatest dilution at which optical density (O.D.) 
was greater than the mean (plus 2 standard deviations) O.D values observed for naïve 
mouse sera assayed against both DS and DK AMA-1 at 1/100.  
 
4.3.3. Parasite challenge and monitoring of within host dynamics  
 
Two weeks after the boost immunisation, groups of immunized mice (18 per group) 
were further randomized into groups of six and challenged with 105 parasites of 
either genotype DS alone, genotype DK alone or a mixture of genotype DS and DK 
(Table 4.1).  Thus, mice infected with both genotypes received twice as many 
parasites as those infected with one genotype.  A two-fold difference in infective 
dose has negligible effects on the population dynamics of the parasite (Timms et al. 
2001).   During the course of infection, we measured body weights and took blood 
samples from the tail to (i) make Giemsa-stained blood smears, (ii) estimate red 
blood cell density by flow cytometry (Beckman Coulter), and (iii) for genotype-
specific real-time quantitative PCR (qPCR) assays as described previously (Bell et 
al. 2006). For amplification of the DK genotype, we used primers previously 
designed to amplify AS/AJ genotypes as described elsewhere (Bell et al. 2006).  DS 
genotype-specific primers were as follows: DS forward 5' GGA AAA GGT ATA 
ACT AAT CAA AAA TCT ACT AAA 3'; DS reverse 5' CAG GAG AAA TGT 
TTA CAT CTG CTT T 3'. 
 
4.3.4. Trait definition and statistical analyses 
 
Since P. chabaudi has a 24 hour replication cycle, the total number of parasites 
present in any period can be estimated by summing the daily parasite counts.  Data 
were analysed using General Linear Models (GLMs) in MINITAB (Minitab, version 
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14).  To meet normality and homogeneity of variance assumptions, data on 
antibodies, weight and red blood cell density were log transformed while all parasite 
densities and proportions were square root transformed.  GLMs were used to test 
whether the magnitude of protection differed between the three antigen 
immunizations (DK AMA-1, DS AMA-1, or the bi-allelic form); that is whether 
there was a statistical interaction between infecting genotype and immunizing 
treatments.  Maximal models (response variable = infecting genotype + immunizing 
treatment + infecting genotype x immunization treatment) were tested in the first 
instance, and minimal models were obtained by dropping non-significant terms 
successively, beginning with highest order interactions, to obtain the significant 
minimal model.  For analyses of within host selection, we asked for mixed genotype 
infections, whether the frequency of genotype DS in the parasite population differed 





4.4  Results 
 
Table 4.1 gives details of the immunization treatments, infecting genotype and 
sample size of the experiment.  Some mice died; these were included in the 
calculation of daily densities until death, and in the analyses of peak parasite 
densities since death always occurred as initial parasitaemias were declining.   
 
4.4.1. Pre- challenge anti-AMA-1 IgG2b antibodies 
 
Figure 4.1 illustrates the data from a pilot experiment where IgG2b antigen-specific 
antibodies were measured to each of the immunizing antigens and the cross-
reactivity between them.  All antigen immunization treatments generated antibody 
titres that were higher than those present in sham-immunized controls (sham-
immunized versus antigen immunized: F1,62=8.92, p=0.004).  IgG2b antibodies were 
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specific for the antigen they had been exposed to during immunization (immunizing 
treatment x ELISA antigen: F1,40=9.99, p=0.003).  For example, anti-DS AMA-1 
IgG2b antibody titres were higher when assayed against the homologous DS antigen 
than the heterologous DK antigen and vice versa.  Thus, neither antigen elicited a 
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Figure 4.1. IGg2b antibody levels from the serum of mice in the pilot experiment.  Mice 
were either sham-immunized or immunised with one of the two antigens (DS AMA-1, DK 
AMA-1).  Each of the treatments used to immunize mice and the AMA-1 test antigen used to 
coat ELISA plates are shown on the x axis.  Dots represent the antibody titre against a 
particular immunizing antigen.  Horizontal lines indicate mean antibody levels.  Antibody 
levels in antigen immunized groups of mice were higher than in sham-immunized controls 
(p<0.001) and, among the immunized mice, the levels induced between the antigen 
immunized groups differed (immunizing treatment x ELISA antigen: p=0.003) with higher 




Figure 4.2 illustrates the IgG2b antibody titres in mice from the main experiment 
three days prior to parasite infection.  All antigen immunization treatments induced 
antibody titres that were higher than those present in sham-immunized mice (sham-
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immunized v immunized: F1,106=58.89, p<0.001).  Among antigen-immunized 
groups, titres did not differ (F2,69=2.56, p=0.085)  In those mice which had been 
immunized with the bi-allelic form, antibodies were not more specifically 
recognising either component antigen (F1,35=0.61, p=0.44).  These data show that 
immunization successfully elicited antibody responses, and that, at least as measured 
by IgG2b titres, these responses were of equal magnitude in all immunized groups.  
Among antigen-immunized mice, antibody titres prior to challenge did not predict 














Figure 4.2.  IgG2b antibody levels from the serum of mice in the main experiment.  Mice 
were either sham-immunized, or immunized with one of the antigen immunization 
treatments (DS AMA-1, DK AMA-1 or the bi-allelic formulation).  Each of the treatments 
used to immunize mice and the AMA-1 test antigen used to coat ELISA plates are shown on 
the x axis.  Dots represent the antibody titre for individual mice against a particular 
immunizing antigen.  Mice that were sham-immunized or immunized with the bi-allelic 
formulation were assayed for antibody responses against both DS and DK AMA-1 antigens.  
 
 
Horizontal lines indicate mean antibody levels.  Antibody levels in antigen immunized 
groups of mice were higher than in sham-immunized controls (p<0.001), and among the 
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4.4.2.  Bi-allelic immunization did not generate a greater anti-morbidity 
response than did mono-allelic immunization 
 
Red blood cell density and weight kinetics following parasite challenge for each of 
the immunization treatments are illustrated in Fig. 4.3A-F, and the minimum red 
blood cell density and minimum weight reached are illustrated in Fig. 4.3G-H.  In 
sham-immunized control mice, genotype DK was less virulent than genotype DS, 
induced less anaemia and less weight loss (Fig. 4.3A-H; anaemia: F2,14=6.29, p= 
0.011; weight loss: F2,14=9.97, p=0.002).   
 
Immunization protected mice against anaemia induced by infection with any of the 
genotypes (Fig. 4.3A-C, G; sham-immunized v immunized: F1,69=16.94, p<0.001).  
Bi-allelic immunization reduced anaemia no more than did immunization with either 
of the alleles alone (Fig. 4.3G; immunizing treatment x infecting genotype: 
F4,44,=0.71, p=0.59).  All pairwise immunization comparisons were non-significant (p 
>0.5 in all cases).   
  
As infection with genotype DK did not induce any weight loss in sham-immunized 
controls (Fig. 4.3D) the protective effects of immunization were analyzed only for 
infections that contained genotype DS (Fig. 4.3E-F).  We found that all 
immunizations protected mice against weight loss due to DS infections (Fig. 4.3E-F, 
H; sham-immunized v immunized: F1,45=11.13, p=0.002).  Similar to the anaemia 
data, we found that immunization with either the bi-allelic form or either of the 
alleles alone afforded similar levels of protection against weight loss (Fig. 4.3H; 
immunizing treatment x infecting genotype: F2,29=2.43, p=0.11).  All pairwise 
immunization comparisons were non-significant (p>0.5 in all cases).   
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Together, these results show that immunization with the bi-allelic vaccine does not 
afford the host greater protection from morbidity, as measured by anaemia and 
weight loss.  Immunization with either of the variants alone provided protection 
which was as effective as that induced by the two variants together. 
 
4.4.3. Bi-allelic immunization did not generate greater anti-parasite response 
than did mono-allelic immunization 
 
Parasite dynamics under each of the treatments are illustrated in Fig. 4.4.  Genotype 
DS achieved higher parasite density in sham-immunized control mice than did 
genotype DK (infecting genotype: F1,10=7.03 =0.024).  
 
All three immunizations reduced peak parasite densities relative to those which had 
received a sham inoculation (Fig. 4.4D, sham-immunized v immunized: F1,69= 11.55, 
p=0.001).  The extent of anti-parasite protection depended on the identity of the 
immunising antigen and the identity of the challenge genotype (Fig. 4.4D; 
immunizing treatment x infecting genotype:  F4,44=8.71, p <0.001).  We found that 
protection was genotype-specific: immunization with DS AMA-1 antigen reduced 
DS parasite densities more than it reduced the densities of genotype DK, and vice 
versa (among single antigen immunized groups, immunizing treatment x infecting 
genotype: F1,19=36.26, p<0.001).   
























































































































































































































































Figure 4.3. Legend on next page 
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Figure 4.3. Effect of Plasmodium chabaudi infection (genotype (clone) DK alone, DS alone 
or DS+DK) and immunization (sham-immunized control, DK AMA-1, DS AMA-1, or bi-
allelic form) on the kinetics of minimum red blood cell density (left panels) and minimum 
weight (right panels).  In A-F lines represent the change in RBC density (left panels) and 
weight (right panels) over time.  Each line represents the mean of up to 6 mice (+/- 1 s.e.m) 
that were infected with DK alone (A and D), DS alone (B and E) or a mixed genotype (C and 
F) infection during immunization with either a sham-inoculation control (solid thick black 
line), DK AMA-1 (open triangle), DS AMA-1 (open squares), or the bi-allelic mixture 
(dotted black line).  In G-H bars represent the minimum red blood cell density (left panel) 
and minimum weight (right panel) reached during infection with genotype DK alone (grey 
bars), DS alone (black bars) or a mixture of both genotypes (black and white bars) under 
each of the immunization treatments.  Each bar represents the least squares mean of up to 6 
mice (+/- 1 s.e.m). 
 
When I compared the extent of anti-parasite protection between the immunized 
groups we found that under no circumstances did the bi-allelic immunization afford 
greater protection than did immunization with a single allele.  For example, 
immunization with DS AMA-1 reduced the peak density of DK infections and 
infections with both genotypes together, but the bi-allelic immunization did not 
protect against DS alone (Fig. 4.4D; immunizing treatment x infecting genotype: 
F2,30=9.84, p=0.001).  Although the bi-allelic immunization reduced the densities of 
genotype DK, reduction was no greater than with a single DK AMA-1 immunization 
(Fig. 4.4D; immunizing treatment x infecting genotype F2,29=4.09, p=0.027).   
 
Together these results show that bi-allelic immunization did not afford the host 
greater anti-parasite protection than did mono-allelic immunization.  Unlike 
morbidity, where protection was induced regardless of the antigen used in 
immunization, we found that immunization with a single allele achieved better 
protection against the homologous genotype, and bi-allelic immunisation never did 
as well.  Indeed, I found just one of the variants (DS AMA-1) to be the most 
effective at reducing parasite densities. 
 
 













































































































































Figure 4.4. Legend on next page 
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Figure 4.4. Kinetics of Plasmodium chabaudi infections (genotype (clone) DK alone, DS 
alone or both together) following immunization (DK AMA-1, DS AMA-1, or bi-allelic 
formulation or sham-immunized control).  In A-C, lines represent the change in parasite 
density over time.  Each line represents the mean of up to 6 mice (+/- 1 s.e.m) that were 
infected with DK alone (A), DS alone (B) or a mixed genotype (C) infection during 
immunization with either a sham-inoculation control (solid thick black line), DK AMA-1 
(open triangle), DS AMA-1 (open squares), or the bi-allelic mixture (dotted black line).  In 
(D), bars represent peak parasite densities reached during infection with genotype DK alone 
(grey bars), DS alone (black bars) or a mixture of both genotypes (black and white diagonal) 
under each of the immunization treatments.  Each bar represents the least squares mean of up 
to 6 mice (+/- 1 s.e.m). 
 
 
4.4.4. Vaccine-induced anti-parasite protection was genotype specific in 
mixed infections and independent of genotype virulence 
 
To examine how the antigenic composition of the immunising formulation affects 
within-host selection (relative frequency) in mixed genotype infections, and whether 
heterologous immunity less effectively controlled the virulent genotype, I compared 
the frequency of genotype DS in mixed infections (Fig. 4.5).   
 
I found that antigen immunization altered genotype frequencies. In sham-immunized 
mice, and those immunized with the bi-allelic formulation, DS made up about 60% 
of all the parasites present in the infections.  Thus, immunization with a mixture of 
DS and DK AMA-1 had negligible effect on genotype frequency and thus within 
host selection (Fig. 4.5A; sham-immunized versus bi-allelic immunization: F1,10= 
2.02, p=0.19).  In contrast, immunization with a single antigen reduced parasites in a 
genotype-specific manner, facilitating the heterologous genotype (Fig. 4.5A,B; 
immunizing treatment F1,10= 105.54, p<0.001).  Immunization with DK AMA-1 
increased the frequency of genotype DS, while DS AMA-1 immunization increased 
the frequency of DK.  These effects were essentially symmetrical.  Thus, there was 
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no evidence that the more virulent genotype, DS, was less affected by heterologous 





































































































Figure 4.5. Proportion of genotype DS in mixed DS and DK infections following 
immunization with DK AMA-1, DS AMA-1, the bi-allelic formulation, or in sham-
immunized controls.  (A)  Lines represents the proportion of genotype DS through time in 
control (solid black line), DK AMA-1 (open triangles), DS AMA-1 (open diamonds) or bi-
allelic (dotted black line) immunized mice.  Each line represents the mean of up to 6 mice 
(+/- 1 s.e.m).  (B)  Bar graphs represent the proportion of total parasites in a mixed infection 
that were DS under each of the immunization treatments.  Each bar represents the least 
squares mean of up to 6 mice with 95% confidence intervals.  The black horizontal dotted 
line represents the proportion of DS present in the inoculum. 
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4.5. Discussion 
 
In this study, I investigated (i) whether immunization with a single or bi-allelic 
AMA-1 formulation afforded the host the greatest protection from morbidity and 
parasite infection, (ii) how these different vaccination regimes altered clonal 
compositions in mixed infections, and (iii) whether a more virulent genotype was 
less successfully controlled by vaccine-induced protective responses.  Addressing 
each of these in turn, I found the following. (i) Bi-allelic immunization did not 
generate better anti-morbidity or anti-parasite protection than did single allele 
immunization.  Rather, immunization with one of the two variants alone (DS) 
provided the best protection.  (ii) Both single variant immunizations reduced the 
frequency of homologous genotypes in mixed infections; bi-allelic immunization had 
no impact on within-host selection.  (iii) There was no evidence that the more 
virulent genotype (DS) was better at evading vaccine-induced immunity than was the 
less virulent genotype.   
 
Rightly, protecting individual hosts from morbidity is one of the goals of malaria 
vaccines directed against the blood-stage of infection.  If infection densities are 
positively correlated with host morbidity (virulence) (Mackinnon et al. 2008) multi-
allele vaccines could potentially improve the health of the host by suppressing more 
of the parasite population and reducing strain-specific responses. Subject to the usual 
cautions about generalising from animal models (reviewed in this context by Råberg 
et al. 2006 and Wargo et al. 2007), the results presented here argue against that, and 
suggest that protective efficacy may not be increased by including alternative 
variants of AMA-1.  My in vivo observations are consistent with previous results 
showing that immunization of rhesus monkeys with only one of two PfAMA-1 
variants is sufficient to induce cross protective antibody responses as measured by 
GIA and ELISA assays in vitro (Miura et al. 2007).  My results are also consistent 
with another study which demonstrated that mice and rabbits immunized with two 
allelic variants of domain I and II of the full length AMA-1 ectodomain from Indian 
P. falciparum isolates were able to inhibit in vitro parasite growth, but to no greater 
extent than with either of the allelic variants alone (Lalitha et al. 2008).   
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My results also demonstrate strain-specific anti-parasite responses (Fig. 4.4D) need 
not result in strain-specific protection against disease (Fig. 4.3G,H).  The observation 
that there are two different types of anti-malarial responses – immunity against the 
parasite itself and immunity against disease – is poorly understood on a molecular 
basis although  the distinction is widely appreciated (Schofield & Grau 2005).  An 
explanation for the two different responses observed here could be that the 
specificity of the anti-AMA-1 antibody response lies with the generation of 
inhibitory antibodies which may target the hypervariable region located around a 
conserved hydrophobic pocket on domain I (Coley et al. 2007).  The presence of 
such antibodies could determine the observed parasitaemias.  For bi-allelic 
immunizations there may exist a dominant epitope in one allelic form of AMA-1.  
Thus, high titres of cross-reactive antibodies may be sufficient to lessen morbidity 
(hence the similar effects for mono-and-bi-allelic vaccination on morbidity) but the 
inhibitory antibodies are more effective at controlling parasite numbers by inhibiting 
invasion.  In my pilot studies I did not observe a disproportionate IgG2b antibody 
response to one of the immunizing antigens (Fig. 4.1).  However, since immunization 
with AMA-1 is likely to induce a repertoire of IgG isotypes (Burns et al. 2004; 
Eisenhut 2007; Gray et al. 2007; Osier et al. 2008) some of the other isotypes may be 
sufficiently cross-reactive.  An implication of this may be that while strain-specific 
immunization may alter allele frequencies in parasite populations, this need not have 
clinical consequences in a vaccinated host. Changes in allele frequencies without 
public health consequences have been seen in some other diseases, such as pertussis 
(reviewed in Read and Mackinnon 2008). 
 
The ‘Combination B’ malaria vaccine, one of the few to reach field trials, 
demonstrated strain specific anti-parasite effects despite being comprised of an allele 
of each of 3 asexual blood stage proteins, MSP-1, MSP-2 and RESA (ring-infected 
erythrocyte surface antigen) (Genton et al. 2002).  Of particular interest was that 
vaccination increased the frequency of parasites with an MSP-2 genotype belonging 
to the FC27 allelic family.  No representatives of this allelic family, which had been 
found previously to be associated with severe morbidity, were included in the 
vaccine (Engelbrecht et al. 1995; Genton et al. 2002; Genton et al. 2003). Selection 
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for the FC27 form of MSP-2 could have been because of strain-specific protection 
(Fluck et al. 2004; Fluck et al. 2007), or because the vaccine was less effective at 
protecting against more virulent strains (Mackinnon & Read 2004a; Mackinnon et al. 
2008; Read & Mackinnon 2008).  In the study I report here, I looked at the relative 
proportion of the more virulent genotype in a mixed infection under the different 
immunization compositions.  In sham-immunized control mice and those which 
received the bi-allelic immunization, the more virulent genotype (DS) was 
proportionally the most dominant.  Thus, bi-allelic immunization did not alter within 
host selection.  On the other hand, immunization with a single AMA-1 variant did 
facilitate evasion of the heterologous genotype in mixed infections.  In my 
experiments, this effect was symmetrical (Fig. 4.5), so that immunization with AMA-
1 appears to induce protective responses that are strain-specific and evasion is 
independent of parasite virulence. 
 
Nevertheless, selection for virulence could be an inadvertent consequence of 
including just one allele from a given locus in a vaccine, as apparently happened in 
the Combination B trial.  As far as I am aware, there are no reports that variants of 
AMA-1 have different intrinsic virulence, so that the strain specific immunity against 
this locus I report here and that has been seen by others (Crewther et al. 1996; Healer 
et al. 2004), should not directly alter virulence.  But caution is necessary for all 
antigens involved in processes like cell invasion which are associated with 
pathogenesis.  Population-level association studies for disease severity should be 
performed for all antigens included in candidate vaccines.  Should associations like 
that for MSP-2 be found (Engelbrecht et al. 1995), I suggest on the basis of my 
results that there would be a strong case for including all known variants at that locus 
in the vaccine.  This would not confer short term clinical advantage, but it would be 
the safest way to avoid inadvertent selection for virulent variants, which would put 
unvaccinated people at greater risk. 
  
More generally, though, we still have some way to go to understand the potential for 
vaccine-driven virulence evolution, even in the P. chabaudi model.  One 
experimental study demonstrated that parasites from a single P. chabaudi genotype 
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serially passaged through whole-parasite immunized mice evolved to be more 
virulent than parasite lines that those evolved in naïve hosts (Mackinnon & Read 
2004a).  That study was the first to show under controlled conditions that 
immunization can favour the evolution of more virulent parasites. The implication 
was that more virulent variants had a selective advantage in immunized hosts.  In the 
study I report here, which did not involve serial passage, I saw no signs of such an 
advantage.  DS, the more virulent genotype, dominated in mice immunized with the 
bi-allelic form, but to the same extent as in non-immunized mice.  In single antigen 
immunized mice, strain-specific immunity dominated with symmetrical effects for 
both genotypes.  Competition experiments with other P. chabaudi genotypes also 
failed to find an increased advantage to virulence in immunized hosts (Grech et al. 
2008).  It may be that the accelerated evolution of virulence seen during serial 
passage in immunized hosts (Mackinnon & Read 2004a; Mackinnon and Read 
2004b) is a feature of selection of virulence variants on an antigenically identical 
background.  In future experiments, I will serially passage single P. chabaudi 
genotypes through AMA-1 immunized and naïve mice to determine whether 
vaccination can drive the evolution of virulence to be greater when measured in 
naïve hosts. 
 
My experiments concerned antigenic polymorphism at a single target antigen.  
Considerably more work has focused on vaccines combining single variants from 
multiple antigenic loci (Richie & Saul 2002; Heppner et al. 2005; Garcia et al. 2006).  
For example, animal and human phase I trails have shown safety, tolerability and 
immunogenicity of formulations containing AMA-1 and MSP-1 (2002; Burns et al. 
2003; Pan et al. 2004; Faber et al. 2007; Hu et al. 2008).  Moreover, such 
‘multivalent’ vaccines have been shown to reduce parasitaemias in mice of distinct 
MHC haplotypes (Doolan et al. 1996) and against infections with different parasite 
strains as well as subspecies of different virulence (Scorza et al. 2008).  Thus, multi-
valency may be required to induce antibody responses against a repertoire of 
polymorphic parasite antigens (Bouharoun-Tayoun et al. 1995; Bull & Marsh 2002; 
Wipasa et al. 2002a; Wipasa et al. 2002b; Doolan et al. 2003; Moorthy et al. 2004; 
Eisenhut 2007; Osier et al. 2008) in the human outbred population exposed to 
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multiple parasite genotypes (Doolan & Hoffman 2001; Genton et al. 2002; Plebanski 
et al. 2002; Cortes et al. 2003; Doolan et al. 2003).  I suspect that multi-valent 
vaccines will prove to be a more efficient means of generating protection against the 
widest range of parasite genotypes.  Certainly, I found no evidence that the anti-
morbidity and anti-parasitic potency of a malaria vaccine would be enhanced by 
increasing the number of variants of a particular antigen.   
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Theory and some data suggest that more virulent malaria parasites may be less 
readily controlled by immunization, raising the possibility that a malaria vaccine 
could select for more virulent parasites.  In this study, we tested whether the 
protective effects of vaccination with the malaria vaccine candidate apical membrane 
antigen (AMA-1) depended on the virulence of the challenge parasites.  A single 
Plasmodium chabaudi genotype was serially passaged through immunologically 
naïve mice which generated parasites that caused more anaemia and weight loss, and 
which were able to achieve higher densities and persist for longer before immune 
clearance.  These more virulent parasites were less readily controlled by immunity 
induced by immunization with homologous recombinant AMA-1 than were the less 
virulent parasite from which they were derived.  Thus, vaccination has the potential 
to selectively favor more virulent parasites.  These results may go some way to 
explaining why parasites serially passaged through whole-parasite immunized mice 
become virulent more rapidly than those evolved through naïve mice, and an 
observed example of selection imposed by malaria vaccines during a field trial.  The 
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data argue for further consideration of the evolutionary consequences of pathogen 
virulence on vaccination. 
5.2. Introduction 
 
Any form of medically therapeutic intervention has the potential to impose selection 
on pathogen populations.  The fact that malaria parasites developed drug resistance 
within 5-30 years of first using a drug is indicative of their potential to rapidly evolve 
(Peters 1987; Hyde 2005).  Currently, there is no vaccine against malaria, and 
therefore we do not know formally how vaccines may impose selection on 
Plasmodium populations.  
 
The trial of the malaria vaccine known as ‘Combination B’, provided the first field 
evidence that a vaccine against this disease could impose selection (Genton et al. 
2002; Genton et al. 2003).  One component of the vaccine was the Merozoite Surface 
Protein 2 (MSP-2).  MSP-2 is known to exist as two allelic families, the 3D7 type 
and the FC27 type.  In follow up surveillance studies, the prevalence of parasites 
with the 3D7 type, included in the vaccine, was reduced in vaccinees compared to 
those which had received a placebo (Genton et al. 2003).  The prevalence of parasites 
which carried the FC27 type was unaffected.  Interestingly, the FC27 type had 
previously been associated with more virulent infections (Engelbrecht et al. 1995).  
This trial raised the question as to whether vaccination had imposed selection that 
was strain (genotype)-specific (Fluck et al. 2004; Fluck et al. 2007) or whether the 
vaccine was just less effective at controlling more virulent variants.   
 
Immunization has been shown to impose selection on malaria parasites in a strain 
(genotype)-specific manner (Crewther et al. 1996; Fluck et al. 2004; Darko et al. 
2005; Martinelli et al. 2005; Cheesman et al. 2006). However, evidence to support 
the possibility that vaccination may select for more virulent genotypes has also 
started to appear.  Evolutionary theory suggests there are two possible advantages to 
virulence.  First, higher virulence is associated with a greater total transmission 
potential across the course of infection.  This could be achieved by more 
transmissible forms per day of infection, a longer transmission period due to reduced 
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immune clearance, or a combination of both processes (Anderson & May 1982; 
Mackinnon & Read 2004a; Mackinnon & Read 2004b; Frank & Schmid-Hempel 
2008; Schmid-Hempel 2008).  Second, competition experiments between genotypes 
which differ in virulence have shown a transmission advantage to virulence (de 
Roode et al. 2005; Bell et al. 2006).  It is possible that vaccination could alter one or 
more of the parasite benefits of virulence and thus enhance selection for more 
virulent genotypes. 
 
In line with predictions, when single P. chabaudi genotypes are serially passaged (by 
syringe transfer of parasites in blood from one host to another) through whole-
parasite immunized or naïve mice, genotypes evolved through immunized animals 
have higher virulence (here defined as harm to host following infection) when 
measured on naïve mice, even after mosquito transmission (Mackinnon & Read 
2004b).  That study was the first to show under controlled conditions that 
immunization can favour the evolution of more virulent parasites.  In another study, 
which did not involve serial passage, selection for virulence was measured by 
comparing vaccine efficacy of AMA-1 derived from P. chabaudi genotype DK 
against two antigenically distinct parasites which differed in virulence but were 
identical at the ama-1 sequence (Grech et al. 2008 in prep).  The more virulent 
genotype was found to be less well controlled.  Similarly, in the same experiment 
when DK AMA-1 vaccine efficacy was tested against a virulent lineage and the 
ancestral genotype from which it was derived by serial passage through 
immunologically naïve mice, the virulent lineage was less well controlled by 
heterologous immunization.  Those studies have suggested that there is a within-host 
advantage to virulence in immunized hosts. 
 
However, other studies have presented conflicting data.  AMA-1 derived from P. 
chabaudi genotype DS tested against the same P. chabaudi parasites used by Grech 
et al (2008) found that the more virulent genotype was not harder to control (Chapter 
3).  Furthermore, reciprocal DK AMA-1/DS AMA-1 immunization and parasite 
challenge trails appeared to induce protective responses that were genotype-specific, 
independent of parasite virulence [Chapter 4, Appendix 1 (Barclay et al. 2008a)].  
Chapter 5- Serial passage 97
Competition experiments have also failed to find an increased advantage to virulence 
in immunized hosts (Grech et al. 2008).  Additionally, CD4+ T cells were shown not 
to enhance selection for virulence during competitive interactions [Chapter 6, 
Appendix 2 (Barclay et al. 2008b)].  Those results suggested that the CD4+-
dependent immune response, and mechanisms that act to enhance it such as 
vaccination, may not have the undesirable affect of strengthening selection for 
virulence. 
 
One of the explanations for the contrasting results above has been that the selection 
imposed by vaccination may depend on the fine specificity of the protective response 
induced by alternative vaccine antigens (Chapter 3).  Another explanation has been 
that accelerated evolution of virulence seen during serial passage (Mackinnon & 
Read 2004a; Mackinnon & Read 2004b) may be a feature of selection of virulence 
variants on antigenically identical backgrounds [Chapter 4, Appendix 1 (Barclay et 
al. 2008b)].  The aim of this study was to directly test whether there was a within-
host advantage to parasite virulence between two parasites with antigenically 
identical backgrounds.  A virulent lineage was derived by serial passage of a single 
P. chabaudi genotype through immunologically naïve mice. The more virulent 
lineage and the less virulent genotype from which the line was derived were then 
used to infect AMA-1 immunized mice.  Morbidity measurements as well as the 
parasitological status of the host were used to determine whether there was within-
host advantage to virulence in immunized hosts.   
 
Since there are currently at least six different vaccines based on the AMA-1 allele 
from the P. falciparum 3D7 strain currently in efficacy trials in humans (Polhemus et 
al. 2007; Maher 2008; Thera et al. 2008), deciphering whether AMA-1 has the 
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5.3. Material and Methods 
 
5.3.1. Parasites, hosts and serial passage 
 
Isolates containing Plasmodium chabaudi adami were originally collected from 
thicket rats (Thamnomys rutilans) in the Congo (Brazzaville) (Cater and Walliker 
1976).  P. c. adami were cloned, genotyped and are stored in liquid nitrogen with 
subscript codes used to identify their position in clonal history.  The protocol for 
serial passage followed that of Mackinnon and Read (2004a).  In this study I used 
DK122 as the ancestral genotype.  Ancestral parasites were repeatedly passaged in 
mice (female C57BL/6) that were naïve to malaria infection for 30 mouse 
generations to derive a parasite line known as DK294.  Herein, the ancestral DK 
genotype will be referred to as DKancestral and the line derived by serial passage as 
DKderived.   Passages involved the syringe transfer to a fresh mouse of 0.1 ml of diluted 
blood containing 5x105 parasites from a donor mouse that had been infected 7 days 
previously.  Day 7 post infection is during the period of rapid population growth, and 
is about 2 days prior to peak parasitaemia, after which population size rapidly 
declines.   
 
5.3.2. Immunization and experimental set-up 
 
Immunization protocols followed those of (Anders et al. 1998) and (Crewther et al. 
1996).  Rabbits were immunized with the highly immunogenic ectodomain of the full 
AMA-1 protein derived from parasite DK emulsified in Montanide ISA 720.  For 
primary immunizations, rabbits received a total of 100-200 µg of emulsified antigen 
between two intramuscular sites.  Rabbits were boosted at 4-8 week intervals with 
the same amount of antigen injected intramuscularly and subcutaneously.  
Immunoglobulin G (IgG) was isolated from the sera of rabbits by affinity 
chromatography on protein A-Sepharose columns (Pharmacia/Amrad).  Prior to 
immunization experimental mice were randomized into four groups (Table 5.1).  For 
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the transfer of antibodies to mice, three milligrams of purified anti-DK AMA-1 IgG 
(hereafter referred to as DK AMA-1) was administered intraperitoneally one day 
before parasite infection and again 3 hours before parasite infection.   Control mice 




Parasite  Control DK AMA-1 
DK ancestral 4 4 
DK derived 4[1] 4[1] 
 
 
Table 5.1 Experimental design.  Groups of mice (4 per group) either sham-immunized 
(control) or immunized with recombinant DK AMA-1.  Infection was with DKancestral or  
DK derived. The number of mice found dead during the experiment are indicated by the number 
in brackets.   
 
 
Groups of treated mice (control sham-immunized or DK AMA-1) were infected 
either with DKancestral or DKderived 3 hours after the boost immunization.  Mice were 6-
8 week old female C57BL/6J and were injected intraperitoneally with 105 parasites as 
described elsewhere (Mackinnon & Read 1999).   
 
I followed the infection dynamics for 29 days.  From the first day of parasite 
infection (day 0), I daily measured body weights and took blood samples from the 
tail of experimental mice to estimate RBC density (by flow cytometry; Beckman 
Coulter).  From day 4 post parasite infection onwards, I daily took blood samples 
from the tail to make Giemsa-stained blood smears for estimating daily parasite 
densities.  I chose day 4 as this is around the first day that parasites can be detected in 
the blood using microscopy.  Since P. chabaudi has a 24 hour replication cycle, the 
total number of parasites in any period can be estimated by summing the daily 
parasite counts.   
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5.3.3. Sequencing of the AMA-1 alleles of P. chabaudi 
 
Primers were designed to amplify the ama-1 gene as two fragments.  Primer 
sequences were: Forward 5' GGG TCC AAG ATA TTG TAG 3' and reverse 5' TGG 
TGT TTG TGT GTG ATG C 3'.  Primer sequences for fragment 2 were: Forward 5' 
CTT GGG TAA TTG TTC CGA 3' and reverse 5' GGT TTC CCA ATC TTC ACG 
3'.  PCR was performed using Plantinum® Tag DNA polymerase (Invitrogen), with 
the thermocycle profile; 95oC for 7 mins, 50 oC for 1 min, 72 oC for 2 min, followed 
by 95 oC for 3 mins, 51 oC for 1 min, 72 oC for 2 min, followed by (93 oC for 1 min, 
52 oC for 1 min, 72 oC for 1 min) x 28, ending at 72 oC for 10 mins.  DNA was 
amplified using ImmolaseTM  DNA polymerase (Bioline).  Sequencing reactions were 
performed using a Prism BigDye Terminator Cycle Sequence Kit Version 3.1 (ABI) 
and the University of Edinburgh SBS Sequencing service ran the products of the 
reactions in-house on an ABI 3730 sequencer.  Sequences were analyzed using 
Lasergene 7 (DNAstar, Inc). 
 
5.3.4. Trait definition and statistical analyses 
 
Here I define virulence as the maximum change in red blood cells (anaemia) and 
weight, as well as the total parasite density reached across the course of an infection.  
Thus, an increase in virulence is defined as more severe anaemia, weight loss, and a 
greater number of parasites during infection of naïve mice with a derived line 
compared to an ancestral genotype.   
 
I used General Liner Models (GLM) in MINITAB (release 14, MINITAB Inc.) to test 
whether serial passage had derived a line with increased virulence and whether those 
traits also accrued under AMA-1 immunization; that is whether there was a statistical 
interaction between immunization and infecting parasite.  The response variables 
included minimum red blood cell density, minimum weight and total parasite density.  
Explanatory variables included infecting parasite (DKancestral or DKderived) and 
immunization (control sham-immunized or DK AMA-1).  Initial red cell density and 
weights were used as a co-variate.  Maximal models (response variable = 
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immunization + infecting parasite + all higher order interactions) were tested in the 
first instance, and minimal models were obtained by dropping non-significant terms 
successively, beginning with the highest order interactions, to obtain the significant 
minimal model.  All data were log transformed to meet normality assumptions of the 
model. 
 
During the experiment two mice died; these were included in the calculation of daily 
densities until death, and in the analyses of peak parasite densities since death always 
occurred as initial parasitaemias were declining.   
 
5.4. Results  
 
The treatment groups including number of mice per group and number of deaths 
during the experiment are shown in Table 5.1. 
 
In sham-immunised mice, infections with DKderived induced higher parasite densities 
(Fig 1; F1,6=19.74, p=0.004), caused more anaemia (Fig. 5.2, 3; F1,5 =8.31, p=0.034) 
and weight loss (Fig. 5.2,3; F1,5 =14.50, p=0.013) than did infections with DKancestral.  
Thus, serial passage resulted in more virulent parasites which were less easily 
controlled by immunologically naive mice.  The AMA-1 nucleotide sequence of the 
DKancestral and the DKderived genotype were unaffected by serial passage, with identity 
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Figure 5.1. Effect of Plasmodium chabaudi infection (DKancestral or DKderived) and 
immunization (sham control or recombinant DK AMA-1) on the kinetics of total asexual 
parasite density.  Lines (A) represent the change in parasite density over time.  Each line 
represents the mean of 4 mice (+/- 1 s.e.m) that were sham-immunized and infected with 
DKancestral (solid black line), or DKderived (solid black line open square), or immunized with 
recombinant DK AMA-1 and infected with DKancestral (dotted black line), or DKderived (dotted 
black line open square).  The bar graph (B) represents the total parasite density reached 
during infection with genotype DKancestral (black bars) or DKderived (grey bars).  Each bar 
represents the least squares mean of up to 6 mice (+/- 1 s.e.m). 
 
Parasite density kinetics under AMA-1 immunization and in sham-immunized 
control mice are illustrated in Fig. 5.1.  Immunization reduced parasite densities for 
the ancestral and derived genotypes (F1,6 = 190.60, p =<0.001 and F1,6=20.24, 
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p=0.004 respectively), but the extent of the reduction differed between them 
(immunization x infecting parasite interaction: F1,12 = 53.61, p =<0.001), with the 
protection less effective against DKderived (Fig. 5.1). Thus, serial passage generated 
parasites which were less well controlled by immunization with recombinant 
homologous AMA-1 than were the parasites from which they were derived. 
 
The kinetics of red blood cell density and weight loss of the ancestral and derived 
genotype under AMA-1 immunization and in sham-immunized mice are illustrated 
in Figures 5.2 and 5.3.  Immunization protected against anaemia (Fig. 5.2A,3A; F1,12 
= 8.65, p=0.012), and the magnitude of protection was similar against DKancestral and 
DKderived (immunization x infecting parasite interaction F1,11 = 0.37, p= 0.55).  
Immunization also protected against weight loss (Fig. 5.2B,3B; F1,12 =7.61, p=0.017), 
almost more effectively against the ancestral genotype than against the more virulent 
derived line (immunization x infecting parasite interaction: F1,11 = 4.71, p=0.053).  
Thus, in contrast to the anti-parasite protection, AMA-1 immunization was equally 
protective against anaemia induced by the two lines.  Protection against weight loss, 
on the other hand was more ambiguous, being almost significantly more effective 
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Figure 5.2. Legend on next page 
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Figure 5.2. Effect of Plasmodium chabaudi genotype infection (DKancestral or DKderived) and 
immunization (sham or with recombinant DK AMA-1) on red blood cell density and weight 
kinetics.  Lines represent the change in RBC density (A) and weight (B) over time.  Each 
line represents the mean of 4 mice (+/- 1 s.e.m) that were treated with a control sham-
immunization and infected with DKancestral (solid black line) or DKderived (solid black line open 
square), or immunized with DK AMA-1 and infected with DKancestral (dotted black line), or 
































































































Figure 5.3. Minimum red blood cell density, and minimum weight reached during infection 
with DKancestral or DKderived in sham-immunized or DK AMA-1 immunized mice.  Each bar 
represents the minimum red blood cell density (A) or minimum weight (B) reached during 
infection with DKancestral (black bars) or DKderived (grey bars).  Each bar represents the least 
squares mean of up to 6 mice (+/- 1 s.e.m). 
 
 




DKancestral      
DYRIPSGKCPVMGKGITIQNSKVSFLTRVATGNQKVREGGLAFPQTDVNISPITIDNLKL 60 
DKderived         
DYRIPSGKCPVMGKGITIQNSKVSFLTRVATGNQKVREGGLAFPQTDVNISPITIDNLKL 60 
                 
************************************************************ 
 
DKancestral      
MYKDHKEILALNDMSLCAKHASFYVPGTNVNTAYRHPAVYDKSNKTCYILYVAAQENMGP 120 
DKderived         
MYKDHKEILALNDMSLCAKHASFYVPGTNVNTAYRHPAVYDKSNKTCYILYVAAQENMGP 120 
                 
************************************************************ 
 
DKancestral      
RYCSNEEDNENQPFCFTPEKKDEYKNLSYLTKNLREDWETSCPNKSIQNAKFGVWVDGYC 180 
DKderived         
RYCSNEEDNENQPFCFTPEKKDEYKNLSYLTKNLREDWETSCPNKSIQNAKFGVWVDGYC 180 
                 
************************************************************ 
 
DKancestral      
SEYQKKEVHDNKTLLECNQIVFNESASDQPKQYEKHLEDTAKIRRGIVDRNGKLIGEALL 240 
DKderived         
SEYQKKEVHDNKTLLECNQIVFNESASDQPKQYEKHLEDTAKIRRGIVDRNGKLIGEALL 240 
                 
************************************************************ 
 
DKancestral      
PIGSYRADQVKSKGKGYNWANYDKKTKKCYIFNKKPTCLINDKDFVATTALSSLEEGPQE 300 
DKderived         
PIGSYRADQVKSKGKGYNWANYDKKTKKCYIFNKKPTCLINDKDFVATTALSSLEEGPQE 300 
                 
************************************************************ 
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DKancestral      
SFPCDIYKKKIAEEIKVMNVNRNNNGNDTIKFPRIFISDDKESLNCPCEPTQLTQSTCKF 360 
DKdeived         
SFPCDIYKKKIAEEIKVMNVNRNNNGNDTIKFPRIFISDDKESLNCPCEPTQLTQSTCKF 360 
                 
************************************************************ 
 
DKancestral      FVCNCVEKRQFISENNEVEIKDEFKSEYESPINQ 394 
DKderived         FVCNCVEKRQFISENNEVEIKDEFKSEYESPINQ 394 





Figure 5.4.  Protein alignment of AMA-1 fragment from DKancestral and DKderived and.  The 









In this study, as in many others (Ebert 1998; Mackinnon & Read 2004a; Mackinnon 
& Read 2004b), serial passage produced parasites that in naïve mice were able to 
induce more anaemia and weight loss, and achieve higher parasite densities than 
were the ancestral parasites.  The derived lineage was less effectively controlled by 
immunity induced by AMA-1 vaccination.  This decreased sensitivity to vaccination 
was not associated with the presence at detectable levels of mutations in AMA-1.  
Thus determinants at sites other than the target of vaccination must affect vaccine 
efficacy.  Whether these are virulence determinants remains to be formally 
determined.  Nonetheless, the data do show that selection imposed by immunity 
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induced by recombinant antigen immunisation has the potential to increase the 
frequency of virulent parasites.  
 
In the trial of the Combination B malaria vaccine it was unclear whether parasites 
which were carrying the more virulent MSP FC27 allele were unaffected by 
vaccination because of strain-specificity or whether the vaccine was just less 
effective at controlling those more virulent parasites.  This study demonstrates that 
the latter is possible: immunization may result in a within-host advantage to 
virulence.  My results support the implication from serial passage experiments 
through whole-parasite immunized hosts (Mackinnon & Read 2004b) and suggest 
the same selection for virulence may occur with immunity generated by candidate 
malaria vaccines.  
 
There are two possible within host advantages to virulence in an immunized host: 
enhanced competitive interactions in mixed infections and/or increased transmission 
potential.  In mixed P. chabaudi infections, competitive suppression of a less virulent 
genotype by a more virulent genotype has now explicitly been shown to be a positive 
selector for virulence (de Roode et al. 2005; Bell et al. 2006).  In one study, 
competitive interactions were shown to be weakly immune-mediated, raising 
concerns that vaccination may enhance competitive interactions and thus the force of 
this selection for virulence (Råberg et al. 2006).  However, another study 
convincingly demonstrated competitive interactions not to be immune-mediated 
[Chapter 6, Appendix 2 (Barclay et al. 2008b)].  Moreover, direct immunization with 
AMA-1 found no evidence that competitive suppression was enhanced by 
vaccination (Grech et al. 2008).  These results have suggested that the selection 
imposed by vaccination may not select for virulence by enhancing competitive 
interactions.  On the other hand higher parasite virulence may result in an increased 
transmission potential (Frank 1996; Mackinnon et al. 2008).  This could be achieved 
either by increasing the number of transmissible unit forms per day, by reducing 
immune clearance resulting in a more durable infection, or a combination of both 
mechanisms (Anderson & May 1982; Mackinnon & Read 2004a; Mackinnon & 
Read 2004b; Frank & Schmid-Hempel 2008; Schmid-Hempel 2008).  In this study I 
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observed that the derived lineage reached higher parasite densities and persisted for 
longer compared to ancestral genotype.  An explanation for this could be that that the 
advantage to virulence in an immunized host was avoidance of immune clearance.  
 
However, the result that a more virulent strain may have a selective advantage in 
immunized hosts may only go some way to explaining the selection observed with 
the Combination B vaccine trial.  For instance, immunization of mice with an AMA-
1 antigen derived from a more virulent P. chabaudi parasite observed anti-parasitic 
heterologous protection, independent of virulence (Chapter 3)  Furthermore, 
reciprocal DK AMA-1/DS AMA-1 immunization and parasite challenge trails 
appeared to induce protective responses that were strain (genotype)-specific [Chapter 
2; Chapter 4, Appendix 1 (Barclay et al. 2008b)].  Thus it is possible that both strain-
specificity and virulence differences have the potential to mediate vaccine-induced 
selection and this may depend on a number of factors including the fine specificity of 
the immune response induced by vaccination, the antigenic identity of the infecting 
parasites and the nature of the virulence difference.   
 
In this study I saw no difference in AMA-1 sequences between the derived lineage 
and the ancestral genotype.  Thus, serial passage through naïve mice did not select 
for variants at the AMA-1 locus (Fig. 5.4).  Clearly, the derived lineage caused more 
aggressive infections (Fig. 5.2, 5.3) and was less well controlled under AMA-1 
vaccination (Fig. 5.1).  Whether these phenotypic changes are heritably stable could 
be determined by passage through mosquitoes and/or by genomic comparison of the 
ancestral genotype and the derived lineage.  There is evidence for parasite heritable 
differences associated with virulence.  For example, molecular studies in P. 
falciparum have identified a sequence type called ‘sy2’ associated with rosetting, 
dominantly expressed in parasite isolates from children with severe malaria (Rowe et 
al. 1995; Chen et al. 1998; Bull et al. 2005).  Parasites sequestering in the placenta 
and giving rise to pregnancy-associated malaria share a common phenotype 
(adherence of infected red blood cells to chondroitin sulphate A via PfEMP-1) and 
some candidate var genes responsible for this phenotype have been identified 
(Salanti et al. 2004; Francis et al. 2007).  In the case of the Combination B malaria 
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vaccine the MSP2 FC27 allele, the type not included in the vaccine formulation, had 
itself been previously associated with more morbid infections (Engelbrecht et al. 
1995; Genton et al. 2002).  Population-level association studies for disease severity 
will be of importance for monitoring selection imposed in future vaccine field trials.  
 
Of notable interest, I found that AMA-1 immunization was stronger against the 
ancestral genotype densities but equally protective against anaemia.    The notion that 
there are two different types of anti-malarial immunity -immunity against the parasite 
itself and immunity against disease- is poorly understood on a molecular basis 
although  the distinction is widely appreciated (Schofield & Grau 2005).  
Mathematical models of epidemiological data suggest that immunity to clinical 
disease develops faster (and thus earlier in life) than does anti-parasitic immunity.  I 
view the fact that the two types of immunity may develop on different time scales to 
be of importance on two fronts.  First, both the parasitological status of the host as 
well as measurements of disease should be monitored during vaccine efficacy trials 
as the outcome of a trail could be interpreted differently depending on the 
measurement used.  Second, mathematical models of virulence evolution caution 
against malaria vaccines which reduce symptomatic disease while still maintaining 
parasite transmission (Mackinnon & Read 1999; Gandon et al. 2001; Gandon & Day 
2003; Gandon & Day 2007).  Such vaccines are expected to select for more virulent 
strains as the cost of virulence (host death) is removed by vaccination.  Those 
evolved strains are expected to cause more severe morbidity if transmitted to an 
unvaccinated host.  Since the work presented here and that by others (Mackinnon & 
Read 2004b; Grech et al. 2008 in prep) suggest that more virulent parasites may have 
a selective advantage in immunized hosts, one should be aware that the selection 
imposed by vaccination on individuals may have important evolutionary 
consequences for future host population disease morbidity.  Evolved virulence in 
response to vaccination has been described for two poultry diseases: Marek’s disease 
and Infectious Bursal Disease (van den Berg et al. 2000; Witter 2001; Davidson & 
Nair 2004; Rautenschlein & Haase 2005; Nouen et al. 2006).  In both these diseases 
failed vaccines were undermined by strains that were more virulent.  
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In these experiments I looked at whether heterogeneity induced by immunization 
affected selection for virulence.  Of course, heterogeneity exists on a number of 
levels which may influence how any within-host and between-host selection for 
virulence plays out (Garamszegi 2006; Williams & Day 2008).  For example, host 
susceptibility can depend on a range of factors including age, gender, nutritional 
status and concomitant infection with other pathogens (Williams & Day 2008).  
Thus, considering all aspects of host-pathogen interactions will be of importance in 
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6. CD4+ T cells do not mediate within-host 
competition between genetically diverse malaria 
parasites 
                                                                                                                                                                
This chapter, with a few minor editorial changes, has been published as Victoria C. 
Barclay, Brian H.K. Chan, Robin F. Anders, Andrew F. Read. 2008.  CD4+ T cells 
do not mediate within-host competition between genetically diverse malaria 
parasites.   Proceedings of the Royal Society of London Series B. 275: 1171-1179 
(See Thesis Appendix 2). 
 
6.1. Abstract  
 
Ecological interactions between microparasite populations in the same host are an 
important source of selection on pathogen traits such as virulence and drug 
resistance.  In the rodent malaria Plasmodium chabaudi in laboratory mice, parasites 
which are more virulent can competitively suppress less virulent parasites in mixed 
infections.  There is evidence that some of this suppression is due to immune-
mediated apparent competition, an immune response elicited by one parasite 
population suppress the population density of another.  This raises the question 
whether enhanced immunity following vaccination would intensify competitive 
interactions, thus strengthening selection for virulence in Plasmodium populations.   
Using the P. chabaudi model, I studied mixed infections of virulent and avirulent 
genotypes in mice depleted of CD4+ T cells. Enhanced efficacy of CD4+ T-cell 
dependent responses is the aim of several candidate malaria vaccines.  I hypothesized 
that if immune-mediated interactions were involved in competition, removal of 
CD4+ T cells would alleviate competitive suppression of the avirulent genotype.  
Instead, I found no alleviation of competition in the acute phase, and significant 
enhancement of competitive suppression after parasite densities had peaked. Thus the 
host immune response may actually be alleviating other forms of competition, such 
as that over red blood cells.  My results suggest that the CD4+-dependent immune 
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response, and mechanisms which act to enhance it such as vaccination, may not have 
the undesirable affect of exacerbating within-host competition and hence the strength 
of this source of selection for virulence. 
6.2. Introduction 
 
Parasitic infections are often genetically diverse, with hosts concurrently infected by 
more than one genotype. Crowding, where pathogen populations within a host are 
suppressed by the presence of competitor strains, can affect the health and 
infectiousness of individual hosts, as well as the evolution of medically relevant traits 
such as virulence and drug resistance (Read & Taylor 2001) .  For example, selection 
for increased virulence is expected when a slower growing parasite is out-competed 
by a faster growing, more virulent parasite (Bremermann & Pickering 1983; van 
Baalan & Sabelis 1995; Frank 1996; Gandon et al. 2001; Alder & Losada 2002).  
Similarly, the relative fitness of drug resistant strains, and hence their rate of spread 
in a population, can be substantially enhanced when co-infecting drug-sensitive 
competitors are removed by chemotherapy (Bremermann & Pickering 1983; van 
Baalan & Sabelis 1995; Frank 1996; Hastings 1997 ; Mackinnon & Hastings 1998; 
Hastings & D'Alessandro 2000; Gandon et al. 2001; Alder & Losada 2002; Hastings 
2003; Mackinnon 2005a; Hastings 2006).  Analogous evolutionary processes can 
affect the rate of evolution of epitope variants in response to strain (genotype)-
specific vaccination (Lipsitch & Samore 2002; Read & Mackinnon 2008).  
 
Infections with the human malaria parasite Plasmodium falciparum frequently 
consist of more than one genotype (Walliker et al. 1976; Anderson et al. 2000; 
Awadalla et al. 2001; Jafari et al. 2004), and a variety of epidemiological evidence is 
consistent with crowding (Daubersies et al. 1996; Mercereau-Puijalon 1996; Arnot 
1998; Smith et al. 1999; Bruce et al. 2000; Hastings 2003; Talisuna et al. 2006).  In 
the rodent malaria model Plasmodium chabaudi in laboratory mice there is a strong 
relationship between parasite virulence and crowding such that more virulent 
genotypes have a competitive advantage (de Roode et al. 2003; de Roode et al. 
2005a; de Roode et al. 2005b; Bell et al. 2006). 
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A number of biological mechanisms may underlie competition between genotypes 
within hosts (Read & Taylor 2001).  One of these is immune-mediated apparent 
competition (Holt 1977), where increasing densities of one pathogen population 
elicits a host response which suppresses the population of another.  T-cell dependent 
immune-mediated competition has been demonstrated in P. chabaudi (Råberg et al. 
2006): in nude mice, which cannot produce mature T cells, competition was less 
severe than in nude mice reconstituted with T cells.  Because many malaria vaccines 
currently under trial are aimed at inducing T cell-dependent responses, that 
experiment raised the question of whether vaccination might exacerbate in-host 
competition and thus affect pathogen evolution, for instance by strengthening 
selection for competitive ability and hence virulence.   
 
The effects of immunity on in-host competition are unlikely to be simple. The 
immune response to Plasmodium infection has both pathogen genotype transcending 
(non-specific) and genotype specific components. Protection is generally thought to 
become more specific during later stages of infection (Jarra & Brown 1989; Buckling 
& Read 2001; Mackinnon & Read 2003; Stevenson & Riley 2004; Martinelli et al. 
2005; Cheesman et al. 2006). Thus, in contrast to non-specific immunity, which 
could generate immune-mediated apparent competition, specific immunity could in 
principle act to alleviate competition (Råberg et al. 2006). Here I extend the study by 
Råberg et al. (2006) by focusing on a specific subset of T-cells, in order to further 
investigate the importance of immunity in determining competitive outcomes within 
hosts. 
 
T cells can be divided into two major categories, CD4+ and CD8+ cells.  It is well 
established from both experimental animal models and field studies in humans that 
CD4+ T cells play a pivotal role in the development of blood stage immunity to 
Plasmodium infection (Good & Doolan 1999; Pombo et al. 2002).  They are initially 
required to produce cytokines which amplify the phagocytic and parasitocidal 
response of the innate immune response and later on to dampen this response to limit 
immunopathology.  As the response becomes more adaptive they are required to help 
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B cells produce antibodies which are essential for parasite clearance (Urban et al. 
2005; Stephens & Langhorne 2006). 
 
Since CD4+ T cells have been described as having such a crucial role in natural 
immunity to the blood stage of infection, and vaccine programmes strive to mimic 
and enhance this response (e.g. Stephens and Langhorne 2006), I have begun to 
investigate the specific role of these cells during competition in mixed infections of 
P. chabaudi. Specifically I looked at the acute phase of infection, where any 
interactions between the parasite and the host immune response can strongly 
influence host health (Urban et al. 2005).  I chose two parasite genotypes which had 
been shown previously to differ in competitive ability and compared the extent of 
competition in immunocompetent and CD4+ T cell depleted mice.  I hypothesised 
two possible scenarios: (i) if T-cell dependent immunity induces a non-specific 
response, then a numerically subdominant genotype would experience a stronger 
immune response in a mixed infection than when on its own.  Thus, competition 
should be eased in CD4+ T cell depleted mice; (ii) if the immune response is largely 
genotype-specific and primarily elicited against the numerically dominant genotype, 
then CD4+ T cell depletion may exacerbate other forms of competition, such as 
competition for limited resources such as red blood cells.  
 
6.3. Material and methods 
 
6.3.1 Parasites and hosts 
 
Isolates containing Plasmodium were originally collected from wild caught thicket 
rats (Thamnomys rutilans) from different geographical areas of the African continent 
(Carter and Walliker 1976; Beale et al. 1978).  P. chabaudi chabaudi were isolated 
from the blood of rats from the Central African Republic, while P. c. adami were 
isolated from the blood of rats from the Congo (Brazzaville).  Laboratory rodents 
were infected with sub-inoculations of blood and the parasites were genotyped.  
Genotyped genotypes were stored as frozen stabilites in liquid nitrogen with 
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subscript codes used to identify their position in clonal history (Beale et al. 1978; 
Mackinnon & Read 1999b).   
 
In this experiment I used P. c. chabaudi genotype AS12062 and P. c. adami genotype 
DK108.   Herein these genotypes will be referred to as AS and DK.  These genotypes 
were chosen based on their relative virulence and non-lethality.  Pilot studies showed 
that genotype DK achieved higher parasite densities when genotype AS was absent 
than when AS was present. In contrast, genotype AS was not competitively 
suppressed by DK.  Hosts were inbred female C57BL/6J mice age 6-8 weeks (Harlan 
England) maintained as described previously (de Roode et al. 2004b). 
 
6.3.2.  Depletion of CD4+ T lymphocytes in vivo 
 
A rat monoclonal antibody, GK1.5, was used to deplete CD4+ T cells.  A non-
depleting rat monoclonal antibody of the same isotype (IgG 14131, Sigma) was used 
as a control. Experimental mice were injected intra-peritoneally with 500 µg of the 
appropriate purified antibody in phosphate-buffered saline (PBS) 5 days before 
parasite challenge, and then by 250 µg 4 days and 1 day before parasite challenge 
and weekly after challenge.   
 
A fluorescent activated cell sorter (FACS) was used to confirm CD4+ T depletion.  
20 µl of blood was taken from a tail snip 1 day prior to parasite challenge and once a 
week throughout the experiment.  Single cell suspensions were made by removing 
red blood cells using Lympholyte according to the manufactures instructions 
(Cedarlane, Canada). Approximately 1 x 106 cells were then transferred to a round 
bottomed plate and re-suspended in FACS buffer (PBS with 2% FCS with 0.05% 
sodium azide) before incubation for 20 minutes at 4oC with Allophycocyanin (APC) 
labeled anti-CD4+ antibody (Pharmingen). Cells were washed 3 times in FACS 
buffer.  Samples were collected on a FACSCalibur, and 10,000 live events were 
collected for the majority of samples. FlowJo (TreeStar, Ca) was used to analyse the 
data. 
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6.3.3.   Experimental setup and sampling 
 
Groups of five mice were treated as follows: (i) control antibodies and challenged 
with 106 AS parasites; (ii) control antibodies and challenged with 106 DK parasites; 
(iii) control antibodies and challenged with 106 AS and 106 DK; (iv) anti-CD4 
antibodies and challenged with 106AS; (v) anti-CD4 antibodies and challenged with 
106 DK, (vi) anti-CD4 antibodies and challenged with 106 AS and 106 DK.  
 
Parasites were delivered by intra-peritoneal injection.  I used the same dose of each 
genotype in single and mixed infections (rather than the same total dose in single and 
mixed infections) because the aim of the study was to compare the performance of a 
genotype when it is on its own with its performance when it is in a mixed infection. 
A two-fold difference in infective dose has negligible effects on the population 
dynamics of the parasite (Timms et al. 2001).  In addition I included 2 extra control 
groups, each of two mice, which were not challenged with malaria, one group treated 
with anti-CD4 antibodies and one group with control antibodies.  These mice were 
used to check that CD4+ T cell depletion was continuous throughout the experiment 
as the number of peripheral T cells are lower than normal during the acute stage of 
disease (Hviid et al. 1997).   
 
During the course of infection I measured body weights and took blood samples from 
the tail to make Giemsa-stained blood smears and to estimate RBC density (by flow 
cytometry; Beckman Coulter) and for genotype-specific real-time quantitative PCR 
(qPCR) assays.  
 
One mouse died during the experiment (CD4+ T cell depleted, mixed infection) and 
was included in the analyses only where possible. For unknown reasons, two 
infections (both non-depleted, a DK-only and an AS-only) achieved a peak parasite 
density two orders of magnitude lower than all others, and these were excluded from 
all analyses. 
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6.3.4.  Quantitative PCR 
 
Samples were taken in the morning as this is the stage when most parasites are in the 
ring or early trophozoite stage in the peripheral blood (de Roode et al. 2004).  From 
each mouse, 5 µl of tail blood was taken and added to 100µL of citrate saline on ice.  
Samples were subsequently pelleted by centrifugation and the citrate saline was 
removed.  Blood was stored at -80oC until required.  DNA extraction was performed 
using the BloodPrepkit (Applied Biosystems) on the ABI prism 6100 Nucleic Acid 
prep-station according to manufacturer’s instructions.  DNA was eluted in a total 
volume of 200 µL and stored at -80oC until quantification.  Genotype-specific qPCR 
was performed as described previously (Bell et al. 2006) with the addition of the DK 
specific reverse primer: 5' AGG CAT GTT TTG CAC ACA ATG A 3'.  
 
6.3.5. Trait definition and statistical analyses 
 
I define competitive suppression to be a reduction of parasite numbers when another 
genotype is present, which I tested for by comparing the performance of a genotype 
in single and mixed infections. Performance was measured as the clonal density 
summed over a defined time period. P. chabaudi has a 24 hour replication cycle, so 
the total number of parasites present in any period can be estimated by summing the 
daily parasite counts. Thus, to test whether competitive suppression was CD4+ T-cell 
mediated, I asked, for each genotype, whether the magnitude of any competitive 
suppression differed between intact control and CD4+ T cell-depleted hosts; that is, 
whether there was a statistical interaction between immune treatment (intact control 
vs  CD4+ T cell-depleted hosts) and infection type (single vs mixed). 
 
The effects of competition and CD4+ depletion on the performance of individual 
genotype and red blood cell density were first examined by using general linear 
models (GLM) in the statistical package MINITAB (release 14, MINITAB Inc.).  For 
GLM analysis, response variables included mean total parasite density and mean 
RBC density, with initial RBC as a covariate.  Explanatory variables for GLM 
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included CD4+ depletion (depleted or intact control) and competition (genotype 
alone or in mixed infection).  Maximal models (response variable = CD4+ depletion 
+ competition + all higher order interactions) were tested in the first instance, and 
minimal models were obtained by dropping non-significant terms successively, 
beginning with highest order interactions, to obtain the significant minimal model.  
Second, we used repeated measures analyses, which take into account the importance 
of day post-infection. These analyses were performed as described by Råberg et al. 
(2006) using the statistical package SAS 9.1 (SAS Institute 1999). Briefly, the 
analyses were performed with PROC MIXED, using the REPEATED statement 
(subject=mouse), the Satterthwaite approximation of the denominator degrees of 
freedom, and the autoregressive covariance structure AR(1). Within each treatment 
group, the peak day varied ± 2 days, presumably as a result of slight differences in 
inoculation dose. To control for this variation, I centered the peak day at the median 
peak day within each treatment group. All density data was transformed using [log10 





6.4.  Results 
 
 
Mice treated with the anti-CD4+ T cell antibody were successfully depleted of CD4+ 
T cells, both prior to parasite challenge and during the whole course of the 
experiment (Fig. 6.1).  CD4+ T cell depletion resulted in more parasites of both 




















































































































































Figure 6.1.  FACS plots of number of cells analyzed and percentage of CD4+ T cells in (A) 
CD4+ T cell depleted and (B) intact control mice.  Percentage of CD4+ T cells was analyzed: 
(i) one day before parasite challenge and; (ii-iv) once a week throughout the experiment. 
Each graph is a representative of one mouse from either the CD4+ T cell depleted or 




6.4.1. Genotype DK  
 
As found with other pairs of genotypes (de Roode et al. 2003; de Roode et al. 2005a; 
de Roode et al. 2005b; Bell et al. 2006), I found here that the relatively avirulent 
genotype was competitively suppressed by the more virulent genotype, with DK 
achieving lower parasite densities when AS was present than when it was absent 
(Fig. 6.2A; Table 6.1).  However, the extent of competitive suppression of genotype 
DK was similar regardless of CD4+ T cell depletion (Table 6.1; depletion x 
competition interaction n.s.).  Thus, there was no evidence that the competitive 
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suppression of the total number of DK parasites present in an infection was mediated 
by CD4+ T cell dependent immunity.   
 
However, repeated-measures analysis of the period where CD4+ T cell depletion 
affected parasite densities (day 6 onwards) showed a weak but significant three-way 
depletion x competition x day interaction (Table 6.2).  To investigate this further, and 
following Råberg et al (2006), I divided the data into three parts: days 6-8; days 9-
11; and days 12-14, and repeated the analyses with each of these (Fig. 6.2A,C-E; 
Table 6.3).  During each of these time periods there were significant depletion x 
competition or depletion x competition x day interactions.  Inspection of Fig. 2A and 
C shows that the three-way interaction in the first period is a very weak effect from 
which it is difficult to conclude much, given the rapid alterations in infection kinetics 
during that period caused by depletion. In the other two periods, there are significant 
competition x depletion interactions (Fig. 6.2D,D; Table 6.3), with more severe 
competitive suppression in CD4+ T cell depleted mice than in control mice.  Thus, 
there was no evidence that competitive suppression is CD4+ T cell-mediated: once 
the initial wave of parasitaemia began to subside, competitive suppression was 
exacerbated rather than alleviated in CD4+ depleted mice.  
 
6.4.2.  Genotype AS 
  
There was no evidence of competitive suppression of AS by DK, irrespective of 
immune treatment (Fig. 6.2B; Table 6.1).  Repeated-measures analysis from day 6 
onwards, when CD4+ depletion had an effect, revealed no evidence of interactions 
between depletion and competition (Table 6.2).  However for comparison with the 
analysis of genotype DK, I repeated the same analyses for AS on days 6-8, 9-11 and 
12-14 (Table 6.4).  In none of these time periods was there any evidence of 































Figure 6.2.  Parasite densities through time of (A) genotype DK and (B) genotype AS, and 
(C-E) average densities of DK during the periods denoted by the vertical dotted lines.  
Asexual density from qPCR of CD4+ T cell depleted mice and intact control (normal) mice 
with single infections in CD4+ T cell depleted mice and intact control (normal) mice with 
mixed infections.  Mean densities (± 1 S.E.M) were calculated from all mice which were 
alive on the respective day of sampling (up to five).  The interaction plots (C-E) show total 
numbers of DK parasites when the competitor genotype AS is absent (single infection) or 
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lines).  Competition x depletion interactions: (c) F1,16 = 1, P=0.33, (d) F1,17 = 5.11, P=0.0372, 





  DK  days  2-14 AS days 2-14 
Effect df F P df F P 
CD4+ depletion 1,15 82.7 <0.001 1, 15 93.36 <0.000 
Competition 1,15 84.2 <0.001 1, 15 2.05 0.17 
CD4+ depletion x 
competition 
1,15 0.6 0.74 1, 15 0.94 0.94 
 
Table 6.1. GLM analyses of the effects of CD4+ T cell depletion, competition 
(presence/absence of co-infecting clonal genotype) and their interaction on the total number 






 DK days 6-14 AS days 6-14 
Effect df F  P df F  P  
CD4+ depletion 1, 16 74.52 <.0001 1, 17 51.58 <.0001 
Competition 1, 16 17.92 0.0006 1, 17 1.86 0.19 
Day 8, 101 30.80 <.0001 8, 108 40.85 <.0001 
CD4+ depletion x competition 1, 16 2.65 0.12 1, 17 0.02 0.88 
CD4+ depletion x day 8, 101 22.35 <.0001 8, 108 15.67 <.0001 
Competition x day 8, 101 3.67 0.0009 8, 108 0.91 0.51 
CD4+ depletion x  competition 
 x day 
8, 101 2.10 0.042 8, 108 0.47 0.87 
 
Table 6.2. Repeated measure analyses of the effects of CD4+ depletion, competition 
(presence/absence of coinfecting clonal genotype) and day post-infection on the daily 
densities of the two parasite genotypes DK and AS for days 6-14 post-infection. 
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Clone DK Days 6-8 Days 9-11 Days 12-14 
Effect df F P df F P df F P 
CD4+ depletion 1, 16 12.61 0.0026 1, 17 54.79 <.0001 1, 14 105.95 <.0001 
Competition 1, 16 62.31 <0.001 1, 17 47.53 <.0001 1, 14 1.33 0.26 
Day 2, 29 15.32 <0.001 2, 30 39.12 <.0001 2, 28 2.22 0.12 
CD4+ depletion 
 x competition 
1, 16 1.00 0.33 1, 17 5.11 0.037 1, 14 4.57 0.049 
CD4+ depletion  
x day 
2, 29 2.88 0.071 2, 30 11.87 0.0002 2, 28 23.78 <.0001 
Competition 
 x day 
2, 29 12.34 0.0001 2, 30 2.32 0.11 2,28 0.64 0.53 
CD4+ depletion  
x competition x 
day 
2, 29 3.78 0.034 2, 30 2.30 0.11 2,28 0.17 0.84 
 
Table 6.3.  Repeated measure analyses of the effects of CD4+ depletion, competition 
(presence/absence of coinfecting clonal genotype) and day post-infection on the daily 
parasite density of genotype DK for days 6-8, 9-11 and 12-14 post-infection. 
 
 
Clone AS Days 6-8 Days 9-11 Days 12-14  
Effect df F P df F P df F P 
CD4+ depletion 1, 14 17.58 0.0008 1, 15 31.83 <0.001 1, 14 58.71 <0.001 
Competition 1, 14 0.3 0.58 1, 15 2.08 0.16 1, 14 1.60 0.22 
Day 2, 28 39.82 <0.001 2, 29 89.06 <0.001 27 6.52 0.0049 
CD4+ depletion  
x competition 
1, 14 0.01 0.91 1, 15 0.11 0.74 1, 14 0.03 0.86 
CD4+ depletion  
x day 
2, 28 12.17 0.0001 2, 29 3.03 0.06 27 15.34 <0.001 
Competition 
 x day 
2, 28 0.22 0.80 2, 29 3.13 0.058 27 0.76 0.47 
CD4+ depletion 
 x  competition 
x day 
2, 28 1.20 0.31 2, 29 0.08 0.92 27 0.70 0.50 
 
Table 6.4.  Repeated measure analyses of the effects of CD4+ depletion, competition 
(presence/absence of coinfecting clonal genotype) and day post-infection on the daily 
parasite density of genotype AS for days 6-8, 9-11 and 12-14 post-infection. 
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6.4.3.  Red blood cells  
 
Red blood cell density over time for the different treatment groups are shown in fig 
3. Uninfected red blood cells form an important resource for malaria parasites.  To 
assess whether the potential for competition over this resource differed between 
CD4+ depleted and intact control mice I compared the red blood cell densities in 
mice with mixed infections.  Repeated measures analysis of days 6-14 revealed that 
CD4+ depleted mice had significantly lower red blood cell densities during this time 
period (Fig. 3C: F1,34.7=4.35, p=0.045). There was also a significant depletion x day 
interaction (F8,94.1=2.58, p=0.014). Separate analyses of days 6-8, 9-11, and 12-14 
























































































Figure 6.3. Legend on next page 
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Figure 6.3.  Mean red blood cell densities (± 1 S.E.M) over time. (A) CD4+ T cell depleted 
and intact mice infected with DK. (B) Depleted and intact mice infected with AS. (C) 





 Days 6-8 Days 9-11 Days 12-14 
Effect df F P df F P df F P 
CD4+ depletion 1, 21 1.77 0.14 1, 23 10.75 0.0033 1, 19 4.57 0.045 
day 2, 36 42.18 <0.001 2,37 11.98 <.0001 2,38 0.33 0.72 
CD4+ depletion 
 x day 
2, 26 3.18 0.05 2, 37 0.65 0.52 2, 28 0.08 0.92 
 
 
Table 6.5.  Repeated measure analyses of the effects of CD4+ depletion and day post-







I found no evidence that CD4+ T cells enhanced competition during mixed genotype 
infections with P. chabaudi (Fig. 6.2A; Table 6.1).  Specifically, during the peak 
stages of acute infection (days 6-8) suppression was independent of CD4+ T cells 
(Fig. 6.2C; Table 6.3).  After the peak of infection (day 9+), CD4+ T cells acted to 
alleviate competition, such that upon their removal competitive suppression was 
enhanced (Fig. 2D, E; Table 6.3).  In addition, the presence of CD4+ T cells did not 
cause suppression of the dominant genotype (Fig. 6.2B; Table 6.4).   
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The immune response to Plasmodium infection has both pathogen genotype 
transcending (non-specific) and genotype specific components, with protection 
becoming more specific during later stages of infection (see Introduction).  Here I 
found that after the peak of acute infection (day 9 onwards), there was no 
competitive suppression of DK parasites in intact control mice, whereas in CD4+ T 
cell depleted mice there was still evidence of competition (Fig. 6.2D,E; Table 6.3).  
Both genotypes did better in depleted mice, probably because of an impaired early 
antibody production through lack of T cell help and possibly the reduced recruitment 
and activation of macrophages for the uptake of infected cells.  Thus, in normal 
hosts, a largely genotype-specific adaptive immune response towards a numerically 
dominant genotype may act to alleviate competition by regulating clonal genotype 
populations and limiting other forms of competition, for example competition for red 
blood cells.   
 
During the peak of infection (days 6-8), competition was CD4+ T cell-independent so 
that the extent of competitive suppression of genotype DK was similar in intact 
control and CD4+ T cell depleted mice (Fig. 6.2A,C; Table 6.3).  A number of 
biological mechanisms could be the proximate cause of competitive suppression 
during the peak of infection.  First, there may be direct interference between two 
infecting strains.  This has not yet been demonstrated in any parasites, but pathogenic 
bacteria can produce allelopathic substances that actively suppress competitors 
(Riley & Gordon 1999) and competing viruses can produce interference molecules 
(Hart & Cloyd 1990).  Second, competition may be influenced by non-specific 
components of the innate immune response (CD4+ T cell-independent).  Third, there 
may be competition for resources as genotypes infecting mice simultaneously must 
divide the available red blood cells and other resources such as blood glucose 
between them (Hellriegel 1992; Hetzel & Anderson 1996; de Roode et al. 2005b; 
Gurarie et al. 2006).  CD4+ T cell depleted mice were more anaemic than control 
mice (Fig. 6.3; Table 6.5), so that if red cells are limiting, there is more potential for 
competition for that resource in depleted mice.  Mathematical models have suggested 
that during mixed-infection the proximate cause of competitive advantage may be 
attributable to an earlier and wider red blood cell preference of dominant genotypes 
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(Hellriegel 1992; Gravenor et al. 1995; McKenzie & Bossert 1997; Jakeman et al. 
1999; Mason & McKenzie 1999; McQueen et al. 2004; Antia et al. 2007).  Because 
these predictions are based on data from rodent malaria, they could be tested directly 
by transferring red blood cells of different ages into a single mouse and determine 
their loss following infection, or indirectly by measuring competition in untreated 
mice, and mice treated with erythropoietin (Suzuki et al. 2006).   
 
My conclusion that competition is not CD4+ T cell mediated apparently contradicts 
the recent finding of T-cell mediated apparent competition (Råberg et al. (2006).  In 
that study, the authors looked at mixed infections with P. chabaudi in nude mice 
(which lack the ability to produce mature T cells) and compared the extent of 
competition with that in nude mice re-constituted with T cells. There was still 
pronounced competition in all animals, but there was some alleviation of competitive 
suppression in nude mice towards the end of the acute phase of infection, when the 
initial wave of parasitaemia was waning.  This period corresponds roughly to days 9-
14 in fig 2.  A number of experimental differences could explain the contrasting 
results of Råberg et al. (2006) and the present study.  First, different mouse strains 
were used in the two studies and host genotype has previously been shown to 
quantitatively affect the outcome of competition (de Roode et al. 2004b).  Second, 
different pairs of genotypes were used, and P. chabaudi genotypes can induce 
different levels of strain-specific immunity (Cheesman et al. 2006).  Third, there was 
a difference in the method used to modulate T cell-dependent immunity.  Nude mice 
lack the ability to produce any mature T cells, including both CD4+ and CD8+ T 
cells.  The role of CD8+ T cells during malaria infection in mice is still unclear 
(Lamb et al. 2006), but it could be that they are involved in the relatively small 
component of competition which was shown to be immune-mediated competition in 
reconstituted nude mice (Råberg et al. 2006).  In addition, the repertoire of serum 
antibodies (including both natural antibodies and antigen elicited antibodies) in the 
CD4+ T cell depleted mice will be different from that in nude mice.  Nude mice grow 
up producing only T-cell independent antibodies, while in the CD4+ T cell depleted 
mice there will be both T-cell independent and persisting T-cell dependent antibodies 
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(produced by existing plasma cells in the bone marrow) and these may cross react 
with the parasite. 
 
Taken together, the present study and that of Råberg et al. (2006) show that the effect 
of T-cell dependent immunity on competition is relatively weak, and may be either 
positive or negative depending on specific details of host and parasite. Rather than 
further dissection of any immune mechanism mediating competition, one could use 
this malaria model system to look at the strength of competition in hosts immunized 
by a variety of different candidate vaccines towards the blood stage of infection. 
Meanwhile, the result I report here suggest that vaccines which enhance CD4+-
dependent immunity will not increase the selection in favour of virulence arising 







7. Vaccine-induced strain specific immunity does not 
enhance competitive interactions between genetically 
diverse malaria parasites  
 
In prep for publication in American Naturalist 
 
Victoria C. Barclay1,2, Brian H.K. Chan2, Lars Råberg3, Robin. F. Anders4 and 
Andrew F. Read1,2  
1School of Biological Sciences, University of Edinburgh EH9 3JT, UK 
2Centre for Infectious Disease Dynamics, Departments of Biology and Entomology, 
The Pennsylvania State University, University Park, 16802, USA. 
3 Department of Animal Ecology, Lund University, 223 62, Lund, Sweden 




Given that a large majority of infections with human malaria in the field constitute 
more than one genotype, it is likely that competitive interactions, where more 
virulent genotypes competitively suppress less virulent genotypes, are a driving force 
for virulence in natural Plasmodium populations.  Medical intervention strategies 
such as drugs and vaccination are likely to alter parasite interactions and thus the 
force of this selection for virulence.  The malaria vaccine candidate Apical 
Membrane Antigen 1 (AMA-1) has a number of polymorphisms, so that 
immunization induces protective responses that are strain-specific.  A proposed 
solution to overcome strain-specificity has been to design vaccines which contain 
more than one allelic form of AMA-1 (multi-allelic vaccines).  AMA-1 vaccination 
could affect the rate of virulence evolution if strain-specificity enhances the 
competitive suppression of a less virulent genotype, or the competitive release of a 
more virulent genotype.  In this study, I investigated how vaccine-induced strain-
specific immunity altered within host competition between genetically diverse P. 
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chabaudi infections.  I also tested whether a bi-allelic AMA-1 vaccine may alter such 
interactions.  I found no evidence that any type of immunization altered within-host 
competitive interactions.  The results from this study further suggest that the 
competitive benefits associated with virulence should not result in a selective 
advantage in an immunized host. 
 
7.2.  Introduction 
 
Within-host competition among different parasite genotypes is predicted to affect the 
epidemiology and evolution of many important parasite traits such as virulence, drug 
resistance and vaccine escape (Read & Taylor 2001).  For instance, competitive 
interactions within hosts alter the costs and benefits of drug resistance and hence the 
spread of resistance in a population.  In the absence of drug treatment, small costs of 
resistance can be magnified if they result in competitive suppression; in the presence 
of drug treatment, survival benefits of resistance can be magnified when sensitive 
competitors are removed. (Hastings 1997 ; Hastings & D'Alessandro 2000; Hastings 
2003; Mackinnon 2005a; Hastings 2006; Wargo et al. 2007)).  Competitive 
interactions also affect the evolution of virulence (Bremermann & Pickering 1983; 
van Baalan & Sabelis 1995; Frank 1996; Gandon et al. 2001; Alder & Losada 2002). 
This is especially so if more virulent strains have higher competitive ability.  
Vaccination programmes have the potential to alter the strength of this force of 
selection for virulence, potentially weakening or strengthening it.  If competition is 
immune-mediated, vaccination could make competition more intense.  Alternatively, 
by suppressing parasite densities, immunization could weaken resource-based 
competition.  These forces would have alternate effects on virulence evolution (Read 
& Mackinnon 2008).  In contrast, if vaccination has a strain (genotype)-specific 
component, it could facilitate the performance of heterologous genotypes (Lipsitch & 
Samore 2002), which need have little to do with virulence.   Here I experimentally 
test which of these occurs following AMA-1 immunization. 
 
In nature, human infections with malaria are often genetically diverse (Babiker et al. 
1991; Conway et al. 1991; Arnot 1998; Babiker et al. 1999; Smith et al. 1999a; 
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Tanner et al. 1999; Jafari et al. 2004).  Mixed infections can arise due to the bite of a 
single mosquito inoculating more than one genotype or via successive bites from 
multiple mosquitoes infected with different genotypes.  A variety of non-
experimental observations imply that competition occurs in human malaria 
(Daubersies et al. 1996; Mercereau-Puijalon 1996; Arnot 1998; Smith et al. 1999b; 
Bruce et al. 2000; Hastings 2003; Talisuna et al. 2006).   In the rodent malaria model 
Plasmodium chabaudi virulence is strongly correlated with competitiveness (Taylor 
et al. 1997; de Roode et al. 2003; de Roode et al. 2004a; de Roode et al. 2004b; de 
Roode et al. 2005a; de Roode et al. 2005b; Bell et al. 2006; Råberg et al. 2006).  In 
this system, avirulent genotypes tend to suffer more than virulent genotypes in mixed 
infections; their replicative and transmission stage densities are severely suppressed 
when co-infecting strains are present. 
 
The impact of vaccination on within-host competition and hence virulence evolution 
could be better predicted if we knew the factors mediating competition.  In theory, 
competitive interactions between different genotypes could be mediated by a number 
of different biological processes, including the host immune response (Holt 1977; 
Read & Taylor 2001).  To date, one experimental study has indicated that 
competition could be immune-mediated (Råberg et al. 2006).  In those experiments 
competitive suppression of an avirulent genotype was significantly less in nude mice, 
which cannot produce mature T cells, than in control mice.  That study raised the 
question of whether current vaccination programmes, which are aimed at inducing T 
cell-dependent responses, might exacerbate this source of selection for virulence.  
Consistent with this, serial passage (i.e. the syringe transfer of malaria infected blood 
from one host to another) of P. chabaudi through whole-parasite immunized hosts 
increased virulence more rapidly than serial passage through immunologically naïve 
mice (Mackinnon & Read 2004a).  Furthermore, more virulent P. chabaudi have 
been shown to be less well controlled by the malaria vaccine candidate Apical 
Membrane Antigen 1 (AMA-1) (Grech et al. 2008 in prep ).  An implication of those 
studies was that immunization may enhance the selective advantage of high 
virulence.   
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However, there are also two studies showing that competition may not be immune-
mediated.  First, competitive interactions were not alleviated during experiments 
which depleted mice of CD4+ T cells, a subset of the immune response identified as 
playing a pivotal role in protection against malaria [Chapter 6, Appendix 2 (Barclay 
et al. 2008a)].  In that study competitive suppression of the avirulent genotype was 
exacerbated in the absence of CD4 T cells, suggesting CD4 T cells may be 
alleviating other forms of competition, such as that for red blood cells.  That study 
highlighted that CD4+-dependent immune responses, and mechanisms that act to 
enhance it such as vaccination, may not have the undesirable affect of exacerbating 
within-host competition.  Second, a direct immunization study also failed to find to 
any evidence that vaccination might exacerbate competitive interactions (Grech et al. 
2008).  In that study immunization of mice was either with the malaria vaccine 
candidate AMA-1 or with live parasite.  Neither type of immunization altered the 
strength of selection within mixed infections in favour of virulence.  In this study I 
have extended on those previous experiments, where the combination of AMA-1 
antigens and parasites genotypes did not involve SSI, to test whether strain-specific 
immunity induced by immunization with AMA-1 is more likely to facilitate the 
release of a more virulent genotype in a mixed P. chabaudi infection than a less 
virulent genotype. 
 
AMA-1 is a well-characterized and functionally important merozoite protein and is 
currently considered a major candidate for a malaria vaccine [reviewed by Remarque 
et al. (2008a)].  Immunoepidemiological studies have shown that AMA-1 is highly 
immunogenic in natural infections (Thomas et al. 1994; Rodrigues et al. 2005; 
Wickramarachchi et al. 2006).  Immunization with AMA-1 confers protection 
against parasite challenge in a number of animal models, probably by inducing 
antibodies which inhibit invasion (Deans et al. 1988; Collins et al. 1994; Crewther et 
al. 1996; Anders et al. 1998; Stowers et al. 2002; Healer et al. 2004).  However, a 
number of studies have demonstrated that protection elicited by this vaccine is strain-
specific (Crewther et al. 1996; Anders et al. 1998; Hodder et al. 2001; Polley et al. 
2003; Cortes et al. 2005; Polhemus et al. 2007).  In theory, vaccine-induced strain-
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specific immunity could enhance competitive interactions by facilitating the 
competitive release of more virulent genotypes in a mixed infection.   
 
One approach to minimizing vaccine-induced strain-specificity has been to design 
vaccines which combine more than one allele of an antigen (Hoffmann & Miller 
1996; Bolad & Berzins 2000; Richie & Saul 2002; Polley et al. 2007).  A growing 
body of evidence suggest that multi-allele vaccines do not afford the host more 
protection from morbidity than do single antigen vaccines (Kennedy et al. 2002; 
Malkin et al. 2005; Miura et al. 2007) but that multi-allelic vaccines should not 
enhance the strength of selection for more virulent genotypes [Chapter 4, Appendix 1 
(Barclay et al. 2008b )].  What remains to be determined is whether multi-allelic 
vaccines will alter competitive interactions between diverse genotypes in mixed 
infections, which we test in this study. 
 
Thus, the aim of this study was to test whether strain-specific immunity, induced by 
AMA-1 vaccination, exacerbated the competitive suppression of a less virulent 
genotype, and/or the competitive release of a more virulent genotype in a mixed P. 
chabaudi infection.  I also investigated how a bi-allelic AMA-1 vaccine may alter 
competitive interactions.  This paper reports further analyses of the experiment 
described by Barclay et al. (2008) (Chapter 4, Appendix 1), which were designed to 
test the within host effects of mono and bi-allelic AMA-1 on host protection and 
parasite selection.  That previously published analysis showed that the immunization 
protocols generated SSI, but did not test for the effects of this on competition1. 
 
 
7.3. Material and methods  
 
                                                 
1 This chapter is split off from Chapter 4 both for clarity and because that chapter and this address 
different issues, and are likely to be for different audiences.  Because this chapter is written as a stand 
alone paper for publication, some repetition of methods is necessary. 
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7.3.1. Parasites and hosts 
 
P. chabaudi adami (P.c.a.) were originally isolated from wild-caught thicket rats 
(Thamnomys rutilans) in the Congo (Brazzaville) (Carter & Walliker 1976).  Isolates 
were genotyped and stored as frozen stabilites in liquid nitrogen with subscript codes 
used to identify their position in clonal history.  In this experiment we used P.c.a. 
genotypes DS500 and DK122.  Studies by others (Crewther et al. 1996) and my own 
pilot studies showed that these genotypes differ in virulence during infection of 
C57BL/6 female mice, with genotype DS generating substantially more parasites and 
inducing greater weight and red blood cell loss relative to DK [see Chapters 3 and 4].  
Hosts were inbred female C57BL/6 mice age 6-8 weeks (Harlan England) 
maintained as described previously (de Roode et al. 2004a). 
 
7.3.2. Immunizations and isotype ELISA 
 
Here I used an immunization protocol adapted from Anders et al. 1998.  Prior to 
immunization, mice were randomized into four groups of eighteen (Table 4.1).  
Immunization was with the highly immunogenic ectodomain of the full AMA-1 
protein termed AMA-1B.  For mono-allelic immunizations (hereafter referred to as 
DS AMA-1 or DK AMA-1), groups of mice were injected intraperitoneally with 
10µg of the appropriate protein emulsified in 100 µl of the adjuvant Montanide ISA 
720 (Seppic, France).  For bi-allelic immunizations, mice were injected with a 
mixture of 5µg of both DS and DK AMA-1, giving the same total dose of antigen as 
for the single antigen immunizations, again emulsified in Montanide ISA 720.  
Control mice were injected with 100µl emulsion of PBS in Montanide ISA 720.  
Mice were given a single booster immunization with the same amount of antigen 
emulsified in Montanide ISA 720 4 weeks after the primary immunization.   


















Sham -imm un   DS 6 3 2 
Sham -imm un 18 DK 6   
Sham -imm un   DS+DK 6   
DK AMA-1   DS 6[2]   
DK AMA-1 18 DK 6[2]   
DK AMA-1   DS+DK 6   
DS AMA-1   DS 6 1  
DS AMA-1 18 DK 6[1]   
DSAMA-1   DS+DK 6 1  
Bi-allelic   DS 6 2 1 
Bi-allelic 18 DK 6   
Bi-allelic   DS+DK 6   
Total   72  7 3 
 
Table 7.1.  Experimental design.  Immunization was either with DK AMA-1, DS AMA-1, a 
formulation containing an equal mix of both forms of AMA-1 (bi-allelic), or immunization 
with adjuvant only (‘sham-immunization’).  Groups of 18 mice were immunized with one of 
the four treatments before being separated into groups of 6.  Infection was with parasites of 
genotype (clone) DK alone, genotype DS alone or a mixture of both. During the experiment 
7 mice were found dead and 3 had to been euthanized due to severe morbidity.  
Euthanization was at predetermined levels of morbidity prescribed by animal care protocols. 
The numbers in brackets highlight those mice that had to be excluded during repeated 
measures analyses due to unknown reasons. 
 
To ensure that antigen immunization successfully generated antibody responses, and 
to determine whether there was any cross-reactivity between the antibodies generated 
to the different immunizing antigens, I first carried out a pilot experiment.  A total of 
11 mice were immunized with DS AMA-1, 11 with DK AMA-1, and 10 were sham-
immunized.  We estimated the quantity of IgG2b antigen-specific antibodies in all 
mice sera 11 days after the booster immunization by ELISA using wells coated with 
DS AMA-1 or DK AMA-1.  Thus the sera from 32 mice were tested in 64 wells.  We 
used IgG2b as previous work in my laboratory showed that C57BL/6 produce this 
isotype in response to P. chabaudi infection (K. Grocock, A. Graham unpublished).  
Protection induced by immunization with recombinant AMA-1 is isotype 
independent (Burns et al. 2004).  Given the lack of cross-reactivity we observed in 
this pilot experiment (see Results below), in the main experiment, we measured 
IgG2b isotype antibodies to each antigen separately only from the sera of mice 
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immunized with a mixture of DS and DK AMA-1 and in sham-immunized control 
mice.   
 
In both the pilot and main experiments, sera fractions were separated by 
centrifugation from 20 µl of blood taken from a tail snip and were stored at -80oC.  
High binding 96 well ELISA Maxisorb immunoplates (Nunc) were coated with 
either DS AMA-1 or DK AMA-1 at a concentration of 1 µg /ml in 0.06M carbonate 
buffer (0.04M NaHCO3, 0.02M NaCO3, pH 9.6) in a final volume of 50ul per well. 
Plates were stored at 4oC overnight to allow the antigen to bind.  Non-specific 
binding was blocked by incubating wells with 5% BSA: carbonate buffer 
(200ul/well) for 2 hours at 37oC.  Wells were then washed three times in Tris 
buffered saline with 0.01% Tween 20 (TBST).  We used end-point dilution methods 
to detect IgG2b titres: serum samples were detected in a serial dilution 1/100-
1/204800 using TBST as a diluent, in a final volume of 50 µl per well and incubated 
for 2 hours at 37oC.  Wells were washed three times in TBST.  HRP conjugated goat 
anti-mouse IgG2b detection antibody (Southern Biotech 1100-05) was diluted 1/4000 
in TBST to a final volume of 50 µl per well.  Plates were incubated for 1 hour at 
37oC.  Wells were washed three times in TBST followed by a final wash in distilled 
water.  ABTS peroxide substrate (Insight Biotechnology) was added at 100 µl per 
well and allowed to develop at room temperature for 20 minutes.  Optical density 
was read at 405nm using a spectrophotometer.  IgG2b isotype antibody titres were 
calculated as the reciprocal of the greatest dilution at which optical density (O.D.) 
was greater than the mean (plus 2 standard deviations) O.D values observed for naïve 
mouse sera assayed against both DS and DK AMA-1 at 1/100.  
 
7.3.3.  Parasite challenge and monitoring of within host dynamics  
 
Two weeks after the boost immunization, groups of immunized mice (18 per group) 
were further randomized into groups of six and challenged with 105 parasites of 
either genotype DS alone, genotype DK alone or a mixture of genotype DS and DK 
(Table 7.1).  I used the same total dose of each genotype in single and mixed 
infections (rather than the same total dose in single and mixed infections) because the 
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aim of the study was to compare the performance of a genotype when on its own, 
with its performance when in a mixed infection.  A twofold difference in infective 
dose has negligible effects on the population dynamics of the parasites (Timms et al. 
2001). 
 
I recorded the infection dynamics between days 6 and 14.  During that time we daily 
measured body weights and took blood samples from the tail to estimate red blood 
cell density (by flow cytometry; Beckman Coulter) and for genotype-specific real-
time quantitative PCR (qPCR) assays (Bell et al. 2006).  The genotype specific 
primers for genotype DS and DK are described elsewhere [Chapter 4, Appendix 1 
(Barclay et al. 2008b ).  P. chabaudi has a 24 hour replication cycle therefore the 
total number of parasites can be estimated daily.  
 
7.3.4. Trait definition and statistical analyses 
 
I define competitive suppression to be a reduction of parasite numbers when another 
genotype is present, and competitive release is improved genotype performance after 
the removal of a competitor.  Evidence for both suppression and release are tested for 
by comparing the performance of a genotype in single and mixed infections.  Thus, 
for each genotype, we asked whether there was a statistical interaction between 
immunizing treatment (sham-immunized control versus DK AMA-1, DS AMA-1 or 
DS+DK AMA-1) and infection type (single versus mixed). 
 
The effects of competition and immunizing treatment on the performance of 
individual genotype and red blood cell density were first examined by using general 
linear models (GLM) in the statistical package MINITAB (release 14, MINITAB Inc.).  
For GLM analysis, response variables included mean total parasite density and mean 
RBC density, with initial RBC as a covariate.  Explanatory variables for GLM 
included immunizing treatment (sham-immunized control, versus DK AMA-1, DS 
AMA-1 or DS+DK AMA-1) and competition (genotype alone or in mixed infection).  
Maximal models (response variable= immunizing treatment + competition + all 
higher order interactions) were tested in the first instance, and minimal models were 
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obtained by dropping non-significant terms successively, beginning with highest 
order interactions, to obtain the significant minimal model.  Second, we used 
repeated measures analyses, which take into account the importance of day post-
infection.  These analyses were performed as described by Råberg et al. (2006) using 
the statistical package SAS 9.1 (SAS Institute 1999). All density data was 
transformed using [log10 (density + 10)] to meet the assumption of normality and 
homogeneity of variance.  Consistent with my previous studies, [Chapter 6, 
Appendix 1 (Barclay et al. 2008a)] analyses focused on the acute phase of infection 
(days 4-14) as it is during the phase that competitive effects are most pronounced (de 




The experimental set-up, including immunizing treatments, infecting genotypes and 
the number of mice that died during the experiment or had to be euthanized due to 
severe morbidity are described in Table 7.1.  Since death always occurred as initial 
parasitaemias were declining these were included in the calculation of daily 
densities.  Four out of the five control-sham immunized mice infected with genotype 
DS died by day 10, thus from day 10 onwards this group was removed from the 
analyses.  Because of missing values due to failed PCR, 5 mice and these had to be 
excluded from the repeated measures analyses.  All antigen immunizations reduced 
parasite densities compared to control infections (DS; control sham-immunized 
versus antigen immunized: F1,44=8.84, p=0.005; DK; control sham-immunized versus 
antigen immunized: F1,43=11.53, p=0.001).  All antigen immunized mice raised 
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Figure 7.1. IGg2b antibody levels from the serum of mice in the pilot experiment (A) and 
the main experiment (B).  Mice were either sham-immunized or immunised with one of the 
two antigens (DS AMA-1, DK AMA-1).  Each of the treatments used to immunize mice and 
the AMA-1 test antigen used to coat ELISA plates are shown on the x axis.  Dots represent 
the antibody titre against a particular immunizing antigen.  Horizontal lines indicate mean 
antibody levels.  (A) Antibody levels in antigen immunized groups of mice were higher than 
in sham-immunized controls (p<0.001) and, among the immunized mice, the levels induced 
between the antigen immunized groups differed (immunizing treatment x ELISA antigen: 
p=0.003) with higher titres against the homologous antigen.  Neither of the immunizing 
antigens induced higher titres (p>0.05).  (B) Mice that were sham-immunized or immunized 
with the bi-allelic formulation were assayed for antibody responses against both DS and DK 
AMA-1 antigens. Horizontal lines indicate mean antibody levels.  Antibody levels in antigen 
immunized groups of mice were higher than in sham-immunized controls (p<0.001), and 
among the antigen immunized mice, antibody titres did not differ (p=0.085).  The antibody 
titres in animals immunized with both antigens were not dominated by responses to either 
one (p=0.44).  
 
7.4.1.  Genotype DK 
 
As found with other pairs of genotypes (de Roode et al. 2005a; de Roode et al. 
2005b; Bell et al. 2006; Grech et al. 2008), here I found in control sham-immunized 
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mice that the less virulent genotype DK was competitively suppressed, achieving 
half parasite densities when DS was present than when it was absent (Fig.7.2; Table 
7.2).  Antigen immunization suppressed parasite replication in both single and mixed 
infections, but there was no evidence that the magnitude of competitive suppression 
was affected by immunization (interaction n.s.; Table 7.2). 
 
Repeated-measures analysis revealed that effects of immunization on competition 
varied by day (significant immunizing x competition x day interaction; Table 7.3).  
Visual inspection of Figs 7.2A-D shows that this is due to possible competitive 
release of genotype DK during DS AMA-1 immunization during early infection (Fig. 
7.2C) 
 
The repeated measures analyses also revealed some evidence of immune-mediated 
competition during DK AMA-1 immunization (Table 7.4; immunization x 
competition interaction, but not for DS AMA-1 or DS+DK AMA-1 immunizations).  
Visual inspection of Fig. 7.2B indicates that competitive suppression was slightly 
more intense in the presence of DK AMA-1 earlier in infection compared to control 
sham-immunized infection, where competitive suppression was most intense 





 DK days 4-14  DS days 4-14  
Effect d.f. F p d.f. F
immunizing treatment 3,37 38.7 <0.001 3,38 20.2 <0.001 
 p 
competition 1,37 6.67 0.014 1,38 1.28 
immunizing treatment x competition 3,37 0.91 0.44 3,38 0.35 0.78 
0.26 
 
Table 7.2.  GLM analyses of the effects of immunizing treatment (control sham-immunized, 
DS AMA-1, DK AMA-1 or DS+DK AMA-1) competition (presence/absence of co-infecting 
clonal genotype) and their interaction on the total number of parasites for days 4-14 post-
infection for parasite genotype DK and DS. 
 
 




 DK days 4-14  DS days 4-14  
Effect d.f. F p d.f. F p 
Immunizing 
treatment 3,51 43.3 <0.001 3,52 17.9 <0.001 
Competition 1,51 7.72 0.008 1,52 1.56 0.22 
Day 8,249 6.45 <0.001 8,256 8.15 <0.001 
Immunizing 
x competition 3,51 2.17 0.1 3,52 0.87 0.46 
Immunizing 
x day 24,249 2.98 <0.001 24,257 4.15 <0.001 
Competition x day 8,249 1.38 0.2 8,256 0.2 0.99 
Immunizing  
x competition 
x day 24,249 1.61 0.039 24,257 3.05 <0.001 
 
Table 7.3.  Repeated-measures analyses of the effects of immunizing treatment (control 
sham-immunized, DS AMA-1, DK AMA-1 or DS+DK AMA-1) competition 
(presence/absence of co-infecting clonal genotype) and day on the total number of parasites 












Effect d.f. F p d.f. F p d.f. F p 
Immunizing 
treatment 1,34 287 <0.001 1,23 4.54 0.044 1,238 10.3 0 
Competition 1,34 18.1 0.002 1,23 0.36 0.556 1,238 2.39 0.13 
Day 8,107 5.96 <0.001 8,140 30.5 <0.001 8,139 9.59 <0.001 
Immunizing  
x competition 1,34 6.79 0.014 1,23 2.05 0.166 1,23.8 0.5 0.49 
Immunizing  
x day 8,107 3.34 0.002 8,140 21 <0.001 8,139 1.69 0.11 
Competition  
x day 8,107 2.06 0.046 8,140 1.78 0.086 8,139 0.47 0.87 
Immunizing  
x competition  
x day 8,107 1.95 0.06 8,140 1.68 0.108 8,139 0.46 0.89 
 
 
Table 7.4.   Repeated-measures analyses of the effects of each antigen immunizing treatment 
(DS AMA-1, DK AMA-1 or DS+DK AMA-1) compared to control sham-immunized, 
competition (presence/absence of co-infecting clonal genotype) and day, on the daily 
parasite density of genotype DK for days 4-14 post-infection. 









Effect d.f. F p d.f. F p d.f. F p 
Immunizing 
treatment 1,29 37 <0.001 1,26.2 0.3 0.59 1,29.8 5.74 0.0228 
Competition 1,29 1.59 0.22 1,26.2 3.14 0.088 1,29.8 3.86 0.06 
Day 8,134 3.78 0.005 8,120 7.7 <0.001 1,133 5.29 <0.001 
Immunizing 
x competition 1,29 2.2 0.15 1,26.2 1.86 0.184 1,29.8 1.36 0.25 
Immunizing 
x day 8,134 6.32 <0.001 8,120 5.95 <0.001 8,133 8.21 <0.001 
Competition 
x day 8,134 0.89 0.53 8,120 2.49 0.015 8,133 1.78 0.08 
Immunizing 
x competition 
x day 8,134 4.46 <0.001 8,120 1.29 0.28 8,133 3.43 0.0013 
 
 
Table  7.5.  Repeated-measures analyses of the effects of each antigen immunizing treatment 
(DS AMA-1, DK AMA-1 or DS+DK AMA-1) compared to control sham-immunized, 
competition (presence/absence of co-infecting clonal genotype) and day, on the daily 



















































Figure 7.2.  Parasite densities through time of genotype DK under the different 
immunization treatments (A-D) and the interaction of total densities across the course of 
infection (E).  A-D represent the asexual parasite density from qPCR in sham-immunized 
controls (A), DK AMA-1 immunized (B), DS AMA-1 immunized (C), and DS+DK AMA-1 
immunized (D), in single (solid black line) or mixed (dotted black line) infections. Mean 
densities (± 1 s.e.m.) were calculated from all mice that were alive on the perspective day of 
sampling (up to six).  The interaction plot (E) shows the total numbers of DK parasites when 
the competitor genotype DS is absent (single infection) or present (mixed infection) in sham-
immunized controls (solid black line), DS AMA-1 immunized (black line open boxes), DK 
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Figure 7.3. Parasite densities through time of genotype DS under the different immunization 
treatments (A-D) and the interaction of total densities across the course of infection (E).  A-
D represent the asexual parasite density from qPCR in sham-immunized controls (A), DS 
AMA-1 immunized (B), DK AMA-1 immunized (C), and DS+DK AMA-1 immunized (D), 
in single (solid black line) or mixed (dotted black line) infections. Mean densities (± 1 
s.e.m.) were calculated from all mice that were alive on the perspective day of sampling (up 
to six).  The interaction plot (E) shows the total numbers of DD parasites when the 
competitor genotype DK is absent (single infection) or present (mixed infection) in sham-
immunized controls (solid black line), DS AMA-1 immunized (black line open boxes), DK 
AMA-1 immunized (black line open triangles) or DS+DK AMA-1 immunized (dotted black 
line). 
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7.4.2. Genotype DS 
 
In control sham-immunized infection there was no evidence of competitive 
suppression of genotype DS by DK (Fig. 7.3A,E; Table 7.2).  As with genotype DK, 
antigen immunization suppressed parasite replication/densities in both single and 
mixed infections, but there was no evidence immunization facilitated the competitive 
release of genotype DS (interaction n.s.; Table 7.2). 
 
Repeated-measures analysis revealed that the effects of immunization on competition 
varied by day (significant immunizing x competition x day interaction; Table 7.3).  
Visual inspection of Figs 7.2A-D shows that this is due to possible competitive 
release of genotype DS during DS+DK AMA-1 immunization during early infection 
(Fig. 7.2D). 
 
The repeated measures analyses also revealed some evidence of immune-mediated 
competition during DS AMA-1 and DS+DK AMA-1 immunization (Table 7.5; 
immunization x competition x day interaction, but not for DK AMA-1 
immunization).  Visual inspection of Fig. 7.3A-D show competitive release of 
genotype DS early in infection (Fig. 7.3B,D) compared to control sham-immunized 
where infection dynamics were similar during single and mixed infection. 
 
Overall, these results demonstrate that neither type of immunization enhanced the 
competitive suppression of the less virulent genotype (DK), or facilitated the 
competitive release of the more virulent genotype (DS) in a mixed infection.  If 
anything, a single heterologous DS AMA-1 immunization may facilitate competitive 
release of the less virulent genotype by removing more of the virulent genotype in 
mixed infection (Fig. 7.2C).  There was very weak contradictory evidence of 
immune-mediated competition (Fig. 7.2B, 3B).  However, since these effects were 
day-specific I conclude that strain-specific immunity does not markedly alter 
competitive interactions. 
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7.5 Discussion 
 
In this study the less virulent P. chabaudi genotype (DK) was suppressed by the 
presence of a co-infecting more virulent genotype (DS).  Immunization with the two 
variant rodent analogues of the malaria vaccine candidate AMA-1 reduced parasites 
in a strain-specific manner.  However, I found no evidence that immunization 
enhanced competitive suppression of the less virulent genotype or facilitated the 
competitive release of the more virulent genotype.  Thus, there was no evidence that 
strain-specific immunization exacerbated or alleviated competition and thus the force 
of this component of selection on virulence.  Furthermore, I found no evidence that a 
bi-allelic AMA-1 vaccine should enhance or alleviate competitive interactions.  
 
The experiments presented in this study contribute towards a growing body of 
evidence which suggest that the competitive benefits associated with virulence need 
not result in a selective advantage in an immunized host [Chapter 6, Appendix 2 
(Barclay et al. (2008a)] (de Roode et al. 2005b; Bell et al. 2006; Grech et al. 2008).  
The finding that strain-specific immunization does not exacerbate within host 
competition is consistent with two experimental studies which suggest that 
vaccination should have negligible impact on this source of selection on virulence 
[Chapter 6, Appendix 2 (Barclay et al. 2008a)] (Grech et al. 2008)].  The first study 
came from my own work, where I indirectly tested whether CD4-T cell dependent 
immunity, or mechanisms which act to enhance it such as vaccination, might 
exacerbate within host competition [Chapter 6, Appendix 2 (Barclay et al. 2008a)].  
In that study, I found no evidence to suggest that vaccination should exacerbate this 
source of selection for virulence.  If anything, the data from that study suggested that, 
after the peak of infection, CD4-dependent immunity may act to alleviate other forms 
of competition, such as resource-based competition (e.g. for red blood cells) 
[Appendix 3 (Mideo et al. 2008b) (Taylor et al. 1997; Antia et al. 2007)].  The 
second study (Grech et al. 2008), used a more direct approach to test whether 
vaccination could exacerbate competitive interactions.  In experiments similar to 
those presented here, mice were immunized with either AMA-1 or with live 
parasites.  Unlike in this study, neither of the genotypes used to infect the AMA-1 
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immunized mice were homologous at the target antigen, therefore the strain-specific 
affect of vaccination was not tested.  The live parasite immunizations involved a 
strain specific component, as one of the genotypes in the infection was always 
identical to the immunizing genotype but because of the experimental design strain-
specific immunity could not be tested for.  That study also found no evidence that 
either type of immunization alleviated or exacerbated competitive suppression. 
 
My previous studies [Chapter 6, Appendix 2 (Barclay et al. 2008a)] and the data 
presented here show no consistency with one study which showed weak immune-
mediated competitive interactions (Råberg et al. 2006)].  In that study, competitive 
suppression of a less virulent P. chabaudi genotype was alleviated during infection 
(post peak days 10-12) of ‘nude’ mice, which have no mature T cells.  The authors 
implied that T-cell dependent immunity, and mechanisms which act to enhance it 
such as vaccination, may mediate competition and thus selection for virulence.  
However, given the relatively small immune-mediated component, and the 
accumulating evidence against this as a mediator of competition, I am inclined to 
think the results from the Råberg et al. 2006 study, were a possibly unique attribute 
of using nude mice. 
 
Previous studies involving serial passage found that genotypes passaged through 
whole-parasite immunized mice evolved virulence faster than those passaged through 
naïve mice, even after mosquito transmission (Mackinnon & Read 2004a).  That 
study implied that there was a selective advantage to virulence; immunity selected 
for those genotypes which proliferated ahead of the immune response and were thus 
most likely to win the race into the syringe for passage.  If this is not a result of a 
competitive advantage, what other mechanisms could explain the selection for more 
virulent genotypes?  In P. chabaudi there are a number of other advantages 
associated with virulence.  For instance, more virulent genotypes are also found to be 
less rapidly cleared by the host (Mackinnon & Read 1999; de Roode et al. 2003; 
Ferguson et al. 2003; de Roode et al. 2004a; de Roode et al. 2004b; de Roode et al. 
2005a; de Roode et al. 2005b; Bell et al. 2006).  Thus, in the case of serial passage 
experiments, immunity may select for those genotypes which are able to evade 
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protective responses, for instance, by undergoing antigenic variation, secreting 
immunomodulatory products or by accessing immunologically privileged sites 
(Rowe et al. 1995; Chen et al. 1998; Salanti et al. 2004; Bull et al. 2005; Francis et 
al. 2007).  Immunization may have enhanced natural-immunity, or imposed some 
unique form of selection, which caused those parasite passaged through whole 
immunized mice to evolve faster.    Thus, in light of the results from my experiments, 
selection imposed by immunity observed during serial passage experiments was 
likely independent of competition (Mackinnon & Read 2004a). 
  
Enhanced immune evasion may go some way to explaining the within host 
advantage to virulence observed during other immunization experiments with AMA-
1 which did not involve serial passage (Chapter 5; Grech et al. 2008 in prep).  In 
those experiments, P. chabaudi genotypes which differed in virulence but were 
identical at the ama-1 sequence to each other and to the vaccine antigen were used to 
infect AMA-1 immunized mice.  The more virulent genotypes were less well 
controlled by vaccine-induced immunity.  Those studies suggested that virulence 
determinants, different from the vaccine target, were likely to be involved in 
selection.  Some of these virulence determinants may be involved in immune 
evasion.  Full genomic analysis of P. chabaudi genotypes may identify such 
virulence genetic determinants.   
 
Immunity against malaria parasites has strain-transcending and strain-specific 
components (Martinelli et al. 2005).  It is generally assumed that during the acute 
phase of infection in naïve animals the response is largely a non-specific cellular 
immune response (Taylor-Robinson 1995; Li et al. 2001).  During the chronic phase, 
the response becomes far more specific as antibody-mediated immunity is deployed 
(Jarra & Brown 1985; Phillips et al. 1997; Mota et al. 1998; Buckling & Read 2001).  
In this study, the presence of a heterologous AMA-1 vaccine appeared to slow 
parasite growth compared to a sham-immunized infection, in what could be 
described as a strain-transcending response (Fig. 7.2A,C, 7.3A,C).  The growth 
dynamics of the virulent genotype were similar regardless of whether the less 
virulent genotype was present or not (Fig. 7.3C).  However, despite no statistical 
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significance, it appeared as though the less virulent genotype gained some advantage 
during heterologous AMA-1 immunization when the more virulent genotype was 
present (Fig. 7.2C).  Thus, the data I present here indicate that analogous processes to 
those observed with anti-malarial drug use are not likely to occur during vaccination; 
strain-specific removal of less virulent genotypes by vaccination should not result in 
competitive release of more virulent genotypes. 
 
The fact I found strain-specific immunity not to alter within host competition should 
not preclude vaccination as a source of selection for virulence.  The use of any form 
of therapy that selectively removes some parasite strains but not others should be 
implemented with caution.  For instance, the trail of the Combination B malaria 
vaccine exerted selective pressure by reducing those parasite strains which carried 
vaccine alleles, but with no affect on parasites which carried vaccine allelic variants 
(Genton et al. 2002; Genton et al. 2003).  Those variants which remained in the 
population were also associated with more severe disease (Engelbrecht et al. 1995).  
One solution to reduce vaccine-induced selection has been to design vaccines which 
contain more than one allelic variant (Bolad & Berzins 2000; Richie & Saul 2002; 
Polley et al. 2007).  Studies so far have reported that these ‘multi-allelic’ vaccines 
may not enhance protection from disease (Miura et al. 2007; Lalitha et al. 2008), but 
should not result in the strain-specific selection induced by mono-allelic vaccines 
[Chapter 4, Appendix 1 (Barclay et al. 2008b)] (Miura et al. 2007; Lalitha et al. 
2008).  In the study I report here, bi-allelic vaccination did not alter competitive 
interaction and should thus not enhance this source of selection for virulence. 
 
The mechanisms that mediate competition are likely to continue drawing interest 
from evolutionary biologists, who have so far identified resource-based competition 
and direct interference, in addition to the immune response, as potential mediators of 
competition.  The current approach is dissecting each mediator appears most 
appropriate.  For instance, the modelling of the data presented in this study has 
identified a possible resource-based mechanism in the strain-specific pattern of 
pathogenesis observed [Appendix 3 (Mideo et al. 2008b)].  Such studies merit the 
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continued collaboration between empiricists and mathematical modellers in studies 
of infectious disease. 
 
In conclusion, the data I present here appear to contribute towards a growing body of 
evidence that vaccination is not likely to alter within host competition between 
genetically diverse malaria parasites, and thus the force of this selection for 
virulence.  Rather than further dissection of competitive interactions with alternative 
vaccines, the most appropriate way forward will be to design experiments to test 
whether any of the other parasite benefits associated with virulence e.g. immune 
evasion, may enhance selection of these strains in an immunized host.  One could 
envisage serial passage experiments through hosts vaccinated with a recombinant 
vaccine antigen such as AMA-1, paralleled by comparative molecular analysis 







8.  General discussion 
 
The aim of this thesis was to investigate whether parasite virulence could result in a 
within host selective advantage in an immunized host and hence whether vaccination 
could promote the evolution of virulence.  I based my research on malaria, one of the 
world’s most devastating diseases, to which there is currently no effective vaccine.  
The hope is that we can study the evolutionary consequences of vaccination before 
any wide-spread implementation.  I used the rodent malaria P. chabaudi as an in vivo 
model system and the P. chabaudi analogue candidate malaria vaccine AMA-1 to 
test a number of my hypotheses.  As each chapter has been written as a stand-alone 
paper, each has a discussion section with the specific findings.  Here I summarise the 
main findings, the practical implications, and also the relevance of animal models in 
these studies.  I also argue that collaborations between experimentalists and 
theoreticians should lead to advancements in the control of infectious diseases.  I 





In Chapter 2, I started by exploring whether a more virulent P. chabaudi genotype 
was less well controlled by heterologous AMA-1 immunization than a less virulent 
genotype.   I found no evidence of a selective advantage of virulence.  Vaccination 
reduced parasites in strain-specific manner.  The affect was asymmetrical in that the 
more virulent genotype was better controlled by vaccination.  Similarly, in Chapter 3 
I also found no selective advantage to virulence when the efficacy of AMA-1 was 
tested against a range of P. chabaudi genotypes which differed in ama-1 sequence 
and/or in virulence.  Vaccination reduced those parasites that were more similar to 
the vaccine target than those that were different.  Together, the results from Chapters 
2 and 3 suggested that vaccination with AMA-1 induces protective responses that are 
strain (genotype)-specific.  Strain-specificity could lead to epitope evolution as the 
removal of one genotype creates a niche for another genotype to fill.  One approach 
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to minimizing strain-specificity has been to design vaccines which contain more than 
one AMA-1 allelic form (multi-allelic vaccines).  However, prior to my thesis there 
was little evidence that multi-allelic vaccines better protect hosts against parasites 
and/or disease, or how such vaccines may alter parasite within-host selection.  In 
Chapter 4, I demonstrated in vivo that immunization with a bi-allelic AMA-1 did not 
afford the host greater protection from parasite infection or morbidity than did 
immunization with either of mono-allelic forms (Barclay et al. 2008b ).  I also found 
no evidence that any vaccination regime favored virulence.  During the discussion of 
Chapter 4, I specifically highlight that selection for virulence could be in inadvertent 
consequence of including just one allele from a given locus in a vaccine, a possible 
explanation for the selection seen during the trial of the Combination B malaria 
vaccine.  Since AMA-1 itself is not a known virulence factor, the strain-specific 
immunity induced by mono-allelic vaccines should not directly alter virulence.  
However, I indicate the importance of population-level disease association studies 
for all antigens included in vaccines in order to prevent inadvertent selection.     
 
Up until this point the results from all my experiments indicated that there was no 
within-host advantage to virulence in an AMA-1 immunized host and that vaccine-
efficacy more likely depended on ama-1 sequence differences.  Those data 
apparently contradicted a previous serial passage experiment, which demonstrated 
that parasites passed through whole-parasite immunized mice evolved virulence 
more rapidly than those passed through naïve mice (Mackinnon & Read 2004a).  I 
thus hypothesized that the selective advantage to virulence may only be observed 
when parasites are from an antigenically identical background.  To test this, in 
Chapter 5, a single P. chabaudi genotype was serially passaged through 
immunologically naïve mice to derive a line which contained parasites that caused 
more anaemia and weight loss, and which were able to achieve higher densities and 
persist for longer before immune clearance.  These more virulent parasites were less 
readily controlled by immunity induced by immunization with homologous 
recombinant AMA-1 than were the less virulent parasite from which they were 
derived.  One of the benefits associated with parasite virulence could be reduced 
immune clearance/immune evasion (Anderson & May 1982; Mackinnon & Read 
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2004a; Mackinnon & Read 2004b; Frank & Schmid-Hempel 2008; Schmid-Hempel 
2008).  An implication of the results from Chapter 5 was that those parasites had a 
selective advantage in an immunized host because they were less readily cleared by 
the immune response. 
 
In Chapter 6, I studied whether vaccination has the potential to exacerbate the 
within-host competitive benefits associated with parasite virulence observed during 
mixed P. chabaudi genotype infections (de Roode et al. 2005; Bell et al. 2006).  I 
found that when mice were depleted of CD4+ T cells, the competitive suppression of 
a less virulent genotype by a more virulent genotype was not alleviated.  Thus CD4-
dependent immune responses, and mechanisms which act to enhance it such as 
vaccination, may not have the undesirable affect of exacerbating within-host 
competition.  Interestingly, I found after the peak of parasite infection that there was 
a significant enhancement of competitive suppression in depleted animals, 
presumably because CD4-dependent responses alleviate other forms of competition, 
such as that of red blood cells.   
 
In Chapter 7, I directly tested whether immunization with any of the mono-allelic 
AMA-1 vaccines used throughout this thesis could alter the competitive interactions 
between malaria parasites and thus the force of this selection on virulence.  I also 
used this experiment to explore how a bi-allelic AMA-1 vaccine may alter 
competitive interactions.  I found no evidence that any vaccine regime enhanced the 
competitive interactions compared to control infections.  
 
8.2. Implications  
 
8.2.1. Vaccine alleles and their association with virulence  
 
 
The main question of this thesis was whether more virulent P. chabaudi genotypes 
had a selective advantage in an immunized host.  The motivation for this work was 
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based on the Combination B malaria vaccine, where only one allelic type of MSP-2 
(from the 3D7 family) was included in the three component vaccine.  The vaccine 
induced a shift in the population towards parasites expressing MSP-2 proteins from 
the alternative allelic family FC27 (Genton et al. 2002).  The FC27-type had been 
reported to be associated with symptomatic (more morbid) infections (Egelbrecht et 
al. 1995; Ofosu-Okyere et al. 2001).   
 
However, a number of other studies have raised concerns to the validity of those 
associations between the FC27-type allele and more morbid infections.  For example, 
the combination of two studies conducted in Senegal found a lower prevalence of 
parasites containing FC27-type alleles among clinical malaria infections than among 
asymptomatic infections, but the symptomatic and asymptomatic groups were not 
matched and sample size was small (Ntoumi et al. 1995; Robert et al. 1996).  
Furthermore, a recent study in Tanzania found that the presence of 3D7-type was 
predictive of clinical symptoms, but again the sample size was very small (Magesa et 
al. 2002).  More recently, one study compared the allelic frequency, which is not 
affected by the multiplicity of infection, of the 3D7 and FC27 allelic families in the 
Wosera region of Papua New Guinea, the same study area used by Egelbrecht et al 
(1995).  The allelic frequency of the 3D7-type and the FC27-type alleles was very 
similar between asymptomatic and symptomatic infections, with the FC27-type 
alleles being slightly more common in the asymptomatic group than the symptomatic 
group (Cortes et al. 2004).  Based on those results the authors suggest that selection 
for parasites expressing FC27-type MSP-2 might not necessarily be associated with 
increased morbidity, but that it will be important to understand the possible effects 
on morbidity that interventions might have on the natural balance between allelic 
types.  Even if allelic-types of the MSP-2 allele are not associated with virulence, as 
mentioned in the conclusion of Chapter 4 [Appendix 1 (Barclay et al. 2008a)], 
caution is necessary for all antigens involved in processes like cell invasion which 
are associated with pathogenesis, and one of the safest ways to avoid inadvertent 
selection would be to include all known variants of that locus in the vaccine. 
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8.2.2. The potential efficacy of multi-allelic vaccines 
 
In Chapter 4 [Appendix 1 (Barclay et al. 2008a)], I found that the vaccination with a 
bi-allelic AMA-1 formulation did not afford the host greater protection from parasite 
infection than did mono-allelic AMA-1 immunization.  However, these results by no 
means preclude the possibility that a multi-allelic AMA-1 vaccine may reduce 
vaccine-induced strain-specificity.  For example, in one study the analysis 355 
PfAMA-1 sequences found that around 10% of the 622 amino acid residues can vary 
between alleles and that linkages between polymorphic residues occur (Remarque et 
al. 2008b).  Using this analysis, the authors designed three diversity-covering (DiCo) 
PfAMA-1 sequences that take account these linkages, and taken together incorporate 
97% of the amino acid variability observed.  Rabbits were then either immunized 
with FVO strain PfAMA-1 or with the DiCo proteins either individually or as a 
mixture.  Animals immunized with the DiCo mix raised antibody titres and inhibited 
parasite growth similarly to animals immunized with strain FVO AMA-1 when 
measured against FCR3 strain parasites.  However, the DiCo mix outperformed 
animals immunized with FVO AMA-1 when assessed against other strains.  Those 
results suggest that including a number of polymorphic residues may increase the 
potency of an AMA-1 vaccine.  Similarly, another study found enhanced protection 
from in vitro parasite invasion of red blood cells when a vaccine contained PfAMA-1 
sequences representing a mixture of major haplotypes from around the world that 
could be grouped into six populations (Duan et al. 2008). 
 
In comparison, MSP-2 is an example of a highly polymorphic merozoite antigen.  
Despite the Combination B vaccine containing the MSP-2 3D7-type, some 3D7-type 
infections still established themselves in immunized children (Genton et al. 2002).  
One study sequenced MSP-2 alleles detected in study participants after vaccination 
to identify breakthrough genotypes, and thus try and identify the regions of the 
protein under selection (Fluck et al. 2007).  The analysis found that highly 
polymorphic non-repetitive blocks were not subject to selection in vaccinated 
individuals, and therefore assumed that responses against these regions were not 
protective.  Instead, a 3D7 family-specific domain containing 50 residues of invariant 
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sequence was postulated as a likely candidate to account for selection observed on 
the level of the allelic family.  Thus, unlike with AMA-1, if protective responses are 
directed against conserved regions, there may be no merit in including a number of 
3D7-type variants in a MSP-2 containing vaccine. 
 
Together these studies highlight that the efficacy of multi-allelic vaccines will not 
only depend on the degree of polymorphisms exhibited by a particular protein, but 
whether these are under selection and are thus important for generating protective 
immunity. 
 
8.2.3.  Malaria vaccine development 
 
As mentioned at the beginning of my thesis, vaccines are a medical triumph and 
should be recognized as such.  The aim of this thesis was by no means to belittle the 
success, or potential, of vaccines in controlling infectious disease.  However, in view 
of my experiments I believe that future vaccines should not only depend on short-
term individual responses, but should take into account and anticipate the population 
dynamical and evolutionary consequences of vaccination as well. 
 
In Chapter 4 (Barclay et al. 2008b), I showed that enhanced protection from parasites 
or disease during vaccination with AMA-1 is not likely to be enhanced by including 
more than one allelic variant.  This may just have been a result of the combination of 
AMA-1 alleles used in that experiment, and as mentioned above, does not preclude 
the potential increased efficacy of multi-allelic vaccines.  However, considerably 
more data from other researchers have indicated that the potency of a malaria vaccine 
may be increased by combining single variants from multiple antigenic loci 
(Hoffmann & Miller 1996; Holder 1999; Richie & Saul 2002; Heppner et al. 2005; 
Garcia et al. 2006).  For example, animal and human phase I trials have shown 
safety, tolerability and immunogenicity of formulations containing AMA-1 and 
MSP-1 (2002; Burns et al. 2003; Pan et al. 2004; Faber et al. 2007; Hu et al. 2008), 
and passive immunization studies of formulations containing AMA-1 support the 
concept of developing ‘multivalent’ blood-stage vaccines (Narum et al. 2006).  
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Moreover, such multivalent vaccines have been shown to reduce parasitaemias in 
mice of distinct MHC haplotypes (Doolan et al. 1996) and against infections with 
different parasite strains as well as subspecies of different virulence (Scorza et al. 
2008).  Thus, multi-valency may be required to induce antibody responses against a 
repertoire of polymorphic parasite antigens (Bouharoun-Tayoun et al. 1995; Bull & 
Marsh 2002; Wipasa et al. 2002a; Wipasa et al. 2002b; Doolan et al. 2003; Moorthy 
et al. 2004; Eisenhut 2007; Osier et al. 2008) in the human outbred population 
exposed to multiple parasite genotypes (Doolan & Hoffman 2001; Genton et al. 
2002; Plebanski et al. 2002; Cortes et al. 2003; Doolan et al. 2003).   
 
Of course, the erythrocytic stage of the life cycle is not the only stage that is targeted 
by vaccination.  Several candidate malaria vaccines to the pre-erythrocytic and 
transmission stages are also progressing through clinical trails (Ballou et al. 2004; 
Moorthy et al. 2004). The most advanced malaria vaccine candidate is RTS,S, a pre-
erythrocytic vaccine, for which pivotal phase III trial design and site preparation is 
underway (Stoute et al. 1997; Stoute et al. 1998; Bojang et al. 2001; Kester et al. 
2001; Alonso et al. 2004; Alonso et al. 2005).  However, it is still not obvious what 
level of efficacy needs to be achieved for a malaria vaccine to be worthwhile since 
even vaccines that only partially protect might offer substantial health benefits, given 
the enormous burden of morbidity and mortality in endemic areas (Greenwood et al. 
2005).  Even RTS, S induces only partial protection against infection and disease in 
clinical trials (Bojang et al. 2001; Alonso et al. 2004).  
 
In Chapters 2-5 of my thesis I consistently observed a lack of correlation between 
protection from parasites and protection from disease (morbidity).  The reasons for 
this are poorly understood at a molecular level but are likely to be due to the parasite 
invasion inhibitory antibodies depending on polymorphic epitopes, whereas 
protection against disease e.g. anaemia, may be more correlated with how fast the 
host can replace red blood cells during recovery.  In view of my results, malaria 
vaccine trials should continue to monitor both the parasitological status of the host as 
well as measurements of disease which will hopefully result in the most accurate 
reflection of vaccine efficacy. 
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Mathematical models of virulence evolution caution against malaria vaccines which 
reduce symptomatic disease while still maintaining parasite transmission (Gandon et 
al. 2001; Gandon & Day 2003; Gandon & Day 2007).  Such vaccines are expected to 
select for more virulent strains as the cost of virulence (host death) is removed by 
vaccination.  Those evolved strains are expected to cause more severe morbidity if 
transmitted to an unvaccinated host.  The results presented in Chapter 5 and that by 
others (Mackinnon and Read 2004a; Grech et al. 2008 in prep) suggest that more 
virulent parasites may have a selective advantage in immunized hosts. Thus, the 
selection imposed by vaccination on individuals may have important evolutionary 
consequences for future host population disease morbidity.   
 
8.2.4. Evolution in biomedicine 
  
This thesis started by describing how evolutionary biology has had little impact in 
biomedicine, and how an increased understanding of evolutionary processes may 
help prevent disasters such as the wide spread evolution of drug resistance.  Thus, it 
appears appropriate that I should discuss how the work presented in this thesis may 
contribute towards the movement of evolutionary thinking into biomedicine. 
 
The quest of my thesis was to investigate whether the parasite benefits associated 
with virulence in P. chabaudi could result in a selective advantage in an immunized 
host.  Although my thesis was based on malaria, the questions that I asked are 
applicable to a number of other diseases (Day et al. 2008).  I hope the results from 
my thesis prompt more evolutionary thinking in those working on malaria vaccines, 
but also during the design and implementation of vaccines against other diseases.  In 
particular I have chosen to highlight Human Papillomavirus (HPV) as this vaccine 
has recently been approved for wide-spread use in young American females (FDA 
2006).  Monitoring the evolutionary consequences of HPV in the population will 
require collaborations between health worker, experimental biologists and bio-
mathematicians.  If these collaborations occur, there is great potential for HPV to be 
Chapter 8- General Discussion 158
one of the first diseases where the evolutionary consequences of vaccination can be 
determined. 
 
Increased evolutionary thinking should prompt those working on vaccines against a 
number of diseases to ask the following questions: 
 
• How should one balance the breadth against the depth of a vaccine i.e. should 
one include many polymorphic antigens or only a few monomorphic ones?   
• Which vaccines, vaccination schemes and coverages minimize the probability 
of appearance of escape mutants?   
• How does the evolutionary pressure on the parasite population depend on the 
relationship between natural and vaccine-induced immunity?   
• Should the aim of vaccination be to reduce symptomatic disease while 
maintaining circulation, or should it be to reduce transmission?   
• Will vaccination select for aggressive strains that efficiently exploit the host, 
or does it select for stealthy avirulent strains that are less visible to the 
immune system? 
 
In view of my experiments I believe that the design of vaccines should not only be 
focused on short-term individual responses, but that it should take into account and 
anticipate the population dynamical and evolutionary consequences of vaccination as 
well. 
 
8.2.5. Theorists and experimentalists 
 
Mathematical models provide an invaluable tool for predicting and understanding the 
epidemiology of infectious disease.  One of the limitations of modelling is that 
predictions and hypotheses usually well exceed the amount of experimental data 
available to which these models can test.  Even when data are available there are 
often caveats, for instance, in sample sizes and data collection methods.  Thus, strong 
collaborations between experimentalists and theorists are necessary if we are to 
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maximise the potential of these two disciplines for infectious disease studies.  During 
my PhD I was lucky enough to work in an inter-disciplinary research group that I 
was exposed to the merits of working with theorists.  In particular, I worked closely 
with Nicole Mideo, a graduate student of Troy Day from Queens University, 
Kingston, Canada.  Nicole used the data I collected during Chapter 6 [Appendix 2 
(Barclay et al. 2008a)] and was able to examine the role of resource alone (red blood 
cells) on the dynamics of two strains in the absence of the immune system.  The 
model provided insights into the strain-specific pattern of pathogenesis, indicating 
that differences in virulence between strains could be explained by differences in 
red-blood-cell-age-specific invasion rates and burst sizes, being lower for the less 
virulent strain [Appendix 3 (Mideo et al. 2008b)].  Unfortunately, studies like this are 
very rare despite the great potential of this type of approach.  An important goal of 
building mathematical models of malaria pathogenesis is to use them to evaluate 
interventions (Mideo et al. 2008a).  For instance, models have demonstrated the 
potential for vaccination to select for increased virulence (Gandon et al. 2001; 
Ganusov & Antia 2006).  There is still great potential for models to lead to better 
predictions about the effects of interventions.  For example, models may help explain 
why passaging malaria parasites through immunized mice results in selection for 
more virulent parasites (Mackinnon & Read 2004a).  In particular, what is the 
mechanism of this increased virulence, i.e. on what trait is selection acting?  With a 
good model of mouse malaria (one that has been derived from, calibrated and 
validated with data), this experiment could be replicated in silico with the aim of 
predicting what kinds of malaria parasites (e.g. those that undergo rapid antigen 
switching, replicated at higher rates or infect RBCs at faster rates) have an advantage 
in immunized hosts (Mideo et al. 2008b).  Achieving this, in studies of malaria and 
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8.3. Relevance of mouse models  
 
In today's post-genomic era with Plasmodium, Anopheles and human genomes at 
hand, optimism abounds that developments in new drug therapies and vaccines will 
emerge (Carlton et al. 2002; Florens et al. 2002; Gardner et al. 2002; Holt et al. 2002; 
Maher 2002; Chauhan & Bhardwaj 2003)  This has meant that researchers have 
become even more dependent upon models for screening molecules involved in 
protection. Animal models play a crucial position and thus an evaluation of their 
merits and limitations is warranted.    
 
Merits of the rodent model systems are that they share many features with human 
malaria.  For instance, the basic biology of rodent and human malaria is similar.  In 
particular, P. chabaudi and P. falciparum both undergo synchronous schizogony, 
capillary sequestration and have preference for mature red blood cells (Mons & 
Sinden 1990).  Genome size, the number of chromosomes and the G+C content are 
similar between the rodent and human parasites (Carlton et al. 2002; Gardner et al. 
2002; Hall et al. 2005).  Surface proteins are conserved between rodent and human 
parasites, with some with the exceptions such as MSP-2 (Marshall et al. 1989; 
Waters et al. 1990; Thompson et al. 2001).  The molecular basis of drug sensitivity 
and resistance are similar between rodent and human parasites (Carlton et al. 1998; 
Carlton et al. 2001; Walliker et al. 2005).  Another merit of the rodent malaria 
system is that it enables in vivo investigations of parasite-host interactions in well 
characterized host genetic backgrounds with a variety of parasite types (Grech et al. 
2006).  In particular, the P. chabaudi system is the only malaria model with a well 
characterized range of genetically distinct parasite clones and distinct virulence 
phenotypes (Mackinnon & Read 1999b; Ferguson & Read 2002).  This well defined 
system allows the generation of results quickly under controlled laboratory settings. 
 
Parallelisms between mice and humans would at a first glance provide support to the 
relevance of the rodent model.  However, there are a number of limitations which 
cannot be ignored.  For instance, unlike human malaria, rodent infections are usually 
short lived, reach high parasite densities and often result in host death (Stevenson et 
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al. 1982; Collins & Jeffery 1999; Mackinnon & Read 1999a).  Furthermore, the 
rodent host and parasite are not a natural combination.  The adaptation of a parasite 
to an artificial host actually translates in immunological terms into defense 
mechanism that in most circumstances are more effective than those seen in the 
natural host. Consequently vaccine candidates that show promise in a given model 
might fail in humans or worse, experimental results may lead to the rejection of 
vaccine candidates that would be effective in humans. For instance, the most 
successful Plasmodium vaccine used to date, RTS/S, relies on an adjuvant inducing 
optimal cytotoxic T lymphocyte (CTL) activity in models. In humans it induces no 
CTL activity, very high antibody levels, yet generates a degree of protection. 
(Alloueche et al. 2003).  Thus, each transfer between species-from rodents to non-
human primates to humans- cannot not be assumed to act uniformly (Chatterjee et al. 
2006). 
 
In malaria vaccine development a dilemma now exists: either we rely on direct 
testing on non-human primates or even humans and accept that progress will be 
slow, though results should be more relevant; or we continue to employ easier 
models (including rodents and in vitro culture), generating data which cannot 
necessarily be extrapolated fully to the human situation.  However, modern genomics 
may provide a valuable link between models and human malaria.  For instance, 
availability of the full genomes of most rodent plasmodia may lead to the selection of 
a preferred rodent Plasmodium species based on knowledge of molecular homologies 
with the corresponding human Plasmodium gene. The same can apply to the 
selection of the best fit between host molecules (Chatterjee et al. 2006).  Another 
approach promoted by some groups is gene replacement to substitute P. falciparum 
genes for rodent Plasmodium genes and similarly, to substitute human genes for 
mouse ones (O'Donnell et al. 2000; McIntosh et al. 2007).  But always there will be a 
real challenge measuring protection against disease. 
 
Overall, rodent malaria systems have allowed huge advancements in drug and 
vaccine development as well as providing models for the study of virulence 
evolution.  In vivo manipulations, such as those preformed in this thesis, provide 
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insights into potential vaccine protection efficacy in humans as well as the 
evolutionary consequences as predicted by mathematical models.  Thus, I view 
rodent malaria as a continued necessity in the research of this disease, but 
extrapolations must of course be made cautiously. 
 
 
8.4. Future directions 
 
8.4.1. Virulence genes 
 
In general the biomedical field is sometimes dominated by people looking for 
epitope evolution with little consideration for virulence.  During this thesis I have 
tried to make it clear that these are not discrete non-overlapping hypotheses 
(virulence evolution could occur due to epitope changes).  However, the virulence 
hypothesis is tested by determining whether vaccine-adapted strains cause more 
disease in unvaccinated individuals.  In malaria, the mechanisms underlying 
virulence are probably complex, involving a large number of genes associated with 
parasite phenotypes such as cell invasion, resetting, cytoadherence and replication.  
In Chapter 5 I demonstrated that serial passage of P. chabaudi through naïve mice 
derived a parasite line which was better able to evade AMA-1 vaccine-induced 
immunity.  One of the caveats of that study was that there was no transmission 
through mosquitoes, where recombination of the sexual stage of the parasite life 
cycle occurs.  However, many laboratory studies in malaria have shown that high or 
low virulence phenotypes accrued through serial passage can be maintained upon 
transmission through mosquitoes (James et al. 1936; Coatney et al. 1961; Alger et al. 
1971; Walliker et al. 1976; Barnwell et al. 1983), although occasional major losses 
(or gains) of virulence do occur (Alger et al. 1971; Walliker et al. 1976; Knowles & 
Walliker 1980). 
 
When a single P. chabaudi genotype was serially passaged through whole-parasite 
immunized or immunologically naïve mice, there was a general reduction in 
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virulence across all lines following mosquito transmission (Mackinnon and Read 
2004a).  The virulence reduction observed in that study might be due to the 
deterministic forces of selection against virulent variants that have lost or reduced the 
ability to transmit through mosquitoes (Ebert et al. 1998).  Another possibility is that 
virulence reductions observed following mosquito transmission are due to the 
systematic resetting during meiosis of the expression of genes that have been 
switched on or up-regulated during asexual serial passage (Mackinnon and Read 
2004a).  In order to replicate how virulence genes may be selected or maintained in 
real world sexual parasites, the most appropriate experimental design would include 
transmission through mosquitoes of selected lines between every passage.   
 
Furthermore, selection for virulence may be an over adaptation to a single host 
genotype and therefore less adapted to outbred diverse population of host.  Thus, it 
would be of particular interest to observe whether lines selected through one host 
genotype are also capable of inducing virulence in a different host genotype.  
 
To confirm whether vaccination is likely to select for increased virulence, future 
experiments will serially passage P. chabaudi through AMA-1 immunized mice and 
test the virulence hypothesis in unvaccinated mice.  That experiment will take all of 
the above into consideration to ensure the most accurate reflection of a real world 
scenario is obtained.  Finally, the discovery of virulence genetic markers would 
allow one to track any adaptation of these genes in response to vaccination.  The 
tools for doing this are being rapidly developed. 
 
8.4.2  Vaccines 
 
An obvious limitation of this thesis is that it is based on a limited number of parasite 
clones and only one candidate vaccine antigen.  In Chapter 4 [Appendix 1 (Barclay et 
al. 2008b )], I show that the potency of a malaria vaccine may not be increased by 
including more than one antigen allele.  However, combining different antigens 
directed against the same or different stages of the Plasmodium life cycle might 
increases vaccine efficacy (Richie & Saul 2002; Heppner et al. 2005; Garcia et al. 
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2006).  It was also be interesting to investigate how these vaccines may alter the 




Parasite fitness is measured by parasite transmission.  In P. chabaudi, asexual 
parasite density is generally found to be positively correlated with transmission 
success (Mackinnon & Read 1999b; de Roode et al. 2005) although there is one 
possible exception (Gadsby et al. 2008).  One of the caveats of this thesis was that I 
did not measure gametocytes or transmission to mosquitoes.  In future experiments it 
will be necessary to investigate not only how vaccination alters the selection of 
asexual parasites, but how vaccination impacts on transmission.  This is possible due 
to advanced molecular techniques which can design gametocyte genotype-specific 
assays using real-time PCR (Wargo et al. 2006; Reece et al. 2008). 
 
 
8.5. Concluding remarks 
 
In conclusion, this thesis has contributed to the scientific community on how a 
malaria vaccine may impose selection on Plasmodium populations.  As with all 
scientific research, my thesis has raised more questions.  I hope that my work will be 
fruitful for those continuing after me, and that I can take forward the invaluable 
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a b s t r a c t
Malaria parasites are frequently polymorphic at the antigenic targets of many candidate vaccines, pre-
sumably as a consequence of selection pressure from protective immune responses. Conventional wisdom
is therefore that vaccines directed against a single variant could select for non-target variants, rendering
the vaccine useless. Many people have argued that a solution is to develop vaccines containing the prod-
ucts of more than one variant of the target. However, we are unaware of any evidence that multi-allele
vaccines better protect hosts against parasites or morbidity. Moreover, selection of antigen-variants is not
the only evolution that could occur in response to vaccination. Increased virulence could also be favored
if more aggressive strains are less well controlled by vaccine-induced immunity. Virulence and antigenic
identity have been confounded in all studies so far, and so we do not know formally from any animal
or human studies whether vaccine failure has been due to evasion of protective responses by variants at
target epitopes, or whether vaccines are just less good at protecting against more aggressive strains.
Using the rodent malaria model Plasmodium chabaudi and recombinant apical membrane antigen-1
(AMA-1), we tested whether a bi-allelic vaccine afforded greater protection from parasite infection and
morbidity than did vaccination with the component alleles alone. We also tested the effect of mono-
and bi-allelic vaccination on within-host selection of mixed P. chabaudi infections, and whether parasite
virulence mediates pathogen titres in immunized hosts. We found that vaccination with the bi-allelic
AMA-1 formulation did not afford the host greater protection from parasite infection or morbidity than did
mono-allelic AMA-1 immunization. Mono-allelic immunization increased the frequency of heterologous
clones in mixed clone infections. There was no evidence that any type of immunization regime favored
virulence. A single AMA-1 variant is a component of candidate malaria vaccines current in human trials;


















but that that mono-allelic
. Introduction
Malaria parasite antigens which are the targets of protective
mmune responses are frequently polymorphic, with antigen-
oding genes having multiple allelic forms [1]. Polymorphisms
ikely arise as a consequence of immune-mediated selection
ecause host responses can be more effective against parasites of
he immunising strain than against different strains (strain-specific
mmunity) [2–6]. Sequence polymorphisms have been directly
∗ Corresponding author at: Centre for Infectious Disease Dynamics, Depart-
ents of Biology and Entomology, The Pennsylvania State University, University
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© 2008 Elsevier Ltd. All rights reserved.
mplicated in antigenic escape [7–9], and in malaria endemic areas,
mmunity is acquired slowly, probably because repeated exposure
s required to generate an effective response against a repertoire
f strains [10–12]. The existence of antigenic polymorphism is
herefore of considerable concern to malaria vaccine developers
ecause it implies that single antigen vaccines will have trou-
le inducing protective immunity against polymorphic targets
13–16].
One approach to minimizing vaccine-induced strain-specificity
as been to design vaccines which combine more than one allele of
n antigen [1,17–19]. However, the inclusion of more than one allelic
orm of an antigen may not be sufficient to overcome substantial
olymorphisms [9], and there is little experimental evidence that
ulti-allele vaccines actually afford the host more protection from
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Furthermore, selection of antigen-variants is not the only evo-
ution that could occur in response to widespread vaccination.
heoretically, vaccination has the potential to cause evolution-
ry change in parasite virulence (parasite-induced host damage)
y altering the way natural selection acts on parasite popula-
ions [20–27]. In experimental evolution experiments, the rodent
alaria Plasmodium chabaudi became virulent more rapidly if
erially passaged through mice previously immunized with live
arasites [28]. The most likely explanation for this is that more
ggressive variants are less well controlled by immunity.
To date, we still do not fully understand how vaccines will
lter gene frequencies in malaria parasite populations. Evidence
or selection in the field comes from a small phase 1-2b trial of
he “Combination B” blood-stage malaria vaccine [29]. This vaccine
ontained a single antigen from each of three polymorphic loci of
. falciparum. One of these loci, merozoite surface protein-2 (MSP-
), is dimorphic, with each parasite having an allele from one of
wo allelic families (labelled 3D7 and FC27). The MSP-2 allele in the
ombination B vaccine came from the 3D7 family. Among parasites
ubsequently acquired by vaccines, 3D7-type alleles were rarer
han in people given a placebo. Vaccination thus selected against
he variant contained in the vaccine. Interestingly, the FC27 allelic
amily is associated with more virulent infections [30]. Therefore,
t is not clear whether the vaccine-imposed selection was due to
mmune specificity [15,31] or whether the vaccine was less good at
ontrolling more virulent infections.
Many candidate vaccines against malaria are directed against
he asexual blood stage, with the principal target being the mero-
oite. Apical merozoite antigen-1 (AMA-1) is a promising vaccine
andidate as it possesses fewer polymorphisms than other mero-
oite antigens [2,13]. AMA-1 is thought to play a major role
uring erythrocyte re-modelling and invasion [32]. Immuniza-
ion with AMA-1 confers protection against parasite challenge
n a number of animal models, probably by inducing antibod-
es which inhibit invasion [2,7,33–36]. Furthermore, humans and
ther species immunized with single allele AMA-1 vaccines raise
ntibodies which inhibit erythrocyte invasion in vitro [13,37]. In
ndemic populations, naturally acquired antibody to P. falciparum
MA-1 (PfAMA-1) is associated with protection from falciparum
alaria [38–42]. At least six different vaccines based on the AMA-
allele from the P. falciparum 3D7 strain are currently in efficacy
rials in humans [43–45].
However, there are more than 60 polymorphic sites in the AMA-
protein, and most of these are non-randomly dispersed point
utations on domain I [46–50]. These point mutations may be
f immunological importance. Protection in mice is strain-specific,
nd growth and invasion inhibition assays (GIA) and ELISA show
hat antibodies from animals and human field sera inhibit growth
n a strain-specific manner [2,13,34,38,43,47]. Allelic replacement
xperiments have directly implicated sequence polymorphism in
ntigenic escape [7], and cross-strain inhibition assays suggest that
he extent of escape correlates with sequence distance between
he vaccine and the target strain [8]. In an attempt to overcome
train-specificity, vaccine researchers are beginning to combine
llelic variants of AMA-1. For example, one group immunized rhe-
us monkeys with a mixture of two allelic forms of PfAMA-1
designated AMA-1-C1) or the component alleles and measured
esponses in vitro using GIA and ELISA [8,51,52]. The resulting anti-
odies were similarly effective regardless of whether immunization
as with a single variant or AMA-1-C1. Another group immunized
ice and rabbits with two allelic variants of domain I and II of
MA-1 ectodomain from P. falciparum isolates. The anti-AMA-1
ntibodies obtained with both proteins were active in an in vitro
arasite growth invasion/inhibition assay, but to no greater extent







ave raised questions about the necessity of using multi-allele vac-
ines.
Here we use the rodent malaria P. chabaudi and two alleles of
he blood-stage malaria vaccine candidate AMA-1 to investigate (i)
hether immunization with a single or bi-allelic AMA-1 variant
ormulation afforded the host the greatest protection from mor-
idity and parasite infection, (ii) how these different vaccination
egimes can alter clonal frequencies in mixed infections, and (iii)
hether more virulent clones are better at evading heterologous
accine-induced protective responses.
. Materials and methods
.1. Parasites and hosts
P. chabaudi adami clones were originally derived from wild-
aught thicket rats (Thamnomys rutilans) in the Congo and stored
s frozen stabilites in liquid nitrogen with subscript codes used to
dentify their position in clonal history [54,55]. In this experiment
e used clones DS500 and DK122 originally cloned from isolates
08XZ and 556KA, respectively. The nucleotide sequences of the DK
nd DS P. chabaudi AMA-1 (PcAMA-1) gene differ at 79 sites [34,56].
osts were inbred female C57BL/6 mice aged 6–8 weeks (Harlan,
ngland) maintained as described previously [57]. Studies by oth-
rs [34] and our own pilot studies showed that these clones differ in
irulence during the infection of C57BL/6 female mice, with clone
S generating substantially more parasites and inducing greater
eight and red blood cell loss relative to DK.
.2. Immunizations and isotype ELISA
Here we used an immunization protocol adapted from Anders
t al. [2]. Prior to immunization, mice were randomized into four
roups of eighteen (Table 1). Immunization was with the highly
mmunogenic ectodomian of the full AMA-1 protein termed AMA-
B. For mono-allelic immunizations (hereafter referred to as DS
MA-1 or DK AMA-1), groups of mice were injected intraperi-
oneally with 10 g of the appropriate protein emulsified in 100 l
f the adjuvant Montanide ISA720 (Seppic, France). For bi-allelic
mmunizations, mice were injected with a mixture of 5 g of both
S and DK AMA-1, giving the same total dose of antigen as for
he single antigen immunizations, again emulsified in Montanide
SA720. Control mice were injected with 100 l emulsion of PBS in
ontanide ISA720. Mice were given a single booster immunization
ith the same amount of antigen emulsified in Montanide ISA720
weeks after the primary immunization.
To ensure that antigen immunization successfully generated
ntibody responses, and to determine whether there was any
ross-reactivity between the antibodies generated to the differ-
nt immunizing antigens, we first carried out a pilot experiment.
total of 11 mice were immunized with DS AMA-1, 11 with DK
MA-1, and 10 were sham-immunized. We estimated the quan-
ity of IgG2b antigen-specific antibodies in all mice sera 11 days
fter the booster immunization by ELISA using wells coated with
S AMA-1 or DK AMA-1. Thus the sera from 32 mice were tested in
4 wells. We used IgG2b as previous work in our laboratory showed
hat C57BL/6 produce this isotype in response to P. chabaudi infec-
ion (K. Grocock, A. Graham, unpublished). Protection induced by
mmunization with recombinant AMA-1 is isotype independent
58b]. Given the lack of cross-reactivity we observed in this pilot
xperiment (see Section 3), in the main experiment, we measured
gG2b isotype antibodies to each antigen separately only from the
era of mice immunized with a mixture of DS and DK AMA-1 and
n sham-immunized control mice.
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Table 1
Experimental design
Number of mice per immunization Infecting clone Number of mice per parasite infection Number of deaths Number of euthanized
Sham-immun
18
DS 6 3 2
Sham-immun DK 6




DK AMA-1 DK 6




DS AMA-1 DK 6
DSAMA-1 DS + DK 6 1
Bi-allelic
18
DS 6 2 1
Bi-allelic DK 6
Bi-allelic DS + DK 6













































































mmunization was either with DK AMA-1, DS AMA-1, a formulation containing a
‘sham-immunization’). Groups of 18 mice were immunized with one of the four tr
K alone, clone DS alone or a mixture of both. During the experiment 7 mice were
redetermined levels of morbidity prescribed by animal care protocols.
In both the pilot and main experiments, sera fractions were
eparated by centrifugation from 20 l of blood taken from a tail
nip and were stored at −80 ◦C. High binding 96 well ELISA Max-
sorb immunoplates (Nunc) were coated with either DS AMA-1
r DK AMA-1 at a concentration of 1 g/ml in 0.06 M carbonate
uffer (0.04 M NaHCO3, 0.02 M NaCO3, pH 9.6) in a final volume of
0 l per well. Plates were stored at 4 ◦C overnight to allow the anti-
en to bind. Non-specific binding was blocked by incubating wells
ith 5% BSA: carbonate buffer (200 l per well) for 2 h at 37 ◦C.
ells were then washed three times in Tris buffered saline with
.01% Tween 20 (TBST). We used end-point dilution methods to
etect IgG2b titres: serum samples were detected in a serial dilu-
ion 1/100-1/204800 using TBST as a diluent, in a final volume of
0 l per well and incubated for 2 h at 37 ◦C. Wells were washed
hree times in TBST. HRP conjugated goat anti-mouse IgG2b detec-
ion antibody (Southern Biotech 1100-05) was diluted 1/4000 in
BST to a final volume of 50 l per well. Plates were incubated for
h at 37 ◦C. Wells were washed three times in TBST followed by
final wash in distilled water. ABTS peroxide substrate (Insight
iotechnology) was added at 100 l per well and allowed to develop
t room temperature for 20 min. Optical density was read at 405 nm
sing a spectrophotometer. IgG2b isotype antibody titres were cal-
ulated as the reciprocal of the greatest dilution at which optical
ensity (O.D.) was greater than the mean (plus 2 standard devia-
ions) O.D. values observed for naïve mouse sera assayed against
oth DS and DK AMA-1 at 1/100.
.3. Parasite challenge and monitoring of within-host dynamics
Two weeks after the boost immunization, groups of immu-
ized mice (18 per group) were further randomized into groups
f six and challenged with 105 parasites of either clone DS alone,
lone DK alone or a mixture of clone DS and DK (Table 1).
hus, mice infected with both clones received twice as many
arasites as those infected with one clone. A two-fold differ-
nce in infective dose has negligible effects on the population
ynamics of the parasite [58a]. During the course of infection,
e measured body weights and took blood samples from the
ail to (i) make Giemsa-stained blood smears, (ii) estimate red
lood cell density by flow cytometry (Beckman Coulter), and (iii)
or genotype-specific real-time quantitative PCR (qPCR) assays as
escribed previously [59]. For amplification of the DK genotype,
e used primers previously designed to amplify AS/AJ genotypes
s described elsewhere [59]. DS genotype-specific primers were as






al mix of both forms of AMA-1 (bi-allelic), or immunization with adjuvant only
nts before being separated into groups of 6. Infection was with parasites of clone
dead and 3 had to been euthanized due to severe morbidity. Euthanization was at
CT AAA-3′; DS reverse 5′-CAG GAG AAA TGT TTA CAT CTG CTT
-3′.
.4. Trait definition and statistical analyses
Since P. chabaudi has a 24-h replication cycle, the total number
f parasites present in any period can be estimated by summing
he daily parasite counts. Data were analysed using General Linear
odels (GLMs) in MINITAB. To meet normality and homogene-
ty of variance assumptions, data on antibodies, weight and red
lood cell density were log transformed while all parasite den-
ities and proportions were square root transformed. GLMs were
sed to test whether the magnitude of protection differed between
he three antigen immunizations (DK AMA-1, DS AMA-1, or the
i-allelic form); that is whether there was a statistical interac-
ion between infecting clone and immunizing treatments. Maximal
odels (response variable = infecting clone + immunizing treat-
ent + infecting clone × immunization treatment) were tested in
he first instance, and minimal models were obtained by drop-
ing non-significant terms successively, beginning with highest
rder interactions, to obtain the significant minimal model. For
nalyses of within-host selection, we asked for mixed clone infec-
ions, whether the frequency of clone DS in the parasite population
iffered between the sham-immunized controls and the antigen
mmunizations.
. Results
Table 1 gives details of the immunization treatments, infecting
lone and sample size of the experiment. Some mice died; these
ere included in the calculation of daily densities until death, and in
he analyses of peak parasite densities since death always occurred
s initial parasiteamias were declining.
.1. Pre-challenge anti-AMA-1 IgG2b antibodies
Fig. 1 illustrates the data from a pilot experiment where IgG2b
ntigen-specific antibodies were measured to each of the immu-
izing antigens and the cross-reactivity between them. All antigen
mmunization treatments generated antibody titres that were
igher than those present in sham-immunized controls (sham-
mmunized versus antigen immunized: F1,62 = 8.92, p = 0.004).
gG2b antibodies were specific for the antigen they had been
xposed to during immunization (immunizing treatment × ELISA
ntigen: F1,40 = 9.99, p = 0.003). For example, anti-DS AMA-1 IgG2b
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Fig. 1. IGg2b antibody levels from the serum of mice in the pilot experiment. Mice
were either sham-immunized or immunised with one of the two atingens (DS AMA-
1, DK AMA-1). Each of the treatments used to immunize mice and the AMA-1 test
antigen used to coat ELISA plates are shown on the x-axis. Dots represent the anti-
body titre against a particular immunizing antigen for a single mouse. Horizontal
lines indicate mean antibody levels. Antibody levels in antigen immunized groups


























































mmunized mice, the levels induced between the antigen immunized groups dif-
ered (immunizing treatment × ELISA antigen: p = 0.003) with higher titres against
he homologous antigen. Neither of the immunising antigens induced higher titres
p > 0.05).
ntibody tires were higher when assayed against the homologous
S antigen than the heterologous DK antigen and vice versa. Thus,
either antigen elicited a stronger response overall.
Fig. 2 illustrates the IgG2b antibody titres in mice from the main
xperiment 3 days prior to parasite infection. All antigen immu-
ization treatments induced antibody titres that were higher than
hose present in sham-immunized mice (sham-immunized versus
mmunized: F1,106 = 58.89, p < 0.001). Among antigen-immunized
roups, titres did not differ (F2,69 = 2.56, p = 0.085). In those mice
hich had been immunized with the bi-allelic form, antibodies
ere not more specifically recognising either component antigen
F1,35 = 0.61, p = 0.44). These data show that immunization success-
ully elicited antibody responses, and that, at least as measured by
gG2b titres, these responses were of equal magnitude in all immu-
ig. 2. IgG2b antibody levels from the serum of mice in the main experiment. Mice
ere either sham-immunized, or immunized with one of the antigen immuniza-
ion treatments (DS AMA-1, DK AMA-1 or the bi-allelic formulation). Each of the
reatments used to immunize mice and the AMA-1 test antigen used to coat ELISA
lates are shown on the x-axis. Dots represent the antibody titre for individual mice
gainst a particular antigen. Mice that were sham-immunized or immunized with
he bi-allelic formulation were assayed for antibody responses against both DS and
K AMA-1 antigens. Horizontal lines indicate mean antibody levels. Antibody levels
n antigen immunized groups of mice were higher than in sham-immunized controls
p < 0.001), and among the antigen immunized mice, antibody titres did not differ
p = 0.085). The antibody titres in animals immunized with both antigens were not




























ized groups. Among antigen-immunized mice, antibody titres
rior to challenge did not predict subsequent parasite intensities,
eight loss or anaemia (all correlations, p > 0.2).
.2. Bi-allelic immunization did not generate a greater
nti-morbidity response than did mono-allelic immunization
Red blood cell density and weight kinetics following parasite
hallenge for each of the immunization treatments are illustrated
n Fig. 3A–F, and the minimum red blood cell density and minimum
eight reached are illustrated in Fig. 3G–H. In sham-immunized
ontrol mice, clone DK was less virulent than clone DS, induced
ess anaemia and less weight loss (Fig. 3A–H; anaemia: F2,14 = 6.29,
= 0.011; weight loss: F2,14 = 9.97, p = 0.002).
Immunization protected mice against anaemia induced by
nfection with any of the clones (Fig. 3A–C, G; sham-immunized
ersus immunized: F1,69 = 16.94, p < 0.001). Bi-allelic immunization
educed anaemia no more than did immunization with either of
he alleles alone (Fig. 3G; immunizing treatment × infecting clone:
4,44 = 0.71, p = 0.59). All pairwise immunization comparisons were
on-significant (p > 0.5 in all cases).
As infection with clone DK did not induce any weight loss in
ham-immunized controls (Fig. 3D) the protective effects of immu-
ization were analysed only for infections that contained clone DS
Fig. 3E–F). We found that all immunizations protected mice against
eight loss due to DS infections (Fig. 3E–F, H; sham-immunized
ersus immunized: F1,45 = 11.13, p = 0.002). Similar to the anaemia
ata, we found that immunization with either the bi-allelic form
r either of the alleles alone afforded similar levels of protec-
ion against weight loss (Fig. 3H; immunizing treatment × infecting
lone: F2,29 = 2.43, p = 0.11). All pairwise immunization comparisons
ere non-significant (p > 0.5 in all cases).
Together, these results show that immunization with the bi-
llelic vaccine does not afford the host greater protection from
orbidity, as measured by anaemia and weight loss. Immuniza-
ion with either of the variants alone provided protection which
as as effective as that induced by the two variants together.
.3. Bi-allelic immunization did not generate greater
nti-parasite response than did mono-allelic immunization
Parasite dynamics under each of the treatments are illus-
rated in Fig. 4. Clone DS achieved higher parasite density in
ham-immunized control mice than did clone DK (infecting clone:
1,10 = 7.03 = 0.024).
All three immunizations reduced peak parasite densities rel-
tive to those which had received a sham inoculation (Fig. 4D;
ham-immunized versus immunized: F1,69 = 11.55, p = 0.001). The
xtent of anti-parasite protection depended on the identity of the
mmunising antigen and the identity of the challenge clone (Fig. 4D;
mmunizing treatment × infecting clone: F4,44 = 8.71, p < 0.001). We
ound that protection was clone-specific: immunization with DS
MA-1 antigen reduced DS parasite densities more than it reduced
he densities of clone DK, and vice versa (among single anti-
en immunized groups, immunizing treatment × infecting clone:
1,19 = 36.26, p < 0.001).
When we compared the extent of anti-parasite protection
etween the immunized groups we found that under no circum-
tances did the bi-allelic immunization afford greater protection
han did immunization with a single allele. For example, immu-
ization with DS AMA-1 reduced the peak density of DK infections
nd infections with both clones together, but the bi-allelic
mmunization did not protect against DS alone (Fig. 4D; immu-
izing treatment × infecting clone: F2,30 = 9.84, p = 0.001). Although
he bi-allelic immunization reduced the densities of clone DK,
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Fig. 3. Effect of Plasmodium chabaudi infection (clone DK alone, DS alone or DS + DK) and immunization (sham-immunized control, DK AMA-1, DS AMA-1, or bi-allelic form)
on the kinetics of minimum red blood cell density (left panels) and minimum weight (right panels). In A–F lines represent the change in RBC density (left panels) and weight
(right panels) over time. Each line represents the mean of up to 6 mice (±1 S.E.M.) that were infected with DK alone (A and D), DS alone (B and E) or a mixed clone (C and F)
infection during immunization with either a sham-inoculation control (solid thick black line), DK AMA-1 (open triangle), DS AMA-1 (open squares), or the bi-allelic mixture
(dotted black line). In G–H bars represent the minimum red blood cell density (left panel) and minimum weight (right panel) reached during infection with clone DK alone
(grey bars), DS alone (black bars) or a mixture of both clones (black and white bars) under each of the immunization treatments. Each bar represents the least squares mean
of up to 6 mice (±1 S.E.M.).
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Fig. 4. Kinetics of P. chabaudi infections (clones DK alone, DS alone or both together)
following immunization (DK AMA-1, DS AMA-1, or bi-allelic formulation or sham-
immunized control). In A–C, lines represent the change in parasite density over time.
Each line represents the mean of up to 6 mice (±1 S.E.M.) that were infected with
DK alone (A), DS alone (B) or a mixed clone (C) infection during immunization with
either a sham-inoculation control (solid thick black line), DK AMA-1 (open triangle),
DS AMA-1 (open squares), or the bi-allelic mixture (dotted black line). In (D), bars









Fig. 5. Proportion of clone DS in mixed DS and DK infections following immuniza-
tion with DK AMA-1, DS AMA-1, the bi-allelic formulation, or in sham-immunized
controls. (A) Lines represents the proportion of clone DS through time in control
(solid black line), DK AMA-1 (open triangles), DS AMA-1 (open diamonds) or bi-
allelic (dotted black line) immunized mice. Each line represents the mean of up
to 6 mice (±1 S.E.M.). (B) Bar graphs represent the proportion of total parasites in


























ars), DS alone (black bars) or a mixture of both clones (black and white diagonal)
nder each of the immunization treatments. Each bar represents the least squares
ean of up to 6 mice (±1 S.E.M.).
eduction was no greater than with a single DK AMA-1 immuniza-
ion (Fig. 4D; immunizing treatment × infecting clone F = 4.09,2,29
= 0.027).
Together these results show that bi-allelic immunization did
ot afford the host greater anti-parasite protection than did





ar represents the least squares mean of up to 6 mice with 95% confidence inter-
als. The black horizontal dotted line represents the proportion DS present in the
noculum.
as induced regardless of the antigen used in immunization,
e found that immunization with a single allele achieved better
rotection against the homologous clone, and bi-allelic immu-
ization never did as well. Indeed, we found just one of the
ariants (DS AMA-1) to be the most effective at reducing parasite
ensities.
.4. Vaccine-induced anti-parasite protection was clone specific
n mixed infections and independent of clone virulence
To examine how the antigenic composition of the immuniz-
ng formulation affects within-host selection (relative frequency)
n mixed clone infections, and whether heterologous immunity
ess effectively controlled the virulent clone, we compared the fre-
uency of clone DS in mixed infections (Fig. 5).
We found that antigen immunization altered clone frequen-
ies. In sham-immunized mice, and those immunized with the
i-allelic formulation, DS made up about 60% of all the parasites
resent in the infections. Thus, immunization with a mixture of DS
nd DK AMA-1 had negligible effect on clone frequency and thus
ithin-host selection (Fig. 5A; sham-immunized versus bi-allelic
mmunization: F1,10 = 2.02, p = 0.19). In contrast, immunization with
single antigen reduced parasites in a clone-specific manner, facili-
ating the heterologous clone (Fig. 5A and B; immunizing treatment
1,10 = 105.54, p < 0.001). Immunization with DK AMA-1 increased
he frequency of clone DS, while DS AMA-1 immunization increased
he frequency of DK. These effects were essentially symmetrical.
hus, there was no evidence that the more virulent clone, DS, was
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. Discussion
In this study, we investigated (i) whether immunization with
single or bi-allelic AMA-1 formulation afforded the host the
reatest protection from morbidity and parasite infection, (ii) how
hese different vaccination regimes altered clonal compositions in
ixed infections, and (iii) whether a more virulent clone was less
uccessfully controlled by vaccine-induced protective responses.
ddressing each of these in turn, we found the following. (i)
i-allelic immunization did not generate better anti-morbidity
r anti-parasite protection than did single allele immunization.
ather, immunization with one of the two variants alone (DS) pro-
ided the best protection. (ii) Both single variant immunizations
educed the frequency of homologous clones in mixed infections;
i-allelic immunization had no impact on within-host selection.
iii) There was no evidence that the more virulent clone (DS) was
etter at evading vaccine-induced immunity than was the less vir-
lent clone.
Rightly, protecting individual hosts from morbidity is one of
he goals of malaria vaccines directed against the blood-stage of
nfection. If infection densities are positively correlated with host
orbidity (virulence) [27] multi-allele vaccines could potentially
mprove the health of the host by suppressing more of the parasite
opulation and reducing strain-specific responses. Subject to the
sual cautions about generalising from animal models (reviewed
n this context by Råberg et al. and Wargo et al. [60,61]), the
esults presented here argue against that, and suggest that protec-
ive efficacy may not be increased by including alternative variants
f AMA-1. Our in vivo observations are consistent with previous
esults showing that immunization of rhesus monkeys with only
ne of two PfAMA-1 variants is sufficient to induce cross-protective
ntibody responses as measured by GIA and ELISA assays in vitro
52]. Our results are also consistent with another study which
emonstrated that mice and rabbits immunized with two allelic
ariants of domain I and II of the full length AMA-1 ectodomain
rom Indian P. falciparum isolates were able to inhibit in vitro para-
ite growth, but to no greater extent than with either of the allelic
ariants alone [53].
Our results also demonstrate strain-specific anti-parasite
esponses (Fig. 4D) need not result in strain-specific protection
gainst disease (Fig. 3G and H). The observation that there are two
ifferent types of anti-malarial responses – immunity against the
arasite itself and immunity against disease – is poorly understood
n a molecular basis although the distinction is widely appreci-
ted [62]. An explanation for the two different responses observed
ere could be that the specificity of the anti-AMA-1 antibody
esponse lies with the generation of inhibitory antibodies which
ay target the hypervariable region located around a conserved
ydrophobic pocket on domain I [63]. The presence of such anti-
odies could determine the observed parasitaemias. For bi-allelic
mmunizations there may exist a dominant epitope in one allelic
orm of AMA-1. Thus, high titres of cross-reactive antibodies may
e sufficient to lessen morbidity (hence the similar effects for
ono-and-bi-allelic vaccination on morbidity) but the inhibitory
ntibodies are more effective at controlling parasite numbers by
nhibiting invasion. In our pilot studies we did not observe a dis-
roportional IgG2b antibody response to one of the immunizing
ntigens (Fig. 1). However, since immunization with AMA-1 is likely
o induce a repertoire of IgG isotypes [58a,64–66] some of the
ther isotypes may be sufficiently cross-reactive. An implication
f this may be that while strain-specific immunization may alter
llele frequencies in parasite populations, this need not have clini-
al consequences in a vaccinated host. Changes in allele frequencies
ithout public health consequences have been seen in some other
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The ‘Combination B’ malaria vaccine, one of the few to reach field
rials, demonstrated strain-specific anti-parasite effects despite
eing comprised of an allele of each of 3 asexual blood stage pro-
eins, MSP-1, MSP-2 and RESA (ring-infected erythrocyte surface
ntigen) [29]. Of particular interest was that vaccination increased
he frequency of parasites with an MSP-2 genotype belonging to the
C27 allelic family. No representatives of this allelic family, which
ad been found previously to be associated with severe morbid-
ty, were included in the vaccine [16,29,30]. Selection for the FC27
orm of MSP-2 could have been because of strain-specific protec-
ion [15,31], or because the vaccine was less effective at protecting
gainst more virulent strains [26–28]. In the study we report here,
e looked at the relative proportion of the more virulent clone
n a mixed infection under the different immunization composi-
ions. In sham-immunized control mice and those which received
he bi-allelic immunization, the more virulent clone (DS) was pro-
ortionally the most dominant. Thus, bi-allelic immunization did
ot alter within-host selection. On the other hand, immunization
ith a single AMA-1 variant did facilitate evasion of the heterolo-
ous clone in mixed infections. In our experiments, this effect was
ymmetrical (Fig. 5), so that immunization with AMA-1 appears to
nduce protective responses that are strain-specific and evasion is
ndependent of parasite virulence.
Nevertheless, selection for virulence could be an inadvertent
onsequence of including just one allele from a given locus in a
accine, as apparently happened in the Combination B trial. As far
s we are aware, there are no reports that variants of AMA-1 have
ifferent intrinsic virulence, so that the strain-specific immunity
gainst this locus we report here and that has been seen by others
7,34], should not directly alter virulence. But caution is necessary
or all antigens involved in processes like cell invasion which are
ssociated with pathogenesis. Population-level association studies
or disease severity should be performed for all antigens included
n candidate vaccines. Should associations like that for MSP-2 be
ound [30], we suggest on the basis of our results that there would
e a strong case for including all known variants at that locus in the
accine. This would not confer short-term clinical advantage, but it
ould be the safest way to avoid inadvertent selection for virulent
ariants, which would put unvaccinated people at greater risk.
More generally, though, we still have some way to go to under-
tand the potential for vaccine-driven virulence evolution, even in
he P. chabaudi model. One experimental study demonstrated that
arasites from a single P. chabaudi clone serially passaged through
hole-parasite immunized mice evolved to be more virulent than
hose evolved in naive hosts [28]. That study was the first to show
nder controlled conditions that immunization can favour the evo-
ution of more virulent parasites. The implication was that more
irulent variants had a selective advantage in immunized hosts. In
he study we report here, which did not involve serial passage, we
aw no signs of such an advantage. DS, the more virulent clone,
ominated in mice immunized with the bi-allelic form, but to the
ame extent as in non-immunized mice. In single antigen immu-
ized mice, strain-specific immunity dominated with symmetrical
ffects for both clones. Competition experiments with other P.
habaudi clones also failed to find an increased advantage to vir-
lence in immunized hosts [67]. It may be that the accelerated
volution of virulence seen during serial passage in immunized
osts [28,68] is a feature of selection of virulence variants on an
ntigenically identical background. In future experiments, we will
erially passage single P. chabaudi clones through AMA-1 immu-
ized and naïve mice to determine whether vaccination can evolve
irulence to be greater when measured in naïve hosts.
Our experiments concerned antigenic polymorphism at a single
arget antigen. Considerably more work has focused on vaccines


























































106 V.C. Barclay et al. / Va
xample, animal and human phase I trails have shown safety, toler-
bility and immunogenecity of formulations containing AMA-1 and
SP-1 [1,71–73]. Moreover, such ‘multi-valent’ vaccines have been
hown to reduce parasitaemias in mice of distinct MHC haplotypes
74] and against infections with different parasite strains as well
s subspecies of different virulence [75]. Thus, multi-valency may
e required to induce antibody responses against a repertoire of
olymorphic parasite antigens [64,66,76–81] in the human outbred
opulation exposed to multiple parasite genotypes [29,78,82–84].
e suspect that multi-valent vaccines will prove to be a more effi-
ient means of generating protection against the widest range of
arasite genotypes. Certainly, we found no evidence that the anti-
orbidity and anti-parasitic potency of a malaria vaccine would
e enhanced by increasing the number of variants of a particular
ntigen.
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AcceptedEcological interactions between microparasite populations in the same host are an important source of
selection on pathogen traits such as virulence and drug resistance. In the rodent malaria model Plasmodium
chabaudi in laboratory mice, parasites that are more virulent can competitively suppress less virulent
parasites in mixed infections. There is evidence that some of this suppression is due to immune-mediated
apparent competition, where an immune response elicited by one parasite population suppress the
population density of another. This raises the question whether enhanced immunity following vaccination
would intensify competitive interactions, thus strengthening selection for virulence in Plasmodium
populations. Using the P. chabaudi model, we studied mixed infections of virulent and avirulent genotypes
in CD4CT cell-depleted mice. Enhanced efficacy of CD4CT cell-dependent responses is the aim of several
candidate malaria vaccines. We hypothesized that if immune-mediated interactions were involved in
competition, removal of the CD4CT cells would alleviate competitive suppression of the avirulent parasite.
Instead, we found no alleviation of competition in the acute phase, and significant enhancement of
competitive suppression after parasite densities had peaked. Thus, the host immune response may actually
be alleviating other forms of competition, such as that over red blood cells. Our results suggest that the
CD4C-dependent immune response, and mechanisms that act to enhance it such as vaccination, may not
have the undesirable affect of exacerbating within-host competition and hence the strength of this source of
selection for virulence.
Keywords: malaria; CD4CT cells; competition1. INTRODUCTION
Parasitic infections are often genetically diverse, with hosts
concurrently infected by more than one genotype.
Crowding, where pathogen populations within a host are
suppressed by the presence of competitor strains, could
affect the health and infectiousness of individual hosts as
well as the evolution of medically relevant traits such as
virulence and drug resistance (Read & Taylor 2001). For
example, selection for increased virulence is expected
when a slower growing parasite is outcompeted by a faster
growing, more virulent parasite (Bremermann & Pickering
1983; van Baalan & Sabelis 1995; Frank 1996; Gandon
et al. 2001; Alder & Losada 2002). Similarly, the relative
fitness of drug-resistant strains, and hence their rate of
spread in a population, could be substantially enhanced
when co-infecting drug-sensitive competitors are removed
by chemotherapy (e.g. Hastings 1997, 2003, 2006;
Mackinnon & Hastings 1998; Hastings & D’Alessandro
2000; Mackinnon 2005). Analogous evolutionary pro-
cesses could affect the rate of evolution of epitope variantsr and address for correspondence: Centre for Infectious
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1171in response to strain-specific vaccination (Lipsitch &
Samore 2002; Read & Mackinnon 2008).
Infections with the human malaria parasite Plasmodium
falciparum frequently consist of more than one genotype
(Anderson et al. 2000; Awadalla et al. 2001; Jafari et al.
2004; Walliker et al. 2005), and a variety of epidemiol-
ogical evidence is consistent with crowding (Daubersies
et al. 1996; Mercereau-Puijalon 1996; Arnot 1998;
Smith et al. 1999; Bruce et al. 2000; Hastings 2003;
Talisuna et al. 2006). In the rodent malaria model
Plasmodium chabaudi in laboratory mice, there is a strong
relationship between parasite virulence and crowding such
that more virulent strains have a competitive advantage
(de Roode et al. 2003, 2005a,b; Bell et al. 2006).
A number of biological mechanisms may underlie
competition between strains within hosts (Read & Taylor
2001). One of these is immune-mediated apparent
competition (Holt 1977), where increasing densities of
one pathogen population elicits a host response that
suppresses the population of another. T cell-dependent
immune-mediated competition has been demonstrated in
P. chabaudi (Råberg et al. 2006): in nude mice, which
cannot produce mature T cells, competition was less
severe than in nude mice reconstituted with T cells.
Because many malaria vaccines currently under trial
are aimed at inducing T cell-dependent responses, that
experiment raised the question of whether vaccinationThis journal is q 2008 The Royal Society
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pathogen evolution, for instance by strengthening selec-
tion for competitive ability and hence virulence.
The effects of immunity on in-host competition are
unlikely to be simple. The immune response to Plasmo-
dium infection has both pathogen genotype-transcending
(non-specific) and genotype-specific components. Protec-
tion is generally thought to become more specific during
later stages of infection (Jarra & Brown 1989; Buckling &
Read 2001; Mackinnon & Read 2003; Stevenson & Riley
2004; Martinelli et al. 2005; Cheesman et al. 2006). Thus,
in contrast to non-specific immunity that could generate
immune-mediated apparent competition, specific immu-
nity could, in principle, act to alleviate competition
(Råberg et al. 2006). Here, we extend the study by Råberg
et al. (2006) by focusing on a specific subset of T cells, in
order to further investigate the importance of immunity in
determining competitive outcomes within hosts.
T cells can be divided into two major categories, CD4C
and CD8C cells. It is well established from both
experimental animal models and field studies in humans
that the CD4CT cells play a pivotal role in the
development of blood stage immunity to Plasmodium
infection (Good & Doolan 1999; Pombo et al. 2002).
They are initially required to produce cytokines that
amplify the phagocytic and parasitocidal response of the
innate immune response and later on to dampen this
response to limit immunopathology. As the response
becomes more adaptive they are required to help B cells
produce antibodies that are essential for parasite clearance
(Urban et al. 2005; Stephens & Langhorne 2006).
Since the CD4CT cells have been described as having
such a crucial role in natural immunity to the blood stage
of infection, and vaccine programmes strive to mimic and
enhance this response (e.g. Stephens & Langhorne 2006),
we have begun to investigate the specific role of these cells
during competition in mixed infections of P. chabaudi.
Specifically we looked at the acute phase of infection,
where any interaction between the parasite and the host
immune response could strongly influence host health
(Urban et al. 2005). We chose two parasite genotypes
that had been shown previously to differ in competitive
ability and compared the extent of competition in
immuno-competent and CD4CT cell-depleted mice.
We hypothesized two possible scenarios: (i) if T cell-
dependent immunity induces a non-specific response,
then a numerically subdominant clone would experience a
stronger immune response in a mixed infection than when
on its own. Thus, competition should be eased in CD4CT
cell-depleted mice. (ii) If the immune response is largely
clone-specific and primarily elicited against the numeri-
cally dominant clone, then CD4CT cell depletion may
exacerbate other forms of competition, such as compe-
tition for limited resources such as red blood cells.2. MATERIAL AND METHODS
(a) Parasites and hosts
Isolates of P. chabaudi were originally collected from
Thamnomys rutilans in the Central African Republic (Beale
et al. 1978). These isolates have been genotyped and are
stored as frozen stabilates in liquid nitrogen with subscript
codes used to identify their position in the clonal history
(Mackinnon & Read 1999). Two genotypes, AS12062 andProc. R. Soc. B (2008)DK108, were chosen based on their relative virulence and
non-lethality. Pilot studies showed that clone DK achieved
higher parasite densities when clone AS was absent than when
AS was present. In contrast, clone AS was not competitively
suppressed by DK. Hosts were inbred female C57BL/
6JolaHsd mice aged six to eight weeks (Harlan England)
maintained as described previously (de Roode et al. 2004).
(b) Depletion of CD4DT lymphocytes in vivo
A rat monoclonal antibody, GK1.5, was used to deplete the
CD4CT cells. A non-depleting rat monoclonal antibody of
the same isotype (IgG 14131, Sigma) was used as a control.
Experimental mice were injected intraperitoneally with
500 mg of the appropriate purified antibody in phosphate-
buffered saline (PBS) 5 days before parasite challenge, and
then with 250 mg antibody 4 days and 1 day before parasite
challenge and weekly after challenge.
A fluorescence-activated cell sorter (FACS) was used to
confirm CD4CT cell depletion. From the tail snip, 20 ml of
blood was taken 1 day prior to injection with the appropriate
antibodies. Single cell suspensions were made by removing
red blood cells using Lympholyte according to the manu-
facturer’s instructions (Cedarlane, Canada). Approximately
1!106 cells were then transferred to a round-bottomed plate
and resuspended in FACS buffer (PBS with 2% FCS with
0.05% sodium azide) before incubation for 20 min at 48C
with Allophycocyanin (APC)-labelled anti-CD4C antibody
(Pharmingen). The cells were washed three times in FACS
buffer. Samples were collected on a FACS Calibre and 10 000
live events were collected for the majority of samples. FlowJo
(TreeStar, CA) was used to analyse the data.
(c) Experimental setup and sampling
Groups offive mice were treated with: (i) control antibodies and
challenged with 106 AS parasites, (ii) control antibodies and
challenged with 106 DK parasites, (iii) control antibodies
and challenged with 106 AS and 106 DK, (iv) anti-CD4
antibodies and challenged with 106 AS, (v) anti-CD4 anti-
bodies and challenged with 106 DK, and (vi) anti-CD4
antibodies and challenged with 106 AS and 106 DK.
Parasites were delivered by intraperitoneal injection. We
used the same dose of each genotype in single and mixed
infections (rather than the same total dose in single and
mixed infections) because the aim of the study was to
compare the performance of a genotype when it is on its
own, with its performance when it is in a mixed infection. A
twofold difference in infective dose has negligible effects on
the population dynamics of the parasite (Timms et al. 2001).
In addition, we included two extra control groups, each of
two mice that were not challenged with malaria, one group
treated with anti-CD4 antibodies and another group with
control antibodies. These mice were used to check whether
CD4CT cell depletion was continuous throughout the
experiment, as the number of peripheral T cells was
lower than normal during the acute stage of disease (Hviid
et al. 1997).
During the course of infection, we measured body weights
and took blood samples from the tail to make Giemsa-stained
blood smears and to estimate RBC density (by flow
cytometry; Beckman Coulter) and for genotype-specific
real-time quantitative PCR (qPCR) assays.
One mouse died during the experiment (CD4CT cell-
depleted, mixed infection) and was included in the analyses
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Figure 1. FACS plots of number of cells analysed and percentage of CD4CT cells in (a) CD4CT cell-depleted and (b) intact
control mice. Percentage of the CD4CT cells was analysed: (i) 1 day before parasite challenge and (ii–iv) once a week throughout
the experiment. Each graph is a representative of one mouse from either the CD4CT cell-depleted or immunocompetent
control group.
CD4CT cells and malaria parasites V. C. Barclay et al. 1173(both non-depleted, a DK-only and an AS-only) achieved a
peak parasite density two orders of magnitude lower than all
others, and these were excluded from all the analyses.(d) Quantitative PCR
Samples were taken in the morning as this is the stage when
most parasites are in the ring or early trophozoite stage in the
peripheral blood, when parasite ploidy is stable (de Roode
et al. 2004). From each mouse, 5 ml of tail blood was taken
and added to 100 ml of citrate saline on ice. Samples were
subsequently pelleted by centrifugation and the citrate saline
was removed. Blood was stored at K808C until required.
DNA extraction was performed using the BloodPrep kit
(Applied Biosystems) on the ABI PRISM 6100 Nucleic Acid
prep-station according to the manufacturer’s instructions.
DNA was eluted in a total volume of 200 ml and stored
at K808C until quantification. Genotype-specific qPCR was
performed as described previously (Bell et al. 2006) with the
addition of the DK-specific reverse primer: 5 0-AGG CAT
GTT TTG CAC ACA ATG A-3 0.(e) Trait definition and statistical analyses
We define competitive suppression to be a reduction of
parasite numbers when another clone is present, which we
tested for by comparing the performance of a clone in
single and mixed infections. Performance was measured as
the clonal density summed over a defined time period.
Plasmodium chabaudi has a 24 hour replication cycle, so the
total number of parasites present in any period can be
estimated by summing the daily parasite counts. Thus, to test
whether competitive suppression was CD4CT cell mediated,
we asked, for each clone, whether the magnitude of any
competitive suppression differed between intact control and
CD4CT cell-depleted hosts; that is, whether there was a
statistical interaction between immune treatment (intact
control versus CD4CT cell-depleted hosts) and infection
type (single versus mixed).Proc. R. Soc. B (2008)The effects of competition and CD4C depletion on the
performance of individual clone and red blood cell density were
first examined by using general linear models (GLM) in the
statistical package MINITAB (release 14, Minitab, Inc.,). For
GLM analysis, response variables included mean total parasite
density and mean RBC density, with initial RBC as a covariate.
Explanatory variables for GLM included CD4C depletion
(depleted or intact control) and competition (clone alone or in
mixed infection). Maximal models (response variableZCD4C
depletion C competition C all higher order interactions) were
tested in the first instance, and minimal models were obtained
by dropping non-significant terms successively, beginning with
highest order interactions, to obtain the significant minimal
model. Second, we used repeated-measures analyses that take
into account the importance of day post-infection. These
analyses were performed as described by Råberg et al. (2006)
using the statistical package SAS v. 9.1 (SAS Institute 1999,
SAS OnlineDoc. v. 8. SAS Institute, Cary, NC). Briefly, the
analyses were performed with PROC MIXED, using the
REPEATED statement (subjectZmouse), the Satterthwaite
approximation of the denominator degrees of freedom, and the
autoregressive covariance structure AR(1). Within each
treatment group, the peak day varied G2 days, presumably as
a result of slight differences in inoculation dose. To control for
this variation, we centred the peak day at the median peak day
within each treatment group. All density data were transformed
using [log (density C10)].3. RESULTS
Mice treated with the anti-CD4CT cell antibody were
successfully depleted of CD4CT cells, both prior to
parasite challenge and during the whole course of the
experiment (figure 1). The CD4CT cell depletion resulted
in more parasites of both clones (figure 2a,b; table 1).
(a) Clone DK
As found with other pairs of clones (de Roode et al.
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Figure 2. Parasite densities through time of (a) clone DK and (b) clone AS, and (c–e) average densities of DK during the periods
denoted by the vertical dashed lines. Asexual density from qPCR of CD4CT cell-depleted mice and intact control (normal)
mice with single infections in CD4CT cell-depleted mice and mixed infections in intact control (normal) mice. Mean
densities (G1 s.e.m.) were calculated from all mice that were alive on the respective day of sampling (up to five). The interaction
plots (c–e) show the total numbers of DK parasites when the competitor clone AS is absent (single infection) or present (mixed
infection) in CD4C-depleted mice (dashed lines) and normal animals (solid lines). Competition!depletion interactions:
(c) F1,16Z1, pZ0.33; (d ) F1,17Z5.11, pZ0.037; and (e) F1,14Z4.57, pZ0.0499 (open squares, CD4
C-depleted single; open
triangles, intact single; filled squares, CD4C-depleted mixed; filled triangles, intact mixed).
Table 1. GLM analyses of the effects of CD4CT cell depletion, competition (presence/absence of co-infecting clone) and their
interaction on the total number of parasites during the first two weeks of infection for parasite clone DK and AS.
DK days 2–14 AS days 2–14
effect d.f. F p d.f. F p
CD4C depletion 1,15 82.7 !0.001 1,15 93.36 !0.000
competition 1,15 84.2 !0.001 1,15 2.05 0.17
CD4C depletion!competition 1,15 0.6 0.74 1,15 0.94 0.94
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Table 3. Repeated-measures analyses of the effects of CD4C depletion, competition (presence/absence of co-infecting clone)
and day post-infection on the daily parasite density of clone DK for days 6–8, 9–11 and 12–14 post-infection.
days 6–8 days 9–11 days 12–14
effect d.f. F p d.f. F p d.f. F p
CD4C depletion 1,16 12.61 0.0026 1,17 54.79 !0.0001 1,14 105.95 !0.0001
competition 1,16 62.31 !0.001 1,17 47.53 !0.0001 1,14 1.33 0.26
day 2,29 15.32 !0.001 2,30 39.12 !0.0001 2,28 2.22 0.12
CD4C depletion! competition 1,16 1 0.33 1,17 5.11 0.037 1,14 4.57 0.049
CD4C depletion! day 2,29 2.88 0.071 2,30 11.87 0.0002 2,28 23.78 !0.0001
competition!day 2,29 12.34 0.0001 2,30 2.32 0.11 2,28 0.64 0.53
CD4C depletion! competition!day 2,29 3.78 0.034 2,30 2.3 0.11 2,28 0.17 0.84
Table 2. Repeated-measures analyses of the effects of CD4C depletion, competition (presence/absence of co-infecting clone)
and day post-infection on the daily densities of the two parasite clones DK and AS for days 6–14 post-infection.
DK days 6–14 AS days 6–14
effect d.f. F p d.f. F p
CD4C depletion 1,16 74.52 !0.0001 1,17 51.58 !0.0001
competition 1,16 17.92 0.0006 1,17 1.86 0.19
day 8,101 30.8 !0.0001 8,108 40.85 !0.0001
CD4C depletion!competition 1,16 2.65 0.12 1,17 0.02 0.88
CD4C depletion!day 8,101 22.35 !0.0001 8,108 15.67 !0.0001
competition!day 8,101 3.67 0.0009 8,108 0.91 0.51
CD4C depletion! competition!day 8,101 2.10 0.042 8,108 0.47 0.87
Table 4. Repeated-measures analyses of the effects of CD4C depletion, competition (presence/absence of co-infecting clone)
and day post-infection on the daily parasite density of clone AS for days 6–8, 9–11 and 12–14 post-infection.
days 6–8 days 9–11 days 12–14
effect d.f. F p d.f. F p d.f. F p
CD4C depletion 1,14 17.58 0.0008 1,15 31.83 !0.001 1,14 58.71 !0.001
competition 1,14 0.3 0.58 1,15 2.08 0.16 1,14 1.6 0.22
day 2,28 39.82 !0.001 2,29 89.06 !0.001 2,27 6.52 0.0049
CD4C depletion! competition 1,14 0.01 0.91 1,15 0.11 0.74 1,14 0.03 0.86
CD4C depletion !day 2,28 12.17 0.0001 2,29 3.03 0.06 2,27 15.34 !0.001
competition!day 2,28 0.22 0.8 2,29 3.13 0.058 2,27 0.76 0.47
CD4C depletion!competition!day 2,28 1.20 0.31 2,29 0.08 0.92 2,27 0.70 0.50
CD4CT cells and malaria parasites V. C. Barclay et al. 1175avirulent clone was competitively suppressed by the more
virulent clone, with DK achieving lower parasite densities
when AS was present than when it was absent (figure 2a;
table 1). However, the extent of competitive suppression of
clone DK was similar regardless of CD4CT cell depletion
(table 1; depletion!competition interaction, n.s.). Thus,
there was no evidence that the competitive suppression of
the total number of DK parasites present in an infection
was mediated by CD4CT cell-dependent immunity.
However, repeated-measures analysis of the period where
CD4CT cell depletion affected parasite densities (day 6
onwards) showed a weak but significant three-way
depletion!competition!day interaction (table 2). To inves-
tigate this further, and following Råberg et al. (2006), we
divided the data into three parts, days 6–8, 9–11 and 12–14,
and repeated the analyses with each of these (figure 2a,c–e;
table 3). During each of these time periods, there were
significant depletion!competition or depletion!compe-
tition!day interactions. Inspection of figure 2a,c showsProc. R. Soc. B (2008)that the three-way interaction in the first period is a very weak
effect from which it is difficult to conclude much, given the
rapid alterations in infection kinetics during that period
caused by depletion. In the other two periods, there are
significant competition!depletion interactions (figures 2d,e;
table 3), with more severe competitive suppression in
CD4CT cell-depleted mice than in control mice. Thus,
there was no evidence that competitive suppression is
CD4CT cell mediated: once the initial wave of parasitaemia
began to subside, competitive suppression was exacerbated
rather than alleviated in CD4C-depleted mice.(b) Clone AS
There was no evidence of competitive suppression of AS
by DK, irrespective of the immune treatment (figure 2b;
table 1). Repeated-measures analysis from day 6 onwards,
when CD4C depletion had an effect, revealed no evidence
of interactions between depletion and competition
(table 2). However, for comparison with the analysis of
Table 5. Repeated-measures analyses of the effects of CD4C depletion and day post-infection on the mean red blood cell density
in mixed infections during days 6–8, 9–11 and 12–14.
days 6–8 days 9–11 days 12–14
effect d.f. F p d.f. F p d.f. F p
CD4C depletion 1,21 1.77 0.14 1,23 10.75 0.0033 1,19 4.57 0.045
day 2,36 42.18 !0.001 2,37 11.98 !0.0001 2,38 0.33 0.72
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6–8, 9–11 and 12–14 (table 4). In none of these time
periods was there any evidence of competitive suppression
(in all cases, competition main effect and depletion!
competition, pO0.15).
(c) Red blood cells
Red blood cell density over time for the different treatment
groups are shown in figure 3. Uninfected red blood cells
form an important resource for malaria parasites. To
assess whether the potential for competition over this
resource differed between CD4C-depleted and intact
control mice, we compared the red blood cell densities
in mice with mixed infections. Repeated-measures
analysis of days 6–14 revealed that CD4C-depleted mice
had significantly lower red blood cell densities during this
time period (F1,34.7Z4.35, pZ0.045; figure 3). There was
also a significant depletion!day interaction (F8,94.1Z
2.58, pZ0.014). Separate analyses of days 6–8, 9–11 and
12–14 showed that the difference in RBC density was most














































Figure 3. Mean red blood cell densities (G1 s.e.m) over time.
(a) CD4CT cell-depleted and intact mice infected with DK
(squares, depleted single; triangles, intact single), (b)
depleted and intact mice infected with AS (squares, depleted
single; triangles, intact single), and (c) depleted and intact
mice infected with DK and AS (squares, depleted mixed;
triangles, intact mixed).4. DISCUSSION
We found no evidence that the CD4CT cells enhanced
competition during mixed genotype infections with
P. chabaudi (figure 2a; table 1). Specifically, during the
peak stages of acute infection (days 6–8) suppression was
independent of the CD4CT cells (figure 2c; table 3). After
the peak of infection (day 9C), the CD4CT cells acted to
alleviate competition such that upon their removal
competitive suppression was enhanced (figure 2d,e;
table 3). In addition, the presence of CD4CT cells did
not cause suppression of the dominant genotype
(figure 2b; table 4).
The immune response to Plasmodium infection has
both pathogen genotype-transcending (non-specific) and
genotype-specific components, with protection becoming
more specific during later stages of infection (see §1).
Here, we found that after the peak of acute infection (day
9 onwards), there was no competitive suppression of DK
parasites in intact control mice; whereas in CD4CT cell-
depleted mice, there was still evidence of competition
(figure 2d,e; table 3). Both clones did better in depleted
mice, probably owing to an impaired early antibody
production through lack of T cell help and possibly the
reduced recruitment and activation of macrophages for
the uptake of infected cells. Thus, in normal hosts, a
largely clone-specific adaptive immune response towards
a numerically dominant genotype may act to alleviate
competition by regulating clonal populations and limiting
other forms of competition, e.g. competition for red
blood cells.Proc. R. Soc. B (2008)
CD4CT cells and malaria parasites V. C. Barclay et al. 1177During the peak of infection (days 6–8), competition
was CD4CT cell independent so that the extent of
competitive suppression of clone DK was similar in intact
control and CD4CT cell-depleted mice (figure 2a,c;
table 3). A number of biological mechanisms could be
the proximate cause of competitive suppression during the
peak of infection. First, there may be direct interference
between two infecting strains. This has not yet been
demonstrated in any parasites, but pathogenic bacteria
can produce allelopathic substances that actively suppress
competitors (Riley & Gordon 1999), and competing
viruses can produce interference molecules (Hart &
Cloyd 1990). Second, the competition may be influenced
by non-specific components of the innate immune
response (CD4CT cell independent). Third, there may
be competition for resources as genotypes infecting mice
simultaneously must divide the available red blood cells
and other resources such as blood glucose between them
(Hellriegel 1992; Hetzel & Anderson 1996; de Roode et al.
2005a; Gurarie et al. 2006). The CD4CT cell-depleted
mice were more anaemic than control mice (figure 3;
table 5), so that if red cells are limiting, there is more
potential for competition for that resource in depleted
mice. Mathematical models have suggested that during
mixed infection, the proximate cause of competitive
advantage may be attributable to an earlier and
wider red blood cell preference of dominant genotypes
(Hellriegel 1992; Gravenor et al. 1995; McKenzie &
Bossert 1997; Jakeman et al. 1999; Mason & McKenzie
1999; McQueen et al. 2004; Antia et al. submitted).
Because these predictions are based on the data from the
rodent malaria model, they could be tested directly by
transferring red blood cells of different ages into a single
mouse and determine their loss following infection, or
indirectly by measuring competition in untreated mice
and mice treated with erythropoietin (Suzuki et al. 2006).
Our conclusion that competition is not CD4CT cell
mediated apparently contradicts the recent finding of T
cell-mediated apparent competition (Råberg et al. 2006).
In that study, the authors looked at mixed infections with
P. chabaudi in nude mice (which lack the ability to produce
mature T cells) and compared the extent of competition
with that in nude mice reconstituted with T cells. There
was still pronounced competition in all animals, but there
was some alleviation of competitive suppression in nude
mice towards the end of the acute phase of infection, when
the initial wave of parasitaemia was waning. This period
corresponds roughly to days 9–14 in figure 2. A number of
experimental differences could explain the contrasting
results of Råberg et al. (2006) and the present study. First,
different mouse strains were used in the two studies and
host genotype has previously been shown to quantitatively
affect the outcome of competition (de Roode et al. 2004).
Second, different pairs of clones were used and P. chabaudi
clone can induce different levels of strain-specific immu-
nity (Cheesman et al. 2006). Third, there was a difference
in the method used to modulate T cell-dependent
immunity. Nude mice lack the ability to produce any
mature T cells, including both CD4C and CD8CT cells.
The role of CD8CT cells during malaria infection in mice
is still unclear (Lamb et al. 2006), but it could be that they
are involved in the relatively small component of
competition that was shown to be immune-mediated
competition in reconstituted nude mice (Råberg et al.Proc. R. Soc. B (2008)2006). In addition, the repertoire of serum antibodies
(including both natural antibodies and antigen elicited
antibodies) in the CD4CT cell-depleted mice will be
different from that in nude mice. Nude mice grow up
producing only T cell-independent antibodies, while in
the CD4CT cell-depleted mice there will be both T cell-
independent and persisting T cell-dependent antibodies
(produced by existing plasma cells in the bone marrow)
and these may cross react with the parasite.
Taken together, the present study and that of Råberg
et al. (2006) show that the effect of T cell-dependent
immunity on competition is relatively weak, and may be
either positive or negative depending on specific details of
host and parasite. Rather than further dissection of any
immune mechanism-mediating competition, one could
use this malaria model system to look at the strength of
competition in hosts immunized by a variety of different
candidate vaccines towards the blood stage of infection.
Meanwhile, the result we report here suggest that vaccines
that enhance CD4C-dependent immunity will not
increase the selection in favour of virulence arising from
in-host competition.
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abstract: Despite considerable success elucidating important im-
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namics of infection in some diseases, little is known about how
differences in these mechanisms result in strain differences in patterns
of pathogenesis. Using a combination of data and theory, we dis-
entangle the role of ecological factors (e.g., resource abundance) in
the dynamics of pathogenesis for the malaria species Plasmodium
chabaudi in CD4 T cell–depleted mice. We build a series of nested
models to systematically test a number of potential regulatory mech-
anisms and determine the “best” model using statistical techniques.
The best-fit model is further tested using an independent data set
from mixed-clone competition experiments. We find that parasites
preferentially invade older red blood cells even when they are more
fecund in younger reticulocytes and that inoculum size has a strong
effect on burst size in reticulocytes. Importantly, the results suggest
that strain-specific differences in virulence arise from differences in
red blood cell age-specific invasion rates and burst sizes, since these
are lower for the less virulent strain, as well as from differences in
levels of erythopoesis induced by each strain. Our analyses highlight
the importance of model selection and validation for revealing new
biological insights.
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Malaria is one of the leading causes of death among in-
fectious diseases in the world, killing more than one mil-
lion people every year (WHO and UNICEF 2005). Despite
this enormous burden and the large proportion of the
world’s population that is threatened by malaria, we know
little about the relative importance of mechanisms that
regulate malaria parasite growth within infected hosts or
how differences in these mechanisms among strains give
rise to different patterns of morbidity and mortality. A
better understanding of these mechanisms is of interest in
its own right and will likely yield important insights for
improving control strategies and understanding the po-
tential evolutionary consequences of these controls.
The rodent model system of malaria Plasmodium cha-
baudi provides an excellent opportunity to address this
question, because controlled and replicated experimental
manipulations are possible. In this article, we combine data
from experimental manipulations with the development
and testing of mathematical models. Our overriding goal
is to provide a quantitative (mathematical) description of
the main mechanisms governing the regulation of P. cha-
baudi growth within hosts and of how these differ among
malaria strains. If a mathematical description cannot be
made for mouse models of malaria, where host and par-
asite genotype together with a vast number of environ-
mental variables can be carefully controlled, then there is
little hope for a quantitative understanding of infection in
humans.
Many factors regulating malaria infection dynamics
have been identified. Among these, immune responses play
a large role in the control of parasite densities and may
take many forms with respect to the trigger and target of
the response (i.e., free-living merozoites or infected red
blood cells [RBCs]), the level of clone specificity of the
response, and the significance of antigenic variation (for
a review, see Stevenson and Riley 2004). Other nonim-
munological mechanisms, however, are also likely to play
a fundamental role. For example, simple resource abun-
dance—such as the availability of RBCs—is likely a key
regulator of parasite growth (Hellriegel 1992; Hetzel and
Anderson 1996; Haydon et al. 2003) because it is primarily
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within these cells that asexual replication occurs. Also, the
age structure of available RBCs could be important
(McQueen and McKenzie 2004; Cromer et al. 2006) be-
cause many malaria species preferentially invade either
young RBCs (reticulocytes) or fully mature normocytes
(Paul et al. 2003). Furthermore, the nature of the host’s
erythropoetic response to malaria-induced anemia will af-
fect both the abundance and age structure of RBCs (Antia
et al. 2008), as will temporal patterns of conversion to
gametocytes during an infection (e.g., Eichner et al. 2001).
Whereas some previous theoretical studies have explored
the role of these factors in determining within-host dy-
namics of malaria, our approach is unique in that we
compare multiple model variations that systematically test
different combinations of these regulatory mechanisms.
Furthermore, we allow for individual variation by fitting
models to data sets from individual hosts and then per-
forming a rigorous statistical analysis of the fit to exper-
imental data.
To dissect the relative importance of these factors and
how they differ among strains, a combination of experi-
mental manipulation and mathematical modeling is re-
quired. Experimental manipulations can be used to remove
some potential regulatory mechanisms so that we can ex-
amine the dynamics of parasite growth when only a few
factors are in operation. In this simplified setting, one can
build mathematical models to describe these dynamics.
Rigorous tests of these models can then be conducted in
this setting through a combination of statistical analyses
and further experimental manipulations. Understanding,
in a quantitative way, the strain-specific differences that
occur in such “stripped-down” situations is an important
step toward understanding the more complete picture in
which all potential regulatory factors interact with one
another.
The results presented here take this approach by fo-
cusing on P. chabaudi infections in mice that have depleted
levels of CD4 T cells. CD4 T cells are essential for de-
veloping an effective immune response against malaria in-
fections (Good and Doolan 1999; Pombo et al. 2002). They
play a crucial role, both early in an infection by activating
macrophages and initiating antiparasitic cell-mediated im-
mune responses and in later stages of infection by helping
B cells to produce antibodies and in regulating the adaptive
immune responses (Langhorne et al. 1990; Urban et al.
2005; Stephens and Langhorne 2006). By removing this
regulatory factor, we can then examine the extent to which
the above-mentioned ecological factors can explain strain-
specific differences in infections.
Material and Methods
Our approach and results have three main components.
The first focuses on data from two clones of Plasmodium
chabaudi, each singly infecting mice that have depleted
levels of CD4 T cells. We build a suite of eight nested
models of increasing complexity that represent eight po-
tential descriptions of the within-host dynamics of infec-
tion. We then fitted each of these eight models to data
using maximum likelihood techniques. Second, we use
model selection criteria to choose the “best” model from
the eight fitted models for each clone. After statistically
determining that the best model does in fact provide a
good fit, we use this model to infer the main mechanisms
underlying the clone-specific differences in infection dy-
namics. Third, we take our best model for each clone and
use it to derive predictions for the expected dynamics when
both clones coinfect a single host. These predictions are
compared with experimental data on coinfection as a fur-
ther independent means of validating the model.
Model Development and Data Fitting
Previous Experimental Data. Experimental infections were
generated using two genetically distinct P. chabaudi clones,
denoted AS and DK, that were originally isolated from
thicket rats Thamnomys rutilans in the Central African
Republic (Beale et al. 1978). In mixed infections, DK is
competitively suppressed by AS (Barclay et al. 2008), and
previous studies have shown a strong relationship between
competitive ability and virulence (de Roode et al. 2003,
2005a, 2005b; Bell et al. 2006).
Fifteen inbred female C57BL/6JolaHsd mice aged 6–8
weeks (Harlan, Bicester, United Kingdom) were depleted
of their CD4 T cells using a rat monoclonal antibody
GK1.5 (for details, see Barclay et al. 2008). Mice were
infected via intraperitoneal injection. Five mice were in-
oculated with 105 AS parasites, five received 106 of this
same clone, and five received 106 DK parasites. Mice were
maintained as described previously (de Roode et al. 2004).
Daily RBC densities were tracked using flow cytometry
(Beckman Coulter, High Wycombe, United Kingdom),
and parasite densities were measured using a genotype-
specific, real-time quantitative polymerase chain reaction
(qPCR). One mouse in each of the AS 105 and DK 106
treatment groups died prematurely; these were therefore
excluded from our analysis.
The Model. Our aim is to understand what factors deter-
mine the clone-specific differences in dynamics of infec-
tion in CD4 T cell–depleted mice. We developed models
that consider clone-specific effects on RBC age structure
and cellular tropism, gametocytogenesis, and erythropoesis
as possibilities. All of these factors were incorporated in a
single large model, and the suite of eight nested models
that are the objects of our analysis were then obtained as
certain special cases of this single model.
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Malaria parasites in most infections display a distinctly
discrete replication cycle during an infection, with syn-
chronous bursting of infected RBCs occurring every 24 h
in P. chabaudi (Carter and Walliker 1975). Our basic model
therefore tracks the infection dynamics in discrete time,
with one time step corresponding to a single day (Moli-
neaux and Dietz 1999). Immediately after bursting, mer-
ozoites begin infecting susceptible RBCs. This process oc-
curs relatively quickly, with the majority of the events
during the 24-h period between bursting events consisting
of development within RBCs (fig. 1). For simplicity, in the
model we census the populations of merozoites and RBCs
immediately after bursting but prior to the infection of
new RBCs. The basic model thus tracks the following
events within a single day: (i) census, (ii) RBC invasion
by merozoites, (iii) RBC turnover (production and natural
death), and (iv) bursting of infected RBCs (fig. 1).
The discrete-time nature of the model requires that we
define distinct classes of RBCs for exploring the impor-
tance of RBC age structure to the within-host dynamics.
In rats, reticulocytes take 30–75 h to mature when released
into the bloodstream, taking longer when the rat is anemic
(Ganzoni et al. 1969; Wiczling and Krzyzanski 2007). This
time frame is in agreement with the 2–3-day maturation
time observed in C57 black mice (S. Reece, personal com-
munication). Because the experimental mice have de-
pressed RBC densities for a substantial duration of the
experiment, we assume that the reticulocytes will, on av-
erage, take 3 days to mature. Thus, we define four age
classes of RBCs: reticulocytes that have been newly intro-
duced to the bloodstream (R1, i), reticulocytes in their sec-
ond day of being in the bloodstream (R2, i), reticulocytes
in their third day of being in the bloodstream (R3, i), and
fully mature normocytes (Ni). The subscript i denotes a
value on day i after parasite inoculation. In addition to
these age classes, there are four classes of infected RBCs
corresponding to each type of blood cell (I1, i, I2, i, I3, i, and
IN, i). Merozoites may infect reticulocytes and normocytes
at different per capita rates (reflecting a particular cell age
“preference”) and may produce different numbers of
daughter merozoites per infected cell on bursting. In the
absence of evidence to the contrary, merozoites are as-
sumed to respond to all reticulocytes the same way, re-
gardless of how many days the RBC has been in the blood-
stream. The production of RBCs varies according to the
density of RBCs (i.e., production is increased when an
individual becomes anemic), as has been well documented
(e.g., Mackey 1997).
Incorporating all of these biological details in a single
model gives the discrete-time dynamics system (see app.
A for model derivation and table 1 for parameter descrip-
tions):
3 Pbi RP p q R 1  exp i1 R j, i[ ( { [ ]})(R  R  R )b  N b  mjp1 1, i 2, i 3, i R i N
Pbi Nq N 1  exp N i{ [ ]}](R  R  R )b  N b  m1, i 2, i 3, i R i N
# (1  d)(1  g), (1)
R p v[K  (R  R  R  N )], (2)1, i1 1, it 2, it 3, it it
R p (1  d)2, i1
Pbi R# R exp  , (3)1, i [ ](R  R  R )b  N b  m1, i 2, i 3, i R i N
R p (1  d)3, i1
Pbi R# R exp  , (4)2, i [ ](R  R  R )b  N b  m1, i 2, i 3, i R i N
Pbi RN p (1  d) R exp i1 3, i{ [ ](R  R  R )b  N b  m1, i 2, i 3, i R i N
Pbi N N exp  . (5)i [ ]}(R  R  R )b  N b  m1, i 2, i 3, i R i N
We fitted eight variations of this model to the data to
determine which factors are important for explaining the
dynamics of disease. These eight variations are all special
cases of the above general model. Briefly, when there is
no age structure, all RBCs (i.e., R1, R2, R3, and N) are
collapsed into a single class and there is no heterogeneity
in burst size or invasion rate. Constant recovery of RBC
deficit means that erythropoesis is a linear function of RBC
density (v is constant under normal conditions and during
anemia; ; see app. A), whereas variable recoveryv p v0 A
assumes that it is a piecewise linear function ( ),v ( v0 A
which accounts for saturation as described earlier. Ga-
metocyte production, governed by the parameter g, is ei-
ther assumed not to occur ( ) or to occur at someg p 0
constant rate throughout infection. The model variations
are as follows (see table C1 for the numbers of fitted pa-
rameters). (1) No age structure, constant recovery of RBC
deficit (RBC recovery), no gametocyte production (GP);
, , , and . (2) No age struc-b p b q p q v p v g p 0R N R N 0 A
ture, constant RBC recovery, constant GP; ,b p bR N
, and . (3) No age structure, variable RBCq p q v p vR N 0 A
recovery, no GP; , , and . (4) Nob p b q p q g p 0R N R N
age structure, variable RBC recovery, constant GP; b pR
and . (5) Age structure, constant RBC recovery,b q p qN R n
no GP; and . (6) Age structure, constantv p v g p 00 A
RBC recovery, constant GP; . (7) Age structure,v p v0 A
variable RBC recovery, no GP; . (8) Age structure,g p 0
variable RBC recovery, constant GP.
Curve Fitting. Initial conditions for individual mice were
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Figure 1: Schematic of asexual blood stage of malaria infections and our model framework. It takes 24 h for Plasmodium chabaudi merozoites to
invade red blood cells (RBCs), replicate, and burst from infected cells. We model this process in discrete time, tracking the number of merozoites
(Pi), reticulocytes of age j (Rj, i), and normocytes (Ni), on day i. RBC invasion occurs quickly relative to this 1-day cycle. We model this invasion
step in continuous time and calculate the number of infected reticulocytes of age j (Ij()) and infected normocytes (IN()) at the end of this process,
when all merozoites are either infecting RBCs or are dead.
determined from experimental measurements of both RBC
and parasite densities taken 2 days after inoculation. Pa-
rameter estimates were obtained from the literature, and
our fitting routine searched a slightly larger parameter
space than the biologically reasonable ranges (see table 1).
We fitted all parameters except for the merozoite and RBC
death rates, which are well known and were fixed for com-
putational practicality (table 1).
The models were fitted to the data from individual mice
using the maximum likelihood method. Our approach was
to lay a coarse grid over the entire parameter space and,
for each parameter set and data point, to calculate the
likelihood of the parameters given the data. When the
likelihood was maximized over a particular grid, we ad-
justed the grid using finer-scale steps over a smaller section
of parameter space. To find our maximum likelihood pa-
rameter estimates, this process was repeated until finer
grids failed to achieve a maximum log likelihood greater
than that of the previous grid, up to four decimal places.
Because we fitted the models to individual mice, we expect
the only uncertainties in our data to be caused by mea-
surement error. An earlier experiment estimated the re-
peatability of RBC densities measured by flow cytometry
and parasite densities measured by qPCR. From this we
know that the error of the log10-transformed RBC and
parasite densities are normally distributed with standard
deviations of 0.034 and 0.2, respectively.
Ideally, we would fit the models to both the RBC and
the parasite data; however, we have less confidence in our
parasite data because of the greater error associated with
them. Furthermore, given the discrete-time nature of our
model, we can make predictions about the density of mer-
ozoites either just after all infected RBCs have burst or
just after all merozoites have died or invaded an RBC but
before any asexual replication within RBCs has occurred.
Our experimental measurements are unlikely to have cap-
tured either of these events exclusively, so it is unclear to
what we should fit these data. Using only the RBCs to fit
the models allows us to avoid this difficulty. Also, because
we do not fit our model directly to the parasite data, the
parasite density predictions generated from best-fit models
provide another qualitative test of the appropriateness of
this model. The parasite predictions to which we quali-
tatively compare our data are those that calculate the den-
sity of parasites that have successfully invaded RBCs prior
to asexual replication.
With this error structure, the probability of observing
10D RBCs per mL of blood, given the model that predicts
10M RBCs per mL of blood, is
21 (D  M)
Pr (DFM) p exp  . (6)
2[ ] 2(0.034)0.034 2p
The likelihood of a particular set of parameters (given the
data) is proportional to the product of the probabilities
of observing the data (given the model predictions). For
numerical accuracy, we take the natural logarithm of the
likelihood, so that
tmax 21 (D  M )q qL p ln exp  , (7) 2{ [ ]} 2(0.034)0.034 2pqp1
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Table 1: Model parameters, published estimates, and test ranges
Parameter Definition Value (range) Reference
qR, qN Mean number of merozoites produced per infected reticulo-
cyte, normocyte
4–10 (2–25) Garnham 1966; Carter and Walli-
ker 1975; Killick-Kendrick and
Peters 1978
bR, bN Invasion rate of reticulocytes, normocytes ([cells/mL]
1 day1) 106 (0–2#105) Hetzel and Anderson 1996a; Antia
et al. 2008
d Death rate of RBCs (day1) .02–.025 (.025) van Putten 1958b; Bannerman 1983
m Death rate of merozoites (day1) 40–50 (48) Garnham 1966; McAlister 1977a
g Proportion of infected RBCs that produce gametocytes !.1 (0–.5) Shutler et al. 2005
t Lag in RBC production (transit time in bone marrow, days) 2–3 (1–4) Mary et al. 1980c; Chang et al.
2004
v Proportion of RBC deficit that is made up each day .15–.25 (0–1) Haydon et al. 2003




where Dq is the log10 of the measured RBC density at time
q and Mq is found by simulating the model for a particular
data set and taking the log10 of the total density of RBCs
(reticulocytes and normocytes) at time q. The best-fit pa-
rameters for a given model maximize the log likelihood
L.
Statistical Analysis
Model Selection and Goodness of Fit. Given the nested na-
ture of our eight model variations, we use the likelihood
ratio test to determine the best-fit model. If the calculated
maximum log likelihoods for models A and B are LA and
LB, respectively, and if model A has fewer fitted parameters,
then we define
Rp 2(L  L ). (8)B A
If R is greater than the x2 critical value, as determined
from a x2 distribution with degrees of freedom equal to
the difference in fitted parameters between models A and
B, then model B is a significantly better fit at the 5% level
(e.g., Hilborn and Mangel 1997; Grimshaw et al. 2001;
Johnson and Omland 2004). We perform these pairwise
model comparisons for each individual mouse to deter-
mine the best-fit model. In addition, we reject any models
with best-fit parameters that are in strong disagreement
with experimentally determined parameter estimates (table
1).
When we choose a best-fit model for each mouse, we
test the goodness of fit of the maximum likelihood pa-
rameters of this model knowing that, given the data, the
likelihood of these parameters is proportional to Lmax. To
perform the goodness-of-fit test, we assume that the model
and parameters are true and we simulate 1,000 artificial
data sets by generating RBC predictions and incorporating
the error structure described in “Curve Fitting.” Because
we assume that the model is true, any of these artificial
data sets could have been the measured one, so we can
generate an expected distribution for Lmax by calculating
the likelihoods of the parameters given these artificial data
sets. If the observed Lmax lies within the 95% highest-
density region of its expected distribution, then the pa-
rameters are considered to be a good fit and are accepted
at the level.a p 5%
Parameter Significance and Parameter Error Estimates. To
determine whether fitted parameters are significant, we set
each parameter in turn to 0, recalculate the maximum
likelihood, and compare this maximum likelihood to the
original using the likelihood ratio test, as described in
“Model Selection and Goodness of Fit.” If the likelihood
score of the model including the parameter is significantly
better than the model with the parameter set to 0, then
the parameter is significant at the 5% level.
To approximate the uncertainty in our estimated pa-
rameters, we generate a probability distribution for each.
We again assume that the best-fit parameters and model
are the true ones, and we generate 100 artificial data sets
for each mouse. This gives us 100 data sets, each of which
could have been the actual measured data set and would
have resulted in a slightly different set of maximum like-
lihood parameter estimates. With each of these synthetic
data sets, we redo the parameter-fitting routine using the
best-fit model and we use these maximum likelihood es-
timates to generate a probability distribution for each
parameter.
Coinfection Experiments
The above model fitting and statistical analysis provide a
rigorous approach for model selection, but all of these
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techniques make use of the original data set for which the
models were constructed. Another powerful approach to
further examine the validity of the model is to test it with
an independent data set. For example, if the model is a
valid description of the disease dynamics in CD4 T cell–
depleted mice, then it can be used to predict how the
dynamics would differ under different conditions. These
predictions can then be tested with new experimental data.
We take this approach by using the best-fit models ob-
tained above to make predictions about the disease dy-
namics that are expected if both clones simultaneously
infect a single host. To generate model predictions, we
extend the model to allow for two distinct clones (see app.
B) and set appropriate parameter values. For clone-specific
burst size and invasion rate parameters, we use the median
values from the two 106 experiments. For the parameters
governing RBC production, we use the mean of the me-
dians from the two clones, except for the time lag, which
must be an integer and thus was set at 2.
The predictions from our model are then compared with
data from an experiment. Specifically, we obtained data
from four mice that received the same anti-CD4 treat-
ment as in the previous experiments, were contempora-
neously inoculated with 106 AS and 106 DK parasites, and
survived to day 19 after inoculation. One mouse (mouse
3) died prematurely in this experiment and was therefore
excluded from the analysis. Experimental details are given
by Barclay et al. (2008).
Results
Model Development and Data Fitting
Maximum log-likelihood values for each model and mouse
are reported in table C1. Using the likelihood ratio test,
model 7 was chosen as the best fit for 10 of the 13 mice.
The three for which model 7 was not the best fit each had
model 8 as a best fit but had maximum likelihood estimates
of gametocyte conversion rates that are not easily recon-
ciled with published values (AS 105 mouse 1, ; ASg p 0.3
105 mouse 3, ; AS 106 mouse 2, ). Em-g p 0.19 g p 0.197
pirical estimates of gametocyte conversion rates are hard
to obtain because only the end product of this process can
be counted and the immune system may quickly dispose
of maturing gametocytes (Taylor and Read 1997). Instead,
some studies have measured the daily proportion of total
parasites (gametocytes and merozoites) that are gameto-
cytes (Buckling et al. 1999; Shutler et al. 2005). This serves
as a reasonable proxy for conversion rate in the absence
of evidence of a strong, gametocyte-specific immune re-
sponse, considering the relatively long life span in the
bloodstream of gametocytes compared with merozoites
(gametocyte half-life is estimated to be 8 h for males and
16 h for females; Reece et al. 2003). In experimental in-
fections with the Plasmodium chabaudi clone DK under
normal conditions, gametocytes make up around 1%–2%
of all circulating parasites and, even at their maximum
density, do not constitute more than 10% (Shutler et al.
2005). Under maximal stimulation, it is possible that con-
version rates reach values above 0.1, but there is no em-
pirical evidence of rates this high being maintained for the
duration of the acute phase of infection; therefore, we
exclude model 8 for these mice. The next best model for
each of these three mice was model 7, so we took this as
the best-fit model for these mice for the remainder of the
analyses. None of our conclusions about inoculum size or
clone effects qualitatively changes by choosing model 8
instead.
The best-fit curves for all mice are in good qualitative
agreement with measured RBC densities (see fig. 2). From
the best-fit model and parameter estimates, we generated
predictions for the parasite dynamics; these are shown,
along with experimental data, in figure 3. Considering that
we did not use these data for fitting, the model does a
good job of qualitatively explaining the parasite dynamics,
with a few notable exceptions. For mouse 4 from the AS
105 experiment, the model predicts unreasonably high par-
asite densities for the second peak. There is one potential
outlier in the RBC measurements for this mouse occurring
on day 10 after inoculation. We omitted this data point,
refitted the model, and found much more reasonable pre-
dictions for the parasite dynamics (as depicted by the blue
line in figs. 2, 3). We denote this modified data set with
one outlier omitted as mouse 4′. Also, for mouse 2 from
the AS 106 experiment, the model fails to capture the tim-
ing of parasite peaks. In this data set there were no obvious
outliers in the RBC measurements, but the RBC dynamics
look very different from those of the other mice in this
experiment. In particular, RBC density drops about 2 days
later than it does in the other mice, despite similar timing
in the parasite peaks, and RBC density fails to show any
real increase after the second parasite peak. This mouse
was excluded from further statistical analysis.
Statistical Analysis
The goodness-of-fit values of model 7 for all mice are given
in the legend of figure 2 and are shown graphically in
figure C1. The fits were very good for all mice and all
parameters were significant for every mouse. Best-fit pa-
rameters for model 7 are shown for individual mice in
table C2, and boxplots of estimated parameter distribu-
tions are shown in figures C2–C4.
Some trends can be seen when comparing estimated
values of certain parameters within individuals. In partic-
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Table 2: Medians of pooled estimated parameter distributions
relative to AS 106 estimated values
Parameter AS 105 AS 106 DK 106 Inoculum size Strain
v0 .759 1 1.312 X X
vA .381 1 1.18 X X
bR 1.02 1 .940
bN .906 1 .791 X
qR 1.943 1 .765 X X
qN 1.002 1 .877 X
Note: We assume that a difference of 10% or greater is evidence of an
effect, as indicated by X.
anemic conditions than when RBC densities are normal
(i.e., ; see fig. C4). In addition, one aspect of thev ! v0 A
importance of RBC age structure is borne out in these
distributions: for every individual, the invasion rate of fully
mature RBCs is higher than for reticulocytes (i.e., b !R
; see fig. C2), often by an order of magnitude. ThesebN
invasion rates control for differences in availability, so they
truly represent a preference for mature RBCs. Despite this
preference, burst size is higher for most individuals in
reticulocytes than in normocytes (i.e., ; see fig. C3).q 1 qR N
Effect of Parasite Clone. By pooling the data from indi-
viduals, we are able to compare the distributions of the
parameter estimates to see what effect parasite clone has
on the infection dynamics and, in particular, to try to
identify the basis for differences in virulence between the
DK (less virulent) and AS (more virulent) clones. We com-
pared only those data from inoculations with 106 parasites
to control for possible inoculum size effects. Boxplots of
the pooled distributions are shown in figure C5, and me-
dian values are listed in table C3. Table 2 contains esti-
mated DK parameter values relative to the AS values, and
we assume, somewhat arbitrarily, that differences of greater
than 10% of the AS value are evidence of a clone effect.
The median invasion rates of reticulocytes are approxi-
mately equal for both clones, but the AS clone has a higher
invasion rate of normocytes than the DK clone. Median
values for burst size are also higher for the AS parasites
than for the DK parasites, and this difference is even more
pronounced in reticulocytes than in normocyctes. The
mice in the AS-infected group have slower rates of RBC
production, both at normal RBC densities and during
anemia.
Effect of Inoculum Size. We also compared the distribu-
tions of the parameter estimates to see what effect inoc-
ulum size has on the infection dynamics. We compared
only those data from inoculations with AS parasites to
control for possible clone effects. Boxplots of the pooled
distributions are shown in figure C6, and median values
are listed in table C3. Estimated parameter values for the
105 experiment relative to those for the 106 experiment are
given in table 2. Median values of RBC invasion rate and
normocyte burst size are approximately equal. However,
there is a marked difference in the median reticulocyte
burst sizes, with the low inoculum size obtaining almost
twice as many merozites per infected reticulocyte than the
high inoculum size. Estimates of RBC production rates are
higher in the 106 inoculum size than in the 105 inoculum
size, both at normal RBC densities and during anemia.
Coinfection Experiments
Model predictions and experimental data from coinfection
experiments are plotted in figures 4 and 5. Despite not
allowing any individual variation except for starting RBC
and parasite densities, the model predictions provide a
reasonable qualitative fit to the data, particularly for the
early phase of the parasite dynamics. The predicted peaks
and troughs in the RBC densities have similar amplitude
to the data, but the timing is slightly different. This is
especially clear in mice 1 and 2, where RBC densities are
predicted to rebound faster than they actually do. This
suggests that RBC production in mice with mixed infec-
tions is slower than in single-clone-infected mice, since
we used the single-clone parameter estimates to generate
these predictions. Despite these differences, the parasite
density predictions are very good, predicting both the cor-
rect timing of peaks and the magnitude of the first wave
of parasites. Model predictions and data start to diverge
after the first peak, with the model overestimating the level
of competitive exclusion of the less virulent DK clone by
the relatively more virulent AS clone.
Discussion
We have used a comprehensive combination of mathe-
matical modeling and experimental data to explore the
relative importance of ecological factors to the within-host
dynamics of Plasmodium chabaudi infections. From our
best-fit model we conclude that RBC availability is an
important regulator of parasite growth in CD4 T cell–
depleted mice, and our systematic approach to model fit-
ting uncovered some of the complexities of this resource
and its interaction with the parasite.
Consistent with previous work (Hetzel and Anderson
1996), we find that the loss of RBCs due to infection is
sufficient to downregulate parasite densities after the initial
peak, and the subsequent increase in RBC production
alone generates a second wave of parasites. Recrudescences
are conventionally explained as outgrowths by antigenic
variants able to escape protective immunity, and it is true
Understanding Pathogenesis in Malaria E223
Figure 4: Experimental data and model predictions for red blood cell (RBC) dynamics in competition experiments. Circles, observed values; solid
lines, model predictions. Infections are with 106 AS and 106 DK parasites; bR, bN, qR, and qN are clone specific and are set to values listed in table
C2 for the 106 single-clone experiments, and v0 and vA are set to the mean of the values obtained from these experiments and t is set to 2, as
obtained from the AS 106 data.
that recrudescences are antigenically distinct from the pri-
mary wave of parasites (Brown and Brown 1965; Phillips
et al. 1997). However, because malaria parasites are gen-
erating antigenic variation through time, recrudences
would be antigenically distinct even if parasite densities
were entirely controlled by RBC dynamics. The relative
importance of immune evasion and resource limitation
remains to be determined in animals with fully intact im-
mune responses.
During periods of anemia, we find that the rate of RBC
production is upregulated (similar to findings in Jakeman
et al. 1999). Intriguingly, we find that mice infected with
the AS clone of P. chabaudi have slower rates of RBC
production than those inoculated with the DK clone. A
similar effect of clone on erythropoesis has been estimated
before (Haydon et al. 2003). In our study, it remains un-
clear whether RBC production is suppressed by the AS
clone or enhanced by the DK clone. If future empirical
studies can establish a baseline response to anemia, this
question could be resolved. Either way, our finding that
mice inoculated with the DK clone suffer less anemia may
help to explain why the AS clone is relatively more virulent
than the DK clone. The details, ubiquity, and adaptive
value of this sort of resource manipulation offer many
avenues for future investigation.
Recent theory has pointed to a role for RBC age struc-
ture in determining relative virulence of P. chabaudi clones,
with more virulent clones estimated to be able to invade
a greater age range of RBCs than less virulent ones (Antia
et al. 2008). Our results echo the importance of age struc-
ture, but our model takes a different approach and suggests
different mechanisms. In particular, Antia et al. (2008)
assume that no invasion is possible for RBCs outside a
predicted age range and estimate the youngest RBCs each
clone is able to infect (8 days for the more virulent clone
and 12 days for the less virulent clone). In contrast, we
allowed for different invasion rates and burst sizes between
types of RBCs and sought to define these types in a bio-
logically meaningful way (i.e., reticulocytes and normo-
cytes). We could then determine whether malaria parasites
interact differently with each type of cell and whether these
interactions differ between clones.
First, we find that the more virulent clone (AS) has an
advantage early on in infections, with a greater invasion
rate of and a higher burst size in normocytes than the less
virulent clone (DK). Second, although both AS and DK
merozoites have lower rates of invasion of reticulocytes,
AS gains a fecundity benefit from these invasions, pro-
ducing more daughter merozoites in younger cells than in
fully mature ones. This likely gives AS a big advantage,
because RBC production increases when anemia sets in
and the system is flushed with reticulocytes. Although no
biological mechanism for this higher burst size in retic-
ulocytes is yet known, potential candidates include the fact
that the larger size of reticulocytes allows more room for
merozoites; that there is a greater structural integrity or
deformability of reticulocytes (Taylor-Robinson and Phil-
lips 1994; meaning that older cells may be more rigid and
likely to rupture under stress); and, given that reticulocytes
are newly introduced into the bloodstream, that their ex-
pected circulation time before clearance by the spleen is
longer (Loeffler et al. 1989) and the relative risk to the
merozoites of undergoing an additional round of asexual
multiplication is lower.
In mice with intact immune systems, P. chabaudi mer-
ozoites infect the most abundant cell type, showing a pref-
erence for normocytes early in infections and then switch-
ing to reticulocytes when the mouse becomes anemic and
the bloodstream flushes with new RBCs (Jarra and Brown
1989; Taylor-Robinson and Phillips 1994). In CD4 T cell–
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Figure 5: Experimental data and model predictions for parasite dynamics in competition experiments. Red, AS parasites; blue, DK parasites; circles,
observed values; solid lines, model predictions. Parameters are the same as in figure 4.
depleted mice, infections become chronic, RBC densities
remain depressed, and the proportion of circulating re-
ticulocytes remains higher than under normal conditions,
although they remain less abundant than mature RBCs
(Taylor-Robinson and Phillips 1994). In broad agreement
with our “fecundity benefit” hypothesis of reticulocyte in-
vasion, other experimental studies have shown that, in
immune-depleted mice, AS parasites continue to show a
preference for reticulocytes (Taylor-Robinson and Phillips
1994); that is, they invade reticulocytes more often than
would be expected given their relative density. In these
mice, the cost of overcoming a lower invasion rate in
reticulocytes may be less than the burst size benefit,
whereas in the presence of an immune response, the cost
of not infecting the most easily accessible cell may be
prohibitively high. Predicting a facultative adjustment of
a parasite life-history trait in response to the host envi-
ronment may be novel in the case of RBC preference and
host immunity, but it is not unprecedented. Rodent ma-
laria parasites have been shown to alter either their in-
vestment in gametocytes or the gametocyte sex ratio in
response to host stress (e.g., Buckling et al. 1999; Paul et
al. 2003; Reece et al. 2005).
Given this empirical evidence of variable investment in
gametocytes throughout infections, and depending on the
host environment, modeling conversion rate as a constant
throughout the course of infection is inadequate. However,
our results suggest that, on average, conversion to ga-
metocytes has no significant effect on the infection dy-
namics. An alternative approach would be to allow this
parameter to vary over time. Although this would perhaps
be more biologically realistic, it would also make the pa-
rameter fitting process computationally impractical. In its
simplest form, our model need not explicitly track ga-
metocytogenesis, as this loss of asexual individuals could
be subsumed by the estimates for burst sizes or invasion
rates.
Our results present some unexpected differences due to
parasite inoculum size. First, inoculum size matters for
RBC production, with higher inoculum sizes inducing
higher production rates. These parameter estimates are
likely due to the fact that, in the experimental data, mice
inoculated with 105 AS parasites reached lower minimum
RBC densities than those who received 106 parasites.
Greater anemia with a lower inoculum size is not consis-
tent with previous results on inoculum size effects (Timms
et al. 2001), although that earlier study was performed in
mice with intact immune systems and with different P.
chabaudi clones. Second, reticulocyte burst sizes are about
twofold higher in the 105 inoculum size experiment than
in the 106 inoculum size experiment. One potential ex-
planation of this is the rigidity of the model framework.
It could be that, with the larger inoculum size as well as
an increased RBC production, the RBCs are maturing
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faster so that what we are modeling as reticulocytes are
functionally fully mature RBCs; we would then expect the
best-fit bR value to be closer to the bN value for the 10
6
inoculum size experiment. A more intriguing possibility
is that burst size is density dependent, so that the mero-
zoites regulate their usage of RBCs.
We found no consistent estimate of the lag in RBC
production from our individual mice. Although published
estimates of the transit time of blood cell precursors to
the bloodstream tend to be around 3 days (Mary et al.
1980; Chang et al. 2004), this process has been estimated
to take as little as 33 h under maximal erythropoetic stim-
ulation (Loeffler et al. 1989). Again, our model did not
allow any flexibility in this parameter over time because
the discretized description of RBC production meant it
had to be an integer. The medians from the pooled dis-
tributions do match up with the predictions about RBC
production rates: the DK clone induced the highest pro-
duction rate and had the shortest lag, whereas inoculation
with a smaller number of merozoites induced the lowest
production rate and had the longest lag. Although the
medians from both high-inoculum-size experiments are
different, the means were more similar (AS, 2.0 days; DK,
1.7 days) and the true transit time need not be an integer.
Both empirical and theoretical studies have attempted
to understand the mechanisms of competition in geneti-
cally diverse malaria infections. Experiments with P. cha-
baudi in athymic mice revealed some evidence for im-
mune-mediated apparent competition when the initial
wave of parasites receded (Råberg et al. 2006), but when
the CD4 T cell–depleted mice used in the analyses re-
ported here were compared with immune-system-intact
control mice, evidence for CD4 T cell–mediated com-
petition could not be found (Barclay et al. 2008). In the
presence of a weak immune response, theory predicts that
competition for RBCs is a limiting factor for coinfecting
parasites (Hellriegel 1992). Our results confirm this: RBC
availability alone can explain the first peak of parasites in
CD4 T cell–depleted mice. The differences in burst sizes
and invasion rates of the clones that were derived from
our single-strain model generate the appropriate relative
heights of the first AS and DK merozoite peaks in coin-
fections. Beyond the initial peak, our model predictions
and the data start to deviate. The model predicts much
stronger competitive suppression of the less virulent DK
clone by the AS clone than what is seen in the data. Our
data are consistent with previous studies in immune-intact
mice, which showed that, after the initial peaks, parasite
densities were no different or higher in competition than
they were in single infections (Bell et al. 2006). The authors
of that article point to the immune response becoming
more clone specific as an explanation of why the com-
petitively superior clone cannot completely suppress the
other. Here, we propose that a similar but CD4 T cell–
independent specific immune response is responsible for
the competitive release of the DK clone for which our
model could not account. Further insights into the dy-
namics of coinfections could be found by fitting our com-
petition model to the available data to see whether dif-
ferences in infection dynamics are solely due to differences
in parameters or, alternatively, whether other mechanisms
(like our proposed immune response) are in operation.
Although we believe that the ability to predict the out-
come of the acute phase of competition experiments pro-
vides strong validation of our model, it could be further
tested in a number of ways. One option is to empirically
test our parameter estimates, although our results show
that there will be substantial variation between individual
mice. Another option is to experiment with other clones
to see whether their relative virulence can be explained by
the mechanisms we have proposed. It would also be in-
teresting to see whether there was more evidence of den-
sity-dependent regulation of RBC usage and burst sizes,
perhaps through experimental manipulation of RBC
availability.
The results presented here take a significant first step
toward a comprehensive model of the within-host dynam-
ics of malaria infections. We have shown that ecological
factors are crucial for explaining infection dynamics and,
with this foundation, we can build up the complexity to-
ward a better understanding of the dynamics in the more
biologically interesting setting of immune-intact hosts.
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APPENDIX A
Model Derivation
The basic structure of the discrete-time model in tracking merozoite density and RBC density is derived by considering
the series of events occurring during a single day. Suppose the number of merozoites and susceptible RBCs of each
age class per microliter of blood at the census point on day i are given by Pi, R1, i, R2, i, R3, i, and Ni. The next event
in the replication cycle is the invasion of susceptible RBCs. We model this as a continuous time process that occurs
quickly, relative to the 24 h discrete-time burst cycle. Free-living merozoites invade reticulocytes and normocytes at
rates bR and bN, respectively, and experience a natural mortality rate m while in the bloodstream. We assume that
merozoites can infect both susceptible and already infected RBCs, but for simplicity (and similar to Hetzel and Anderson
1996) we assume that secondary invasions are lost and do not change the behavior of the primary invasion. Given
these assumptions, we can write differential equations to describe the invasion phase. For and 3 (i.e., the dayj p 1, 2,
after the release of the reticulocyte in the bloodstream),
3
dP
p P b (R  I )  b (N  I )  mP, (A1)R j j N N[ ]dt jp1
dRj p b PR , (A2)R jdt
dN
p b PN, (A3)Ndt
dIj p b PR , (A4)R jdt
dIN p b PN. (A5)Ndt
Pay special attention to the notation in equations (A1)–(A5). The variables in these equations are missing the
subscript i referring to the day in question because these are, in fact, different variables than the Pi, Rj, i, Ni, Ij, i, and
IN, i introduced above. The variables in equations (A1)–(A5) track the dynamics of the different kinds of cells during
the RBC invasion phase only, which occurs as one of the events during each day. The variables subscripted with an
i, however, track these values from one day to the next. Thus, the initial conditions for the above system of differential
equations on day i are , , , , and . The solution to this system isP(0) p P R (0) p R N(0) p N I (0) p 0 I (0) p 0i j j, i i j N
readily found, allowing us to calculate the number of each type of cell after this invasion phase is complete; that is,
, , , and (note that ).R () N() I () I () P() p 0j j N
The next event is RBC turnover through death and erythropoesis. We suppose that a fraction d of all RBCs die,
then RBC aging occurs, and then finally newly produced RBCs enter the age 1 class at a rate that depends on the
RBC density t days earlier. Specifically, we model RBC production in a density-dependent fashion as in Haydon et al.
(2003) but with a time lag of t days between the onset of anemia and the body’s response. This represents the time
it takes for new blood cells to develop in the bone marrow before being released into the bloodstream. Thus, the
number of susceptible age 1 RBCs produced on day i is , where K represents thev[K  (R  R  R  N )]1, it 2, it 3, it it
equilibrium density of RBCs in the absence of both merozoites and natural death and v is the proportion of the RBC
deficit that is made up in one day. Other forms of RBC production, such as a saturating Hill function, have been
suggested (Mackey 1997), but we use this linear form of density dependence for simplicity and we account for a type
of saturation of production by having two separate values of v: one for when RBC level is above 50% of its normal
density (v0) and another for when it is below 50% (vA). We have performed all of the analyses below with a Hill
function as well, and this tended to result in qualitatively reasonable but statistically poorer fits to the data (N. Mideo,
unpublished results). Last, with the above assumptions, the number of susceptible RBCs of age 2 and age 3 on day i
becomes and , respectively, and the number of normocytes becomes(R  I ())(1  d) (R  I ())(1  d) (R 1, i 1 2, i 2 3, i
.I ()  N  I ())(1  d)3 i N
The final event is the bursting of RBCs and the resulting production of merozoites, at which point a new census
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occurs. Using qR and qN as the burst size of infected retoculocytes and normocytes, respectively, the total number of
merozoites produced on day i is then , where g is the proportion of infected
3
[q  I ()  q I ()](1  d)(1  g)R j N Njp1
RBCs that produce gametocytes rather than merozoites (referred to as the conversion rate). Thus, the discrete time
system of equations from one day to the next is
3
P p q I ()  q I () (1  d)(1  g), (A6)i1 R j N N( )
jp1
R p v[K  (R  R  R  N )], (A7)1, i1 1, it 2, it 3, it it
R p (R  I ())(1  d), (A8)2, i1 1, i 1
R p (R  I ())(1  d), (A9)3, i1 2, i 2
N p (R  I ()  N  I ())(1  d). (A10)i1 3, i 3 i N
Finally, we derive explicit expressions for the number of each type of RBC invaded in a particular cycle by finding
general solutions to the differential equations (A1)–(A5). Because the number of total RBCs (uninfected plus infected)
remains constant during a bout of invasion (because RBC production and natural death occur in the next step of the
discrete cycle), the parasite dynamics do not depend on the dynamics of either. Using this fact and the initial conditions
, , , , and , we can first find an expression for P(t) by solving equationR (0) p R N(0) p N P(0) p P I (0) p 0 I (0) p 0j j, i i i j N
(A1). This gives us
P(t) p P exp {t[(R  R  R )b  N b  m]}. (A11)i 1, i 2, i 3, i R i N
Substituting this into equations (A4) and (A5) we find
(1  exp {t[(R  R  R )b  N b  m]})Pb1, i 2, i 3, i R i N i RI (t) p R 1  exp  (A12)j j, i{ [ ]}(R  R  R )b  N b  m1, i 2, i 3, i R i N
for and 3, andj p 1, 2,
(1  exp {t[(R  R  R )b  N b  m]})Pb1, i 2, i 3, i R i N i NI (t) p N 1  exp  . (A13)N i{ [ ]}(R  R  R )b  N b  m1, i 2, i 3, i R i N
Further simplification of these expressions is possible because, given our parameters, the number of parasites declines
to 0 within a single day. This makes biological sense, because free-living parasites have only a matter of minutes to
infect a RBC before they will die naturally. Thus, it is a reasonable approximation to assume that the numbers of
infected cells just before bursting are given by the limits of equations (A12) and (A13) as t goes to infinity. Thus,
Pbi RI () p R 1  exp  , (A14)j j, i{ [ ]}(R  R  R )b  N b  m1, i 2, i 3, i R i N
Pbi NI () p N 1  exp  . (A15)N i{ [ ]}(R  R  R )b  N b  m1, i 2, i 3, i R i N
Substituting the solutions for and into the above discrete time system, equations (A6)–(A10), gives theI () I ()j N
complete model of the main text.
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APPENDIX B
Competition Model with Two Clones
We can extend our original discrete time framework (eqq. [A6]–[A10]) to allow for two different clones of a parasite,
PA and PB. Densities of reticulocytes (on their jth day in the bloodstream) and normocytes infected with parasite A
are given by IjA and INA. Reticulocytes and normocytes infected with parasite B are given by IjB and INB. As before, we
assume that only the first parasite to infect an RBC matters. Subsequent invasions are essentially lost, so we have to
consider only singly infected RBCs. The basic model tracking parasite and RBC densities is given by:
3
P p q I (P , R )  q I (P , N ) (1  d)(1  g), (B1)A, i1 RA jA A, i j, i N NA A, i i[ ]
jp1
3
P p q I (P , R )  q I (P , N ) (1  d)(1  g), (B2)B, i1 RB jB B, i j, i N NB B, i i[ ]
jp1
R p v[K  (R  R  R  N )], (B3)1, i1 1, it 2, it 3, it it
R p [R  I (P , R )  I (P , R )](1  d), (B4)2, i1 1, i 1A A, i 1, i 1B B, i 1, i
R p [R  I (P , R )  I (P , R )](1  d), (B5)3, i1 2, i 2A A, i 2, i 2B B, i 2, i
N p [R  I (P , R )  I (P , R )](1  d) (B6)i1 3, i 3A A, i 3, i 3B B, i 3, i
 [N  I (P , N )  I (P , N )](1  d).i NA A, i i NB B, i i
The dynamics of the invasion phase are now described by the following set of differential equations:
3
dPA p P b (R  I  I )  b (N  I  I )  mP , (B7)A RA j jA jB NA NA NB A[ ]dt jp1
3
dPB p P b (R  I  I )  b (N  I  I )  mP , (B8)B RB j jA jB NB NA NB B[ ]dt jp1
dRj p b P R  b P R , (B9)RA A j RB B jdt
dN
p b P N  b P N, (B10)NA A NB Bdt
dIjA p b P R , (B11)RA A jdt
dINA p b P N, (B12)NA Adt
dIjB p b P R , (B13)RB B jdt
dINB p b P N. (B14)NB Bdt
As before, we can find expressions for PA(t) and PB(t). These expressions are equivalent to equation (A11), except
with strain-specific invasion rates. Given the initial conditions , , , ,R (0) p R N(0) p N P (0) p P P (0) p Pk k, i i A A, i B B,i
, , , and ,I (0) p 0 I (0) p 0 I (0) p 0 I (0) p 0jA jB NA NB
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P (t) p P exp {t[(R  R  R )b  N b  m]}, (B15)A A, i 1, i 2, i 3, i RA i NA
P (t) p P exp {t[(R  R  R )b  N b  m]}. (B16)B B, i 1, i 2, i 3, i RB i NB
Substituting these results into equations (B9) and (B10), we can find expressions for the Rj(t) values and for N(t).
Letting ,Y p R  R  Ri 1, i 2, i 3, i
{1  exp [t(N b  Y b  m)]}P bi NA i RA A, i RAR (t) p R exp j j, i ( N b  Y b  mi NA i RA
{1  exp [t(N b  Y b  m)]}P bi NB i RB B, i RB , (B17))N b  Y b  mi NB i RB
{1  exp [t(N b  Y b  m)]}P bi NA i RA A, i NAN(t) p N exp i ( N b  Y b  mi NA i RA
{1  exp [t(N b  Y b  m)]}P bi NB i RB B, i NB . (B18))N b  Y b  mi NB i RB
To a good approximation,
exp [t(N b  Y b  m)] ≈ exp [t(N b  Y b  m)], (B19)i NA i RA i NB i RB
which allows us to solve for the numbers of different kinds of infected cells just before bursting. As earlier, we take
the limits as t goes to infinity. Thus,
P b P bA, i RA B, i RBP R b (N b  Y b  m) 1  exp  A, i j, i RA i NB i RB { [ ( )]}Y b  N b  m Y b  N b  mi RA i NA i RB i NB
I () p , (B20)jA N (P b b  P b b )  P b (Y b  m)  P b (Y b  m)i A, i RA NB B, i RB NA B, i RB i RA A, i RA i RB
P b P bA, i NA B, i NB( )P N b N b  Y b  m 1  exp  A, i i NA i NB i RB { [ ( )]}Y b  N b  m Y b  N b  mi RA i NA i RB i NB
I () p , (B21)NA
N P  P b b  P (Y b  m)  P b (Y b  m)( )i A, i B, i NA NB B, i i RA A, i NA i RB
P b P bA, i RA B, i RBP R b (N b  Y b  m) 1  exp  B, i j, i RB i NA i RA { [ ( )]}Y b  N b  m Y b  N b  mi RA i NA i RB i NB
I () p , (B22)jB
N P b b  P b b  P b (Y b  m)  P b (Y b  m)( )i A, i RA NB B, i RB NA B, i RB i RA A, i RA i RB
P b P bA, i NA B, i NBP N b (N b  Y b  m) 1  exp  B, i i NB i NA i RA { [ ( )]}Y b  N b  m Y b  N b  mi RA i NA i RB i NB
I () p . (B23)NB
N P  P b b  P (Y b  m)  P b (Y b  m)( )i A, i B, i NA NB B, i i RA A, i NA i RB
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APPENDIX C
Supplementary Results
We use the maximum likelihood method of fitting our model variations to the individual mouse data. Details of the
methodology are presented in the main text. The best-fit parameters for a given model maximize the log likelihood
L; the maximum likelihood values are presented in table C1. We use the likelihood ratio test to compare the fit of
our nested model variations.
As described in “Model Development and Data Fitting,” we reject model 8 as the best fit for the three mice data
sets that chose this model on the basis of the estimated gametocyte conversion rate g. Thus, the best-fit model for
each mouse is model 7 and the best-fit parameters for each individual are given in table C2.
We test the goodness-of-fit of the maximum likelihood parameters of model 7 to the data sets of each individual
mouse. The likelihood of these parameters, given the data, is proportional to Lmax. For this test, we assume that the
model and parameters are true and simulate 1,000 artificial data sets by generating RBC predictions and incorporating
the error structure described in “Curve Fitting.” Each of these data sets represents one that could have been the
measured one; we can generate an expected distribution for Lmax by calculating the likelihoods of the parameters given
these artificial data sets. If the observed Lmax value lies within the 95% highest-density region (HDR) of its expected
distribution, then the parameters are considered to be a good fit and are accepted at the level. In figure C1,a p 5%
we plot these distributions and highlight the location of the observed Lmax within the 95% HDR. The fit is good for
each mouse.
We can use the approach described above for generating artificial data sets to approximate the uncertainty in our
estimated parameters. We generate 100 artificial data sets for each mouse, each of which again could have been the
measured one and would have resulted in a slightly different set of maximum likelihood parameter estimates. With
each of these synthetic data sets, we perform the parameter-fitting routine again using the best-fit model, and we use
these maximum likelihood estimates to generate a probability distribution for each parameter. These distributions are
shown in figures C2–C4.
By pooling the individual probability distributions for each parameter according to experiment (i.e., AS 105, AS 106,
or DK 106), we attempt to identify any effects of parasite clone or inoculum size. Median parameter values, according
to treatment, are presented in table C3 and are shown graphically, along with distributions, in figures C5 and C6.







model1 (4) 2 (5) 3 (5) 4 (6) 5 (6) 6 (7) 7 (7) 8 (8)
AS 105:
1 252.0354 254.2259 198.3124 188.9497 71.9943 60.4726 29.2523 16.5551 8
3 145.7672 148.5523 102.6568 99.7949 74.8265 58.1948 33.6190 31.6321 8
4 41.778 41.3139 34.0503 33.1802 32.7567 31.4321 15.2876 17.1742 7
5 91.2966 97.2707 68.2014 73.0514 65.1489 65.4983 30.5617 30.1121 7
AS 106:
1 95.3124 95.3124 2.5347 3.3676 8.1647 8.1713 21.1703 20.1022 7
2 28.5043 28.1106 17.2592 20.8733 15.0168 13.7768 28.2615 25.6421 8
3 205.2719 205.2719 82.4215 81.7086 21.2089 19.6881 2.6447 3.8579 7
4 101.6202 101.6202 61.5321 56.9027 2.4884 3.0744 14.3611 14.3611 7
5 87.6311 88.0733 33.816 33.816 6.2623 6.2629 .7489 .276 7
DK 106:
1 5.1129 5.376 20.2243 19.9075 22.3498 23.4571 24.9077 25.5997 7
2 113.2633 113.261 96.7325 96.7376 93.2548 93.25448 22.9551 22.9441 7
3 32.8633 32.9051 7.8646 7.7993 5.5394 8.3251 24.2722 24.3229 7
4 260.4084 259.8688 130.6609 128.4231 133.3927 120.12560 86.8485 87.2826 7
Note: Models that share the same number of fitted parameters can be compared directly; that is, a model with a larger Lmax value is significantly better.
For models that differ by one fitted parameter, twice the difference in Lmax values must be greater than 3.84 for a more complex model to provide a significantly
better fit. See “Statistical Analysis” for details.
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Table C2: Estimated parameter values for the best-fit model
Treatment, mouse v0 vA bR # 10
6 bN # 10
6 qR qN t
AS 105:
1 .06901 .18889 1.0889 7.08999 13.8193 9.1826 3
3 .05124 .128 .3918 15.06 21 6.072 3
4 .83897 .5099 9.997 .9889 11.995 22 2
5 .05181 .1309 .7839 12.0610 19.890 6.030 2
AS 106:
1 .04942 .41099 1.0009 16.28 4.649 6.001 3
2 .01877 .5 .589 1.489 2 13.889 1
3 .07664 .5 .2263 12.206 10.999 7.732 3
4 .5 .3715 .8309 3.5002 19 11.021 1
5 .0875 .4491 .843 11.749 15.89 6 2
DK 106:
1 .5 .4389 .8508 4.104 18 7.111 1
2 .04139 .5 .2759 19.825 11.799 5.991 1
3 .1739 .5 .725 7.499 9.46 6.014 1
4 .04983 .3889 .889 10.3891 2.98 8.078 3
Table C3: Medians of pooled estimated parameter distributions
Parameter AS 105 AS 106 DK 106
v0 .0759 .10 .1312
vA .1999 .52509 .6196
bR 1.086 # 10
6 1.065 # 106 1.001 # 106
bN 10.14 # 10
6 11.189 # 106 8.861 # 106
qR 15.778 8.12 6.21
qN 7.998 7.979 7.0
t 3 2 1
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Figure C1: Expected distributions of Lmax, the maximum log likelihood of the best-fit model given the data, for each individual mouse. These
distributions are generated by calculating the log likelihood of the best-fit model and parameters given each of 1,000 artificial data sets. Blue lines,
the observed Lmax (log likelihood of best-fit model and parameters given the measured data). In each case, the blue line is within the 95% highest-
density region of its expected distribution (dashed red lines); therefore, the model is a good fit for each data set.
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Figure C2: Boxplots of the estimated distributions of invasion rate for reticulocytes (top) and normocytes (bottom). Each boxplot contains 100
parameter estimates obtained from refitting simulated data sets (100 data sets per mouse). Horizontal line, median; circles, outliers; each box contains
50% of the values.
Figure C3: Boxplots of the estimated distributions of burst size for reticulocytes (top) and normocytes (bottom). Each boxplot contains 100 parameter
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estimates obtained from refitting simulated data sets (100 data sets per mouse). Horizontal line, median; circles, outliers; each box contains 50% of
the values.
Figure C4: Boxplots of the estimated distributions of RBC production parameters: proportion of RBC deficit made up in one day under normal
conditions (top), proportion of RBC deficit made up in one day under anemic conditions (center), and time lag due to maturation of RBC (bottom).
Each boxplot contains 100 parameter estimates obtained from refitting simulated data sets (100 data sets per mouse). Horizontal line, median; circles,
outliers; each box contains 50% of the values.
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Figure C5: Boxplots of the combined estimated parameter distributions for the AS 106 (gray) and DK 106 (blue) experiments. Each boxplot contains
400 parameter estimates (100 data sets per mouse # 4 mice per strain). Horizontal line, median; circles, outliers; each box contains 50% of the
values.
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Figure C6: Boxplots of the combined estimated parameter distributions for the AS 105 (white) and AS106 (gray) experiments. Each boxplot contains
400 parameter estimates (100 data sets per mouse # 4 mice per dose). Horizontal line, median; circles, outliers; each box contains 50% of the values.
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